<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunol Res</journal-id><journal-id journal-id-type="iso-abbrev">J Immunol Res</journal-id><journal-id journal-id-type="publisher-id">JIR</journal-id><journal-title-group><journal-title>Journal of Immunology Research</journal-title></journal-title-group><issn pub-type="ppub">2314-8861</issn><issn pub-type="epub">2314-7156</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7231083</article-id><article-id pub-id-type="doi">10.1155/2020/1372494</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Human Type I Interferon Antiviral Effects in Respiratory and Reemerging Viral Infections</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4164-7674</contrib-id><name><surname>Acosta</surname><given-names>Patricio L.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9370-1073</contrib-id><name><surname>Byrne</surname><given-names>Alana B.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2903-666X</contrib-id><name><surname>Hijano</surname><given-names>Diego R.</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2635-474X</contrib-id><name><surname>Talarico</surname><given-names>Laura B.</given-names></name><email>ltalarico@conicet.gov.ar</email><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Laboratorio de Investigaciones Infectol&#x000f3;gicas y Biolog&#x000ed;a Molecular, Unidad de Infectolog&#x000ed;a, Departamento de Medicina, Hospital de Ni&#x000f1;os Dr. Ricardo Guti&#x000e9;rrez, Buenos Aires (1425), Argentina</aff><aff id="I2">
<sup>2</sup>Consejo Nacional de Investigaciones Cient&#x000ed;ficas y T&#x000e9;cnicas (CONICET), Buenos Aires (1425), Argentina</aff><aff id="I3">
<sup>3</sup>Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA</aff><author-notes><fn fn-type="other"><p>Academic Editor: Kurt Blaser</p></fn></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>8</day><month>5</month><year>2020</year></pub-date><volume>2020</volume><elocation-id>1372494</elocation-id><history><date date-type="received"><day>4</day><month>11</month><year>2019</year></date><date date-type="rev-recd"><day>17</day><month>2</month><year>2020</year></date><date date-type="accepted"><day>2</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Patricio L. Acosta et al.</copyright-statement><copyright-year>2020</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Type I interferons (IFN-I) are a group of related proteins that help regulate the activity of the immune system and play a key role in host defense against viral infections. Upon infection, the IFN-I are rapidly secreted and induce a wide range of effects that not only act upon innate immune cells but also modulate the adaptive immune system. While IFN-I and many IFN stimulated genes are well-known for their protective antiviral role, recent studies have associated them with potential pathogenic functions. In this review, we summarize the current knowledge regarding the complex effects of human IFN-I responses in respiratory as well as reemerging flavivirus infections of public health significance and the molecular mechanisms by which viral proteins antagonize the establishment of an antiviral host defense. Antiviral effects and immune modulation of IFN-stimulated genes is discussed in resisting and controlling pathogens. Understanding the mechanisms of these processes will be crucial in determining how viral replication can be effectively controlled and in developing safe and effective vaccines and novel therapeutic strategies.</p></abstract><funding-group><award-group><funding-source>Consejo Nacional de Investigaciones Cient&#x000ed;ficas y T&#x000e9;cnicas</funding-source></award-group><award-group><funding-source>Agencia Nacional de Promoci&#x000f3;n Cient&#x000ed;fica y Tecnol&#x000f3;gica</funding-source><award-id>PICT 2015 N&#x000b0;0076</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Type I interferons (IFN-I) are members from a large family of signaling proteins known for their potent antiviral activity. IFN-I were discovered in 1957 by Lindenmann and Isaacs and received their names based on the ability to interfere with influenza virus replication in chick cell culture [<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B3" ref-type="bibr">3</xref>]. In recent years, the knowledge about the mechanism of IFN-I production has quickly expanded.</p><p>IFN-I are produced by most cell types, the best known members of this group are IFN-<italic>&#x003b1;</italic> and IFN-<italic>&#x003b2;</italic>, and it also includes IFN-<italic>&#x003bf;</italic>, IFN-<italic>&#x003b4;</italic>, IFN-<italic>&#x003ba;</italic>, IFN-<italic>&#x003b5;</italic>, IFN-<italic>&#x003c4;</italic>, and IFN-<italic>&#x003c9;</italic> [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>], which directly mediate a potent antiviral response. IFN-<italic>&#x003b1;</italic> includes 13 partially homologous members, encoded by chromosome 9, while IFN-<italic>&#x003b2;</italic> is composed by a single member and the gene is located on chromosome 12 [<xref rid="B4" ref-type="bibr">4</xref>].</p><p>IFN-I production occurs primarily when pattern recognition receptors (PRRs) present on the cell surface or in the cytosolic compartment of virtually all cell types are stimulated by pathogen-associated molecular patterns (PAMPs) [<xref rid="B6" ref-type="bibr">6</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>]. The most widely studied PRRs are Toll-like receptors (TLRs). Ten different TLRs have been identified in humans, all of which detect PAMPs either on the cell surface or the lumen of intracellular vesicles, such as endosomes or lysosomes, and are involved in the recognition of a particular type of PAMP [<xref rid="B6" ref-type="bibr">6</xref>]. TLRs recognize different pathogen components, including double-stranded RNA (dsRNA) (TLR-3), single-stranded RNA (ssRNA) (TLR-7), or CpG DNA [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>]. Other PPRs include retinoic acid-inducible gene-I- (RIG-I-) like receptors (RLRs) and nucleotide-binding oligomerization domain- (NOD-) like receptors (NLRs).</p><p>The recognition of TLR ligands leads to the recruitment of adaptor molecules that contain Toll interleukin-1 receptors (TIR) such as TIR-domain-containing adapter (TRIF), TRIF-related adaptor molecule (TRAM), Myeloid differentiation primary response gene 88 (MyD88), or TIR-domain-containing adaptor protein (TIRAP), leading the activation of molecular cascades that finally promote the activation of nuclear transcription factors such as nuclear factor <italic>&#x003ba;</italic>B (NF-<italic>&#x003ba;</italic>B), IFN regulatory factor 3 (IRF-3), and 7 (IRF-7) [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>], which leads to the induction of genes encoding IFN-I (<xref ref-type="fig" rid="fig1">Figure 1(a)</xref>).</p><p>Both IFN-<italic>&#x003b1;</italic> and IFN-<italic>&#x003b2;</italic> use the same receptor, IFN-<italic>&#x003b1;</italic>/<italic>&#x003b2;</italic> receptor (IFNAR), which is expressed on a vast variety of cell types [<xref rid="B5" ref-type="bibr">5</xref>] (<xref ref-type="fig" rid="fig1">Figure 1(b)</xref>). This receptor is associated with Janus kinase 1 (JAK1) and Tyrosine kinase 2 (TYK2). IFN-<italic>&#x003b1;</italic>/IFN-<italic>&#x003b2;</italic> binding to IFNAR activates JAK1 and TYK2, which subsequently phosphorylate the transcription factor signal transducer and activator of transcription 1 (STAT1) and STAT2 [<xref rid="B13" ref-type="bibr">13</xref>], among other less characterized transcription factors such as STAT3, STAT4, and STAT5. Once phosphorylated, these factors associate with IRF-9 to form the IFN-stimulated gene factor 3 complex (ISGF3). In the nucleus, this complex binds specific DNA sequences containing IFN-stimulated response elements (ISRE) that promote the transcription of hundreds of IFN-stimulated genes (ISGs) including IRF-1, IRF-7, IRF-8, and IRF-9, whose function is to inhibit viral replication and induce an antiviral response in the area of the infected cell [<xref rid="B13" ref-type="bibr">13</xref>&#x02013;<xref rid="B15" ref-type="bibr">15</xref>]. Some ISGs have been widely studied; the best known members include IFN dsRNA-dependent protein kinase R (PKR), 2&#x02032;-5&#x02032;oligoadenilate synthetase (OAS), IFN-inducible transmembrane proteins (IFITM), dsRNA-specific adenosine deaminase (ADAR), and Myxovirus resistance protein A (MxA) and B (MxB) [<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>].</p><p>The viral infectious cycle involves several steps, and ISGs target different stages of the viral cycle. For example, PKR, which was among the first ISG described, is a PRR that recognizes dsRNA, inducing IFN production and further ISG production [<xref rid="B18" ref-type="bibr">18</xref>]. PKR inactivates eIF-2<italic>&#x003b1;</italic>, leading to a global translation blockage of both viral and cellular mRNA [<xref rid="B19" ref-type="bibr">19</xref>]. OAS is also activated by cytoplasmic dsRNA and is subsequently involved in the degradation of RNA (through RNAse L), contributing to the inhibition of protein synthesis and therefore viral replication [<xref rid="B20" ref-type="bibr">20</xref>]. In the case of IFITM, the four members (IFITM-1, IFITM-2, IFITM-3, and IFITM-5) are present in endosomes and lysosomes and have a critical role in the inhibition of viruses that require vesicles for effective infection [<xref rid="B21" ref-type="bibr">21</xref>]. ADAR is a nucleic acid editing enzyme that disrupts base pairing. ADAR catalyzes the deamination of adenosine (A) to produce inosine (I) in dsRNA, inducing the replacement of the AU base pair by IU, which produces dsRNA destabilization [<xref rid="B22" ref-type="bibr">22</xref>]. On the other hand, MxA and MxB play a critical role during viral entry; while MxA acts in the early stages of infection once the virus has traversed the plasmatic membrane, MxB acts at the nuclear stage, inhibiting nuclear entrance [<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>].</p><p>Dendritic cells (DCs) play a key role in the production of IFN-I. Although both myeloid DC (mDC) and plasmacytoid DC (pDC) produce IFN, the latter express specialized TLR-7 and TLR-9 and has a high constitutive expression of IRF-7 that allow them to respond to viruses with rapid and extremely robust IFN-<italic>&#x003b1;</italic> production [<xref rid="B25" ref-type="bibr">25</xref>&#x02013;<xref rid="B27" ref-type="bibr">27</xref>]. Upon activation and production of IFN, pDCs mature into antigen-presenting cells (APC) serving as a key link between the innate and adaptive immune responses [<xref rid="B28" ref-type="bibr">28</xref>]. In addition, DCs produce IL-12, which drives na&#x000ef;ve T cells into Th1-type responses, as well as IFN-<italic>&#x003b1;</italic>, which increases the frequency of IFN-<italic>&#x003b3;</italic> producing CD4<sup>+</sup> T cells [<xref rid="B29" ref-type="bibr">29</xref>]. Moreover, IFN-I also boost natural killer (NK) and CD8<sup>+</sup> T cell responses, promoting both survival and clonal expansion of the latter [<xref rid="B30" ref-type="bibr">30</xref>&#x02013;<xref rid="B32" ref-type="bibr">32</xref>]. IFN-<italic>&#x003b1;</italic> and IFN-<italic>&#x003b2;</italic> lead to an immediate innate antiviral response and stimulate the adaptive immune system, affecting myeloid cells, NK cells, T cells, and B cells to mount an adequate Th1-biased immune response [<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B33" ref-type="bibr">33</xref>].</p><p>Since its discovery, IFN's role as an important player of the immune system against viral infections has become evident. Although IFN is known for its innate beneficial response, recent studies have also linked these immune mediators to pathogenesis.</p><p>This review summarizes the current knowledge of the roles of IFN-I in respiratory virus and reemerging flavivirus infections (<xref rid="tab1" ref-type="table">Table 1</xref>) and on the strategies that different viruses adapt to subvert IFN-I responses, mainly focusing on studies in human cells and subjects.</p></sec><sec id="sec2"><title>2. Human IFN-I Responses to Viral Pathogens</title><sec id="sec2.1"><title>2.1. Human Respiratory Viruses</title><p>Respiratory viruses including influenza virus, respiratory syncytial virus (RSV), human metapneumovirus (hMPV), parainfluenza virus (PIV), human rhinovirus (HRV), and human coronavirus (HCoV) are a major cause of respiratory disease and mortality in humans [<xref rid="B34" ref-type="bibr">34</xref>&#x02013;<xref rid="B36" ref-type="bibr">36</xref>]. The disease can range in severity from mild or asymptomatic upper airway infections to severe wheezing, bronchiolitis, pneumonia, or death. Numerous factors can increase the risk of severe disease, including neurological conditions, chronic lung and/or heart disease, metabolic disorders, or a weakened immune system [<xref rid="B37" ref-type="bibr">37</xref>]. However, the majority of severe cases occur in previously healthy persons [<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>].</p><p>When a cell is infected, the viral sensing activates pathways that trigger host immune responses. The viral presence is detected by several distinct PRRs including TLR-2, 3, 4, 6, 7, and 8, RLRs including RIG-I and MDA5 pathways among others [<xref rid="B38" ref-type="bibr">38</xref>&#x02013;<xref rid="B40" ref-type="bibr">40</xref>]. These signaling pathways converge on IRF-3/IRF-7 and NF-<italic>&#x003ba;</italic>B that promote the induction of IFN-I that inhibit viral replication and contribute to the initiation of more specific adaptive immune responses [<xref rid="B40" ref-type="bibr">40</xref>]. IFN-<italic>&#x003b1;</italic> and IFN-<italic>&#x003b2;</italic> bind to receptor complexes, which activate STAT1 and STAT2 phosphorylation. IRF-9 binds to STAT1/STAT2 heterodimers forming the ISGF3 complex, which translocates to the nucleus to induce transcription of ISGs and to mount an antiviral state within the cell [<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B41" ref-type="bibr">41</xref>].</p><p>Respiratory viruses, like other pathogens, target core molecules of the immune cascade to evade the host response. Like other different viruses, one major strategy used by respiratory viruses is to modulate, evade, or inhibit the IFN response that allows viral replication and transmission [<xref rid="B41" ref-type="bibr">41</xref>&#x02013;<xref rid="B43" ref-type="bibr">43</xref>].</p><sec id="sec2.1.1"><title>2.1.1. Influenza Virus</title><p>Influenza virus is a negative-sense, ssRNA virus that belongs to the <italic>Orthomyxoviridae</italic> family. This pathogen is a leading cause of respiratory illness in humans and causes annual epidemics and pandemics of differing severity [<xref rid="B44" ref-type="bibr">44</xref>]. The human subpopulations most vulnerable to influenza virus infections are children, pregnant women, and persons over 65 years old.</p><p>Influenza virus is primarily recognized by two different types of PRRs: RLRs and TLRs. Regarding the RLR family, RIG-I, LGP2, and MDA5 sense viral RNA during viral replication in the cytoplasm [<xref rid="B45" ref-type="bibr">45</xref>&#x02013;<xref rid="B47" ref-type="bibr">47</xref>]. Once activated, RIG-I and MDA5 interact with the mitochondrial antiviral-signaling protein (MAVS), leading the activation of NF-<italic>&#x003ba;</italic>B and IRF-3 to stimulate IFN production (<xref ref-type="fig" rid="fig2">Figure 2</xref>). On the other hand, LGP2 has been related to the regulation of RIG and MDA5 activation [<xref rid="B48" ref-type="bibr">48</xref>]. Two different TLRs are activated by influenza virus, TLR-3 and TLR-7. The stimulation of TLR-3 in DCs and macrophages signal through TRIF, activating IRF-3/ NF-<italic>&#x003ba;</italic>B, leading to IFN-<italic>&#x003b2;</italic> secretion. On the other hand, TLR-7 in DCs activates MyD88, which activates IRF-7 and produces the secretion of both IFN-<italic>&#x003b1;</italic> and IFN-<italic>&#x003b2;</italic> [<xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>].</p><p>Influenza virus NS1 suppresses IFN synthesis through several different mechanisms [<xref rid="B51" ref-type="bibr">51</xref>&#x02013;<xref rid="B54" ref-type="bibr">54</xref>] (<xref ref-type="fig" rid="fig3">Figure 3</xref>). First, it limits the pretranscriptional induction of IFN by forming a complex with RIG-I and limiting its signaling [<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>]. Second, it directly limits the extent of the antiviral state by inhibiting PKR by sequestering dsRNA and by forming a complex with PKR avoiding its activation [<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>]. Third, it inhibits mRNA maturation by interfering with the effector domain of the 3&#x02032;-end processing [<xref rid="B59" ref-type="bibr">59</xref>]. Finally, NS1 activates phosphatidyl-inositol-3 kinases (PI3K) which can delay apoptosis of infected cells [<xref rid="B60" ref-type="bibr">60</xref>].</p><p>The evidence supporting the role of IFN-I during influenza infection in human populations is limited. Much of the available information focused on animal studies that have yielded mixed results. While some studies have found a protective role of IFN-I, others found no effect or even a pathogenic role [<xref rid="B61" ref-type="bibr">61</xref>&#x02013;<xref rid="B64" ref-type="bibr">64</xref>]. Originally, Hall et al. detected that increased IFN production in nasal washes in children infected with influenza virus was associated with decreased shedding of virus [<xref rid="B65" ref-type="bibr">65</xref>]. Subsequent studies identified the high levels of IFN-I in breastfeeding children infected with influenza virus, providing support to the hypothesis that breastfeeding protects against respiratory viral infection [<xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>]. Additionally, a study of elderly subjects demonstrated that IFN-<italic>&#x003b1;</italic> production is decreased during influenza virus infection and suggested that this impairment can produce multiple defects in their innate and adaptive immune responses that could lead to increased severity [<xref rid="B68" ref-type="bibr">68</xref>]. Likewise, other studies have shown that pregnant women have an attenuated IFN-<italic>&#x003b1;</italic> response to influenza virus [<xref rid="B69" ref-type="bibr">69</xref>].</p><p>As mentioned previously, IFITM are a family of interferon-induced antiviral restriction factors with constitutive expressions in different cell types that are known to be induced by IFN-I. Recent evidence has shown that ISG IFITM3 is a potent antiviral factor in restricting influenza virus infection and a decrease in its expression results in a higher risk of hospitalization [<xref rid="B70" ref-type="bibr">70</xref>, <xref rid="B71" ref-type="bibr">71</xref>].</p></sec><sec id="sec2.1.2"><title>2.1.2. Respiratory Syncytial Virus (RSV)</title><p>RSV is a common virus that belongs to the <italic>Paramyxoviridae</italic> family. RSV is a negative-sense ssRNA virus that causes a wide range of symptoms and the severity can vary from mild to lethal disease [<xref rid="B59" ref-type="bibr">59</xref>]. RSV is especially severe in infants, the elderly, and immunocompromised individuals [<xref rid="B72" ref-type="bibr">72</xref>, <xref rid="B73" ref-type="bibr">73</xref>]. Despite years of research, RSV is the only major etiological agent of acute lower respiratory tract infection (ALRI) for which no vaccine or specific treatments are available.</p><p>Several PRRs are involved in RSV recognition, including TLRs (TLR-2, TLR-3, TLR-4, and TLR-7), RLRs (RIG-I and MDA5), and NLRs (NOD-2). IFN-I production during RSV infection is activated by different mechanisms (<xref ref-type="fig" rid="fig4">Figure 4</xref>). TLR-3 detects dsRNA during viral replication and signals through TRIF, which activates IFN-<italic>&#x003b1;</italic> production through NF-<italic>&#x003ba;</italic>B and IRF-3 pathway [<xref rid="B74" ref-type="bibr">74</xref>]. Other important PRRs for IFN-I production are RIG-I and MDA5 which subsequently link MAVS. This recruits TRAF2/6 and TRAF3 which leads to the activation of IRF-7 and IRF-3 through NF-<italic>&#x003ba;</italic>B [<xref rid="B75" ref-type="bibr">75</xref>]. Together, these IRFs stimulate ISRE sequences that promote IFN-I production [<xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B77" ref-type="bibr">77</xref>]. NLRs also play a role in activating the IFN-I pathway. NOD-2 can recognize RSV ssRNA, thus, mediating IRF-3 and NF-<italic>&#x003ba;</italic>B activation pathways and leading to the IFN-<italic>&#x003b2;</italic> production [<xref rid="B78" ref-type="bibr">78</xref>].</p><p>Although RSV can lead to IFN-I production through multiple pathways, it has been established that this virus in particular is a poor stimulator of IFN-I. Unlike other respiratory viruses, studies have shown a limited role for IFNs in response to RSV infection [<xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B80" ref-type="bibr">80</xref>]. Thereby, NS1 and NS2 (2 proteins encoded by RSV) appear to interact (and interfere) with multiple molecules of the IFN pathway (RIG-I, TRAF3, and IRF-3), which then interfere with IFN synthesis [<xref rid="B81" ref-type="bibr">81</xref>&#x02013;<xref rid="B84" ref-type="bibr">84</xref>] (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Studies of RSV NS1 and NS2 proteins have demonstrated that they are crucial for virus replication <italic>in vitro</italic>, however, through IFN-I antagonism, they contribute to adequate RSV replication <italic>in vivo</italic> (and <italic>in vitro</italic>) [<xref rid="B85" ref-type="bibr">85</xref>]. Using interference RNA that allowed the inhibition of NS1, the expression of IFN-<italic>&#x003b1;</italic> and IFN-<italic>&#x003b2;</italic> was augmented and this increase was associated with a reduction in viral titer [<xref rid="B86" ref-type="bibr">86</xref>]. On the other hand, NS2 has been shown to be the main IFN-I antagonist related to the STAT-2 pathway [<xref rid="B82" ref-type="bibr">82</xref>, <xref rid="B87" ref-type="bibr">87</xref>], thus, inhibiting IFN-<italic>&#x003b1;</italic> and IFN-<italic>&#x003b2;</italic> responses through JAK/STAT signaling [<xref rid="B82" ref-type="bibr">82</xref>, <xref rid="B88" ref-type="bibr">88</xref>].</p><p>One interesting study by Marr et al. showed that RSV-induced IFN-<italic>&#x003b1;</italic> expression by primary pDCs exposed to RSV is strongly correlated with age, observing higher IFN-<italic>&#x003b1;</italic> expression in healthy adults, followed by preschool children and little to no expression in healthy full-term infants [<xref rid="B89" ref-type="bibr">89</xref>]. This analysis of developmental innate immunity associated with poor IFN-I production during the first year of life suggests a role for IFN-I in RSV pathogenesis. Deficits in MAVS or RIG-I signaling events could explain this deficit. Furthermore, infants with severe bronchiolitis have less IFN-I levels when compared to those with moderate disease [<xref rid="B90" ref-type="bibr">90</xref>]. Taken together, these results suggest a critical role for IFN-I in RSV infection.</p></sec><sec id="sec2.1.3"><title>2.1.3. Human Metapneumovirus (hMPV)</title><p>hMPV is a member of the <italic>Paramyxoviridae</italic> family, genus <italic>Metapneumovirus</italic> [<xref rid="B91" ref-type="bibr">91</xref>]. Isolated in 2001 [<xref rid="B91" ref-type="bibr">91</xref>], hMPV is a nonsegmented negative-strand RNA virus [<xref rid="B92" ref-type="bibr">92</xref>] and has been associated with the upper and lower respiratory tract infections with symptoms ranging from colds to pneumonia. hMPV particularly affects children, the elderly, and immunocompromised individuals [<xref rid="B93" ref-type="bibr">93</xref>]. Worldwide, hMPV is recognized as the second most common cause of bronchiolitis and pneumonia in children under 5 years old [<xref rid="B94" ref-type="bibr">94</xref>]. Despite the fact that hMPV is a clinically relevant pathogen, no vaccine is currently available.</p><p>Similar to RSV, two major pathways for the secretion of IFN-I during hMPV infection have been described. Each pathway involves different types of PRRs, one utilizes RLRs and the other TLRs. The former is primarily activated by RIG-I and MDA5, whereas the latter involves TLR-3 and TLR-7. RIG-I- and MDA5-mediated signal transduction begins when viral RNA is sensed in the cytosol. This recognition leads to the activation of IRF-3 and IRF-7 through the MAVS pathway [<xref rid="B75" ref-type="bibr">75</xref>, <xref rid="B95" ref-type="bibr">95</xref>, <xref rid="B96" ref-type="bibr">96</xref>]. TLR-3 activates the IFN pathway through IRF-3 and TLR-7 via IRF-7.</p><p>It is worth noting that the vast majority of cells express IRF-7 only after the activation of IRF-3 (which is expressed constitutively and is activated essentially by the RIG-I/MAVS pathway) or in response to IFNs. Importantly, TLR-7 is the main PRR that participates in sensing hMPV by pDCs, whereas MDA5-MAVS is the major pathway mediating hMPV sensing in conventional DCs [<xref rid="B75" ref-type="bibr">75</xref>].</p><p>Similar to other respiratory viruses, evidence suggests that hMPV has mechanisms for evading IFN-I production through interference in TLR- and RLR-dependent surveillance pathways. Early studies published by Dinwiddie et al. showed that hMPV can inhibit the IFN-<italic>&#x003b1;</italic> pathway in A549 cells. Therefore, this virus abolished the IFN-<italic>&#x003b1;</italic> pathway and downstream ISG signaling through mechanisms that regulate STAT1 activation [<xref rid="B97" ref-type="bibr">97</xref>]. One study supporting this information found that hMPV suppressed IFN-I responses through mechanisms involving the regulation of STAT1, STAT2, JAK1, TYK2, and the surface expression of IFNAR1 [<xref rid="B98" ref-type="bibr">98</xref>]. hMPV proteins impair the activation of PPRs through several different mechanisms. hMPV M2-2 protein interferes with MyD88 adaptor, a critical component for the activation of proinflammatory genes. This protein also interacts with MAVS, altering the production of IFN-<italic>&#x003b2;</italic> and also prevents IRF-3 phosphorylation [<xref rid="B99" ref-type="bibr">99</xref>]. In addition, hMPV G protein alters the recognition by RIG-I thereby influencing the secretion of IFNs, and the small hydrophobic protein can inhibit NF-<italic>&#x003ba;</italic>B, which is an important component in the IFN pathway [<xref rid="B100" ref-type="bibr">100</xref>]. Finally, the hMPV phosphoprotein B1 interferes with RIG-I recognition [<xref rid="B75" ref-type="bibr">75</xref>].</p><p>Studies describing the role of IFN-I in hMPV infections in humans are very limited. One study has shown that IFN-<italic>&#x003b2;</italic> was induced after hMPV infection in children [<xref rid="B101" ref-type="bibr">101</xref>]. In addition, a deleterious effect of IFN-I was reported in a murine model, in which IFN-I contributed to disease pathogenesis due to increased inflammatory lung disease during infection [<xref rid="B102" ref-type="bibr">102</xref>].</p></sec><sec id="sec2.1.4"><title>2.1.4. Parainfluenza Viruses (PIVs)</title><p>PIVs are a group of nonenveloped, negative-sense, ssRNA viruses that belong to the <italic>Paramyxoviridae</italic> family. First isolated in the 1950s, PIVs are composed of five different (antigenic and genetic) types, PIV-1, PIV-2, PIV-3, and PIV-4 with two subtypes PIV-4a and PIV-4b [<xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B103" ref-type="bibr">103</xref>]. The virus was named <italic>Parainfluenza</italic> because it produces influenza-like disease and has a lipid envelope and hemagglutination and neuraminidase activities [<xref rid="B59" ref-type="bibr">59</xref>]. Worldwide, PIVs are important causes of upper and lower respiratory tract illnesses. Although PIV infections are generally self-limiting, some patients require hospitalization and the disease may lead to mortality, especially in children under the age of five years [<xref rid="B104" ref-type="bibr">104</xref>], the elderly, and the immunocompromised individuals.</p><p>All PIVs encode 6 universal proteins, N, P, M, F, HM, and L, and at least one additional protein from the P gene (C, V, D, W, and I), which is not essential for viral replication [<xref rid="B59" ref-type="bibr">59</xref>].</p><p>The innate immune response to PIV is not well-characterized, and little is known about the signaling pathways. Unlike other respiratory viruses, TLR signaling is not described but is thought to play a role in the IFN pathway activation during PIV infection. Regarding RLRs, a study showed that RIG-I is involved in IFN-I induction via IRF-3 after PIV-3 infection [<xref rid="B105" ref-type="bibr">105</xref>]. In addition, MDA5 has also been found to be activated by degraded products of RNase L from PIV [<xref rid="B106" ref-type="bibr">106</xref>].</p><p>This group of viruses is known to encode proteins that block innate immune responses to viral infections, allowing PIV replication. As mentioned above, pathogen RNA synthesis provides strong stimuli to mount an IFN immune response. PIV-1 and PIV-3 encode C proteins, while PIV-2 encodes a V protein. Both proteins, C and V, are involved in the blockade of IFN-I induction by preventing PKR activation [<xref rid="B107" ref-type="bibr">107</xref>&#x02013;<xref rid="B110" ref-type="bibr">110</xref>]. The viral strategy in the case of PIV-1 and PIV-3 is to avoid the IFN production. PIV-1 does not inhibit the IFN pathway, given that the synthesis of the viral RNA can activate IFN production. Rather, the viral C protein modulates its RNA production, preventing MDA5 activation [<xref rid="B109" ref-type="bibr">109</xref>, <xref rid="B111" ref-type="bibr">111</xref>]. This protein also interferes with STAT1, avoiding signaling through this pathway and thus IFN production [<xref rid="B112" ref-type="bibr">112</xref>]. The V protein of PIV-2 interferes with the IFN production in different ways. One of the mechanisms is the inhibition of MDA5 activation [<xref rid="B113" ref-type="bibr">113</xref>]. In addition, the highly conserved V protein Cys-rich domain has been shown to be both necessary and sufficient to limit the activation of the IFN-<italic>&#x003b2;</italic> promoter [<xref rid="B114" ref-type="bibr">114</xref>]. Finally, the V protein interferes with the IFN pathway by abolishing STAT2 signaling [<xref rid="B115" ref-type="bibr">115</xref>]. Interestingly, there is evidence that shows that this protein also regulates viral RNA production (as PIV C protein) [<xref rid="B116" ref-type="bibr">116</xref>].</p><p>Overall, little is known about IFN-I response after the PIV infection in human population studies. An early work detected IFN-I in patients with primary PIV infection [<xref rid="B65" ref-type="bibr">65</xref>]. <italic>In vitro</italic> experiments have shown that PIV-2 induced IFN-<italic>&#x003b1;</italic> by day 2 postinfection, PIV-3 by day 3, and that PIV-1 did not produce this molecule. IFN-<italic>&#x003b2;</italic> production was shown to be poor in all serotypes [<xref rid="B117" ref-type="bibr">117</xref>].</p></sec><sec id="sec2.1.5"><title>2.1.5. Human Rhinovirus (HRV)</title><p>HRV is a small, nonenveloped, positive-sense, ssRNA virus that belongs to the <italic>Picornaviridae</italic> family. The family is divided into three species: rhinovirus A, B, and C [<xref rid="B59" ref-type="bibr">59</xref>]. HRV is a ubiquitous seasonal microorganism and is the most frequent cause of common cold (causing more than 50% of upper respiratory tract infections in humans worldwide). Given that the viral genetic diversity is huge (&#x0003e;160 serotypes), recurrent infections with this virus are frequent. Although HRV infections are not life-threatening, they can be also detected in the lower airways where they can cause severe exacerbations in patients with asthma and chronic obstructive pulmonary disease [<xref rid="B118" ref-type="bibr">118</xref>, <xref rid="B119" ref-type="bibr">119</xref>].</p><p>Different PRRs are involved in HRV recognition, belonging to two different families of receptors: TLRs (TLR-2, 3, 7, and 8) and RLRs (RIG-I and MDA5). TLR-2 on the cell surface recognizes the virus capsid, even without viral replication. In addition, TLR-3, TLR-7, and TLR-8 localized in intracellular compartments are stimulated once the viral particle is internalized and the dsRNA/ssRNA is sensed [<xref rid="B120" ref-type="bibr">120</xref>]. The TLR stimulation leads to the activation of downstream signaling molecules that activate IRF-3, IRF-7, and NF-<italic>&#x003ba;</italic>B, triggering IFN-I secretion. The evidence regarding TLR-3 is somewhat unclear; while one study described an important role for this receptor in the host response against the HRV infection [<xref rid="B121" ref-type="bibr">121</xref>], others found no function for this PRR [<xref rid="B120" ref-type="bibr">120</xref>]. The HRV genome is also recognized by RIG-I and MDA5 (both localized in the cytosol) which can recognize ssRNA and dsRNA, respectively. The RLR stimulation leads to the activation of MAVS and the consequent activation of NF-<italic>&#x003ba;</italic>B and IRF, triggering the production of IFN-I in the airway cells [<xref rid="B120" ref-type="bibr">120</xref>, <xref rid="B122" ref-type="bibr">122</xref>, <xref rid="B123" ref-type="bibr">123</xref>]. Responses mediated by IFN-I <italic>in vivo</italic> are critical for the antiviral effects that limit HRV through the activation of NK cells [<xref rid="B124" ref-type="bibr">124</xref>].</p><p>Similar to other respiratory viruses, HRV seems to suppress IFN synthesis using multiple strategies. Even though IFN evasion mechanisms have been well-studied in other enteroviruses, the information for HRV is scarce. A study showed that the MAVS adaptor is cleaved by 2A and 3C proteases of HRV to stop IFN-I signal transduction [<xref rid="B125" ref-type="bibr">125</xref>]. Furthermore, the 3C proteases have been implicated in the cleavage of RIG-I altering IFN-I production [<xref rid="B126" ref-type="bibr">126</xref>]. Regarding TLRs, despite their crucial role in viral sensing, there is no evidence of TLR signaling evasion by HRV.</p><p>Different studies have attributed susceptibility to HRV infection to impaired IFN-I production that leads to a higher viral load [<xref rid="B127" ref-type="bibr">127</xref>, <xref rid="B128" ref-type="bibr">128</xref>]. Abnormal HRV-induced IFN in asthmatic patients was shown in peripheral blood mononuclear cells (PBMCs) for IFN-<italic>&#x003b1;</italic> and in primary human bronchial epithelial cells for IFN-<italic>&#x003b2;</italic> [<xref rid="B129" ref-type="bibr">129</xref>]. In addition, <italic>in vitro</italic> studies on epithelial cells showed that exogenous IFN-I led to reduced viral load [<xref rid="B130" ref-type="bibr">130</xref>]. Furthermore, this has been confirmed in epithelial cells from asthmatic patients, suggesting a role for IFN-I in limiting induced viral exacerbations [<xref rid="B131" ref-type="bibr">131</xref>]. However, other groups have found no differences between viral loads in asthmatic and control subjects during HRV infections [<xref rid="B132" ref-type="bibr">132</xref>]. Further investigation regarding the role of IFN-I during HRV infections needs to be completed.</p></sec><sec id="sec2.1.6"><title>2.1.6. Human Coronavirus (HCoV)</title><p>The family <italic>Coronaviridae</italic> contains two subfamilies, the <italic>Coronavirinae</italic> and the <italic>Torovirinae</italic>. They are a large group of positive-sense ssRNA genome viruses that can infect mammals and birds, causing a wide variety of diseases which can lead to frequent mutations and infections of new species. They have been divided into four genera, two of which, alphacoronavirus and betacoronavirus contain viruses infecting humans [<xref rid="B133" ref-type="bibr">133</xref>]. To date, four HCoVs (HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1) circulate globally in the human population and contribute to approximately one-third of common cold infections in humans [<xref rid="B134" ref-type="bibr">134</xref>]. HCoVs had been regarded as mildly pathogenic until the early 2000s. At that time, a new disease appeared in China, severe acute respiratory syndrome (SARS), which was quickly attributed to a new HCoV, the SARS-CoV. Following that outbreak, a related but different HCoV producing severe respiratory disease emerged, the Middle East respiratory syndrome coronavirus (MERS-CoV) [<xref rid="B135" ref-type="bibr">135</xref>]. Recently, a novel coronavirus (2019-nCoV) has emerged. The 2019-nCoV is causing an outbreak of unusual viral pneumonia in patients. It initially began in Wuhan, China and has spread to many countries worldwide [<xref rid="B136" ref-type="bibr">136</xref>].</p><p>Similar to previously described respiratory viruses, HCoVs are detected by TLR-3, TLR-7, RIG-I, and MDA5 [<xref rid="B137" ref-type="bibr">137</xref>]. TLR-3 activated by dsRNA stimulates TRIF that activates AP-1, NF-<italic>&#x003ba;</italic>B, IRF-3, and IRF-7 leading to the IFN production [<xref rid="B138" ref-type="bibr">138</xref>]. TLR-7 senses the ssRNA, leading to the activation of IRF-7 that also stimulates IFN secretion. RIG-I and MDA5 sense viral molecules in the cytoplasm, and their activation stimulates MAVS that induces the activation of IRF-3 and NF-<italic>&#x003ba;</italic>B to finally induce the IFN production [<xref rid="B139" ref-type="bibr">139</xref>].</p><p>Like other viruses, HCoVs use multiple mechanisms to evade IFN-I immune response. Evidence shows that different viral structures can inhibit or modulate the IFN production or activity. Thereby, NS protein-16 codified by SARS-CoV and HCoV-229E induces the methylation of viral mRNA cap structures that inhibit recognition by MDA5 [<xref rid="B140" ref-type="bibr">140</xref>, <xref rid="B141" ref-type="bibr">141</xref>]. The papain-like protease (PLPRO) domain of NS protein-3 of SARS-CoV and HCoV-NL63 inhibits the activation of IRF-3 [<xref rid="B142" ref-type="bibr">142</xref>, <xref rid="B143" ref-type="bibr">143</xref>]. Moreover, it was demonstrated that PLPRO encoded by MERS-CoV suppresses the induction of IFN-<italic>&#x003b2;</italic> through its deubiquitinating activity [<xref rid="B144" ref-type="bibr">144</xref>]. Protein M of SARS-CoV inhibits IFN-I production by impeding the formation of the TRAF3-TANK-TBK1/IKK<italic>&#x003f5;</italic> Complex [<xref rid="B145" ref-type="bibr">145</xref>]. ORF9b protein of SARS-CoV was shown to stimulate the degradation of MAVS and TRAF6, inhibiting the IFN-I pathway [<xref rid="B146" ref-type="bibr">146</xref>].</p><p>The IFN response seems to be contributing simultaneously to the protection against viruses and to the pathology induced by the same viral infections. Human pDCs demonstrate a robust IFN-I production after MERS-CoV infection, especially IFN-<italic>&#x003b1;</italic>, and this response is greater than that elicited by SARS-CoV [<xref rid="B147" ref-type="bibr">147</xref>]. High IFN-<italic>&#x003b1;</italic> and IFN-<italic>&#x003b3;</italic> have been associated with early SARS-CoV sequelae suggesting that unregulated IFN responses during acute-phase SARS-CoV may be deleterious for this infection [<xref rid="B148" ref-type="bibr">148</xref>].</p></sec></sec><sec id="sec2.2"><title>2.2. Reemerging Flaviviruses</title><p>The interplay of climatic and environmental changes as well as the growth of the human population and increased urbanization has triggered the reemergence and rapid spread of arthropod-borne viruses significant to public health. Yellow fever virus (YFV), dengue virus (DENV), West Nile virus (WNV), and Zika virus (ZIKV) are mosquito-borne flaviviruses that have reemerged in both hemispheres during recent decades. Other flaviviruses have emerged in specific regions of the world, including the Japanese Encephalitis virus (JEV) and Saint Louis encephalitis virus (SLEV), among others [<xref rid="B149" ref-type="bibr">149</xref>].</p><p>DENV, ZIKV, WNV, YFV, JEV, and SLEV belong to the flavivirus genus of the <italic>Flaviviridae</italic> family, which comprises a diverse group of enveloped, positive-sense, ssRNA viruses transmitted by blood-feeding mosquitoes, causing disease in humans [<xref rid="B150" ref-type="bibr">150</xref>]. The flavivirus RNA genome (11&#x02009;kb), which encodes a single open reading frame flanked by highly structured 5&#x02032; and 3&#x02032; untranslated regions (UTRs), is transcribed as a single polyprotein that is proteolytically processed by host and viral proteases to yield three structural proteins (C, prM, and E) and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5), the latter of which regulate viral translation, transcription, and replication as well as attenuate host antiviral responses [<xref rid="B150" ref-type="bibr">150</xref>].</p><p>In human cells, the host responds to flavivirus infection by recognizing viral nucleic acids through several distinct PRRs including RLRs, TLR-3, 7, and 8, NLRs, and the cyclic GMP-AMP synthase/stimulator of IFN genes- (cGAS-STING-) dependent sensing pathway [<xref rid="B151" ref-type="bibr">151</xref>, <xref rid="B152" ref-type="bibr">152</xref>] (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Among RLRs, RIG-I and MDA5 are involved in the detection of cytoplasmic dsRNA produced during viral replication [<xref rid="B153" ref-type="bibr">153</xref>]. The TLRs of importance during flavivirus infections are TLR-7 and TLR-8, which detect ssRNA as well as TLR-3, which identifies dsRNA produced during viral replication [<xref rid="B152" ref-type="bibr">152</xref>, <xref rid="B153" ref-type="bibr">153</xref>]. Recently, it has been reported that DENV infection activates TLR-9 signaling, which is known to recognize bacterial or viral DNA, by inducing mitochondrial DNA (mtDNA) release in human DCs [<xref rid="B154" ref-type="bibr">154</xref>]. The cGAS-STING pathway, which is known to sense DNA viruses, has also been recently involved in restricting flavivirus infections [<xref rid="B151" ref-type="bibr">151</xref>]. It has been reported that during DENV infection, mtDNA is spilled into the cytoplasm and this subsequently activates the cGAS/STING signaling pathway to stimulate the production of IFN-I [<xref rid="B155" ref-type="bibr">155</xref>]. pDCs are a predominant source of IFN-I during viral infection and TLR7 signaling in pDCs has been reported to promote the contact of these cells with infected cells in a specialized platform that enables viral RNA transfer and antiviral responses [<xref rid="B156" ref-type="bibr">156</xref>]. The binding of viral ssRNA and/or dsRNA to PRRs activates downstream signaling cascades, such as the activation of transcription factors IRF-3 and IRF-7 and NF-<italic>&#x003ba;</italic>B, that result in the induction of IFN-<italic>&#x003b1;</italic> and -<italic>&#x003b2;</italic>. Subsequent secretion of IFN-I and binding to IFNAR activates JAK/STAT dependent- and independent-signaling cascades that result in the transcription of hundreds of ISGs, which encode proteins that inhibit flavivirus replication and spread [<xref rid="B151" ref-type="bibr">151</xref>, <xref rid="B153" ref-type="bibr">153</xref>, <xref rid="B157" ref-type="bibr">157</xref>].</p><p>To facilitate propagation, flaviviruses, like other viruses, have evolved specific strategies involving one or more viral nonstructural proteins to either prevent IFN induction or to inhibit IFN signaling. The inhibition of IFN-I induction is achieved by either sequestration or modification of viral RNA and inhibition of PRRs [<xref rid="B151" ref-type="bibr">151</xref>]. In addition, several flavivirus nonstructural proteins such as NS2A, NS2B-NS3, NS4B, and NS5 have been shown to interfere with IFN signaling pathways through different mechanisms depending on the virus [<xref rid="B152" ref-type="bibr">152</xref>, <xref rid="B158" ref-type="bibr">158</xref>, <xref rid="B159" ref-type="bibr">159</xref>] (<xref ref-type="fig" rid="fig6">Figure 6</xref>). Recently, subgenomic flavivirus RNA (sfRNA), a nongene product encoded in 3&#x02032;UTR generated by incomplete degradation of viral RNA by a cellular 5&#x02032;-3&#x02032; exoribonuclease, has been proposed to play a modulatory role in the host antiviral response in mammalian cells by antagonizing IFN-I, as well as displaying viral interference in insect cells [<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B160" ref-type="bibr">160</xref>&#x02013;<xref rid="B162" ref-type="bibr">162</xref>].</p><p>The protective role of IFN-I against flaviviruses has been extensively demonstrated in mice since IFN-I signaling-deficient mice are highly susceptible to infection by DENV, ZIKV, and WNV [<xref rid="B163" ref-type="bibr">163</xref>&#x02013;<xref rid="B166" ref-type="bibr">166</xref>]. The reported effects of IFN-I in flavivirus infections in human cells and subjects are discussed in the following sections.</p><sec id="sec2.2.1"><title>2.2.1. Dengue Virus (DENV)</title><p>DENV is an acute febrile disease caused by four distinct antigenically related DENV serotypes (DENV-1, -2, -3, and -4) that are transmitted to humans by the bite of <italic>Aedes</italic> spp. mosquitoes, mainly <italic>Aedes aegypti</italic> [<xref rid="B167" ref-type="bibr">167</xref>]. DENV infects an estimated 390 million people every year of which 96 million have apparent DENV infections, with different levels of disease severity [<xref rid="B168" ref-type="bibr">168</xref>]. The clinical manifestations of dengue can range from mild febrile illness with myalgia and rash (formerly known as dengue fever (DF)) to severe forms of disease, characterized by plasma leakage and hemorrhage (dengue hemorrhagic fever (DHF)) leading to potentially life-threatening hypovolemic shock [<xref rid="B169" ref-type="bibr">169</xref>]. At present, several DENV vaccines are under development, including one that has been registered in several countries with high endemicity due to the limited efficacy in na&#x000ef;ve individuals and against all four DENV serotypes [<xref rid="B170" ref-type="bibr">170</xref>].</p><p>DENV has been reported to trigger a robust IFN-I response, which has been shown to be important in controlling DENV infection [<xref rid="B171" ref-type="bibr">171</xref>]. IFN-I has been reported to inhibit DENV infection in a variety of human cells, including hepatoma, fibroblasts, and myeloid cells [<xref rid="B172" ref-type="bibr">172</xref>, <xref rid="B173" ref-type="bibr">173</xref>]. RIG-I and MDA5 sensing of DENV has been critical in the immune response [<xref rid="B39" ref-type="bibr">39</xref>], as knockdown of RIG-I and MDA5 in Huh7 cells resulted in increased DENV replication [<xref rid="B174" ref-type="bibr">174</xref>]. In addition to TLR-3, 7, and 8 [<xref rid="B151" ref-type="bibr">151</xref>], DENV has been reported to activate and upregulate the expression of TLR-2 and 6 in human PBMCs [<xref rid="B175" ref-type="bibr">175</xref>]. NLRs have also been shown to be activated in DENV and WNV infections leading to the formation of the inflammasome complex with subsequent production of inflammatory cytokines of the IL-1<italic>&#x003b2;</italic> family [<xref rid="B176" ref-type="bibr">176</xref>]. DENV sensing by PRRs results in the secretion of IFN-I which triggers the JAK/STAT pathway leading to the production of ISGs with diverse antiviral properties [<xref rid="B151" ref-type="bibr">151</xref>].</p><p>DENV nonstructural proteins have been involved in the downregulation of the IFN pathway in humans, targeting important signaling molecules downstream of PRRs, resulting in the inhibition of IFN-regulated gene expression [<xref rid="B177" ref-type="bibr">177</xref>]. NS4B in combination with NS2A and NS4A have been reported to block IFN-I signaling by decreasing STAT1 phosphorylation in human A549 cells [<xref rid="B178" ref-type="bibr">178</xref>]. Furthermore, the DENV NS2B-NS3 protease complex has been involved in the cleavage of the human adaptor molecule STING or MITA, inhibiting IFN-I production [<xref rid="B179" ref-type="bibr">179</xref>, <xref rid="B180" ref-type="bibr">180</xref>]. Interestingly, DENV cleaves STING in humans but not in nonhuman primates that may serve as its sustaining reservoir in nature [<xref rid="B181" ref-type="bibr">181</xref>]. In addition, the DENV NS2B-NS3 protease interacts with the cellular I<italic>&#x003ba;</italic>B kinase, an important kinase involved in the IFN-I induction, disrupting RIG-I signaling and inhibiting the IFN production [<xref rid="B182" ref-type="bibr">182</xref>]. The DENV polymerase NS5 has also been reported as a potent and specific IFN-I antagonist, due to its binding to human STAT2 for ubiquitin-mediated proteasomal degradation [<xref rid="B183" ref-type="bibr">183</xref>, <xref rid="B184" ref-type="bibr">184</xref>]. The ability of DENV NS5 to bind and degrade human but not mouse STAT2 may be the major reason behind DENV's efficient replication in human but not in wild-type mouse cells [<xref rid="B185" ref-type="bibr">185</xref>]. Recently, increased virulence of different type 1 DENV isolates has been associated with a higher capacity of NS proteins to suppress IFN signaling [<xref rid="B186" ref-type="bibr">186</xref>]. Likewise, sfRNA of DENV strains that are associated with greater epidemic potential prevents the ubiquitination-dependent activation of RIG-I by binding to the ubiquitin ligase tripartite motif protein 25 (TRIM25), subverting the RIG-I pathway, and consequently impairing IFN-I induction [<xref rid="B162" ref-type="bibr">162</xref>].</p><p>The viral control and immune regulation exerted by IFN-I in dengue patients and human cells infected with DENV have been studied in several reports [<xref rid="B172" ref-type="bibr">172</xref>, <xref rid="B173" ref-type="bibr">173</xref>, <xref rid="B187" ref-type="bibr">187</xref>&#x02013;<xref rid="B189" ref-type="bibr">189</xref>]. Even though a strong IFN-I response has been described in dengue patients, the association of this response with disease severity is controversial [<xref rid="B188" ref-type="bibr">188</xref>, <xref rid="B190" ref-type="bibr">190</xref>&#x02013;<xref rid="B192" ref-type="bibr">192</xref>]. While some studies reported similar serum levels of IFN-<italic>&#x003b1;</italic> or IFN-<italic>&#x003b2;</italic> in DF and DHF in Thai and Mexican patients [<xref rid="B188" ref-type="bibr">188</xref>, <xref rid="B191" ref-type="bibr">191</xref>], several other reports from Brazil, Mexico, Colombia, Taiwan, India, and Thailand showed higher levels of IFN-<italic>&#x003b1;</italic> in patients with milder dengue disease [<xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B190" ref-type="bibr">190</xref>, <xref rid="B193" ref-type="bibr">193</xref>&#x02013;<xref rid="B196" ref-type="bibr">196</xref>], suggesting that a robust production of IFN-<italic>&#x003b1;</italic> may be correlated with a better clinical condition with respect to dengue infection and disease progression. Conversely, a recent study from Paraguay reported higher levels of IFN-<italic>&#x003b2;</italic> in severe <italic>vs.</italic> nonsevere dengue children [<xref rid="B197" ref-type="bibr">197</xref>]. Similarly, a study from Northeast Brazil described higher levels of IFN-<italic>&#x003b2;</italic> in primary DHF patients compared to those with primary DF [<xref rid="B198" ref-type="bibr">198</xref>]. Considering the preexisting immunity of patients to DENV, several reports described higher levels of IFN-<italic>&#x003b1;</italic> in patients undergoing primary infection compared to those with secondary DENV infections [<xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B190" ref-type="bibr">190</xref>, <xref rid="B192" ref-type="bibr">192</xref>, <xref rid="B195" ref-type="bibr">195</xref>], while other studies observed a similar expression of IFN-<italic>&#x003b1;</italic> levels in both types of infections [<xref rid="B197" ref-type="bibr">197</xref>, <xref rid="B198" ref-type="bibr">198</xref>]. Furthermore, different serum levels of IFN-<italic>&#x003b1;</italic> and IFN-<italic>&#x003b2;</italic> have been reported in DENV-infected patients [<xref rid="B192" ref-type="bibr">192</xref>], probably due to the differential kinetics of IFN-I induction during DENV infection of human cells [<xref rid="B199" ref-type="bibr">199</xref>, <xref rid="B200" ref-type="bibr">200</xref>].</p></sec><sec id="sec2.2.2"><title>2.2.2. Zika Virus (ZIKV)</title><p>ZIKV is a newly emerging flavivirus transmitted to humans by <italic>Aedes</italic> spp. mosquitoes, including <italic>Aedes aegypti</italic> [<xref rid="B201" ref-type="bibr">201</xref>]. Since the first human ZIKV infection was reported in Uganda in 1964 [<xref rid="B202" ref-type="bibr">202</xref>], human ZIKV infections had remained sporadic and limited to small-scale epidemics in Africa and Southeast Asia for decades [<xref rid="B203" ref-type="bibr">203</xref>, <xref rid="B204" ref-type="bibr">204</xref>], until 2007, when a large outbreak of Zika fever was reported on Yap Island (Micronesia) [<xref rid="B205" ref-type="bibr">205</xref>]. Over the next seven years, outbreaks were reported in other Pacific Islands [<xref rid="B206" ref-type="bibr">206</xref>]. In 2015, the largest outbreak of ZIKV ever reported began in Brazil, with a rapid expansion of the virus in South and Central America [<xref rid="B207" ref-type="bibr">207</xref>&#x02013;<xref rid="B209" ref-type="bibr">209</xref>]. Typically, ZIKV infections can be asymptomatic or manifested as a self-limiting febrile illness characterized by rash, headache, conjunctivitis, arthralgia, and myalgia [<xref rid="B204" ref-type="bibr">204</xref>&#x02013;<xref rid="B207" ref-type="bibr">207</xref>, <xref rid="B209" ref-type="bibr">209</xref>]. However, recent outbreaks in the South Pacific and Latin America reported severe neurological complications, including Guillain-Barr&#x000e9; syndrome (GBS) in adults and microcephaly in newborns [<xref rid="B210" ref-type="bibr">210</xref>&#x02013;<xref rid="B212" ref-type="bibr">212</xref>]. ZIKV has been shown to cross the placental barrier, disrupting brain development [<xref rid="B213" ref-type="bibr">213</xref>]. Recently, ZIKV spread by sexual contact has also been documented [<xref rid="B214" ref-type="bibr">214</xref>]. At present, there is an urgent need for vaccines and therapeutics to combat ZIKV.</p><p>The induction of antiviral immune responses after ZIKV infection of human cells has been reported in several studies [<xref rid="B215" ref-type="bibr">215</xref>&#x02013;<xref rid="B219" ref-type="bibr">219</xref>]. The innate immune response after ZIKV infection of skin cells and endometrial stromal cells was characterized by a strongly enhanced IFN-<italic>&#x003b2;</italic> gene expression and the induction of ISGs, including OAS, ISG15, and MX1 [<xref rid="B215" ref-type="bibr">215</xref>, <xref rid="B216" ref-type="bibr">216</xref>]. Moreover, the transcription of PRRs such as TLR-3, RIG-I, and MDA5 has been reported to be induced upon ZIKV infection of human skin cells [<xref rid="B215" ref-type="bibr">215</xref>]. Similar to DENV, NLR (inflammasome) activation has also been reported in ZIKV infection of monocytes [<xref rid="B220" ref-type="bibr">220</xref>]. Elevated secretion of IFN-<italic>&#x003b2;</italic> was also reported in human lung epithelial cells, which may delay the apoptosis exerted by ZIKV infection [<xref rid="B217" ref-type="bibr">217</xref>]. Schwann cells (SC), which play a central role in peripheral nerve disease and can be the target for damage in GBS, were susceptible to infection with ZIKV and YFV, but not DENV, and ZIKV infection of SC induced expression of IL-6, IFN-<italic>&#x003b2;</italic>, IFN-<italic>&#x003bb;</italic>, IFIT-1, TNF-<italic>&#x003b1;</italic> and IL-23A mRNAs, and negative regulators of IFN signaling [<xref rid="B218" ref-type="bibr">218</xref>]. Furthermore, ZIKV infection of human DCs produced a strong induction of the RLR signaling pathway at the RNA transcription level, but ZIKV was able to block IFN-I signaling by targeting STAT1 and STAT2 phosphorylation [<xref rid="B219" ref-type="bibr">219</xref>].</p><p>The mechanisms by which ZIKV antagonizes IFN-I induction and signaling in human cells, which might contribute to the broad cellular tropism and persistence of ZIKV, have been reported in recent studies [<xref rid="B159" ref-type="bibr">159</xref>, <xref rid="B221" ref-type="bibr">221</xref>&#x02013;<xref rid="B223" ref-type="bibr">223</xref>]. ZIKV NS1 has been reported to interact with RIG-I and downregulate the antiviral signaling pathway [<xref rid="B224" ref-type="bibr">224</xref>]. In addition, Donald et al. reported that sfRNA in ZIKV acts as the antagonist of RIG-I-dependent IFN production [<xref rid="B161" ref-type="bibr">161</xref>]. Furthermore, ZIKV NS4A impairs RLR-MAVS interaction and subsequent induction of antiviral immune responses by binding to the caspase activation and recruitment domain (CARD) of MAVS and thus blocking its accessibility by RLRs [<xref rid="B225" ref-type="bibr">225</xref>, <xref rid="B226" ref-type="bibr">226</xref>]. ZIKV NS3 has been shown to antagonize antiviral gene induction by RIG-I and MDA-5 by binding to and sequestering the scaffold proteins 14-3-3<italic>&#x003b5;</italic>/<italic>&#x003b7;</italic> [<xref rid="B227" ref-type="bibr">227</xref>]. ZIKV NS1, NS2A, NS2B, and NS4B have been shown to interact directly with TANK-binding kinase 1 (TBK1), required for the phosphorylation of IRF-3 [<xref rid="B159" ref-type="bibr">159</xref>, <xref rid="B228" ref-type="bibr">228</xref>]. In addition, the NS2B-NS3 protease complex of ZIKV has been reported to impair the JAK/STAT signaling pathway by promoting the degradation of JAK1 and to block RLR-triggered apoptotic cell death. Furthermore, the cooperation between NS1, NS4B, and NS2B-NS3 further attenuates antiviral immunity, by impairing IFN-induced degradation of NS2B-NS3 [<xref rid="B159" ref-type="bibr">159</xref>]. Similar to DENV, ZIKV NS5 has been reported as a potent antagonist of IFN-I responses by targeting human but not mouse STAT2 for ubiquitin-mediated proteasomal degradation [<xref rid="B183" ref-type="bibr">183</xref>, <xref rid="B185" ref-type="bibr">185</xref>, <xref rid="B221" ref-type="bibr">221</xref>, <xref rid="B222" ref-type="bibr">222</xref>]. However, unlike DENV, ZIKV NS5 did not require the E3 ubiquitin ligase UBR4 interaction, exhibiting a virus-specific mechanism [<xref rid="B222" ref-type="bibr">222</xref>]. In addition, ZIKV NS1 and NS5 interact with NLRP3 and promote assembly of the NLRP3 inflammasome complex resulting in IL-1<italic>&#x003b2;</italic> production and stimulated ZIKV replication [<xref rid="B229" ref-type="bibr">229</xref>&#x02013;<xref rid="B231" ref-type="bibr">231</xref>].</p><p>Recently, ZIKV microcephaly in newborns has been associated with rs3775291 single nucleotide polymorphisms (SNP) at TLR-3 reducing the activation of NF-<italic>&#x003ba;</italic>B and thus decreasing IFN-I responses in mothers infected by ZIKV during pregnancy [<xref rid="B232" ref-type="bibr">232</xref>]. Furthermore, comparative analysis of African and Asian lineage-derived ZIKV strains revealed pronounced differences in the activation of innate immune signaling and inhibition of viral replication which may be related to differential pathogenesis [<xref rid="B233" ref-type="bibr">233</xref>]. Compared to the replication of other ZIKV strains, the replication of Asian ZIKV strain Brazil Fortaleza 2015, which was associated with neurodevelopmental disorders, was less sensitive to the antiviral actions of IFN-I, while infection with this strain induced weaker and delayed innate immune responses <italic>in vitro</italic>.</p></sec><sec id="sec2.2.3"><title>2.2.3. West Nile Virus (WNV)</title><p>WNV is a mosquito-borne flavivirus of international health concern. WNV is maintained in a natural cycle involving primarily <italic>Culex</italic> spp. mosquitoes and avian hosts, but it also infects humans, horses, and other animals [<xref rid="B234" ref-type="bibr">234</xref>]. WNV is endemic in parts of Asia, Africa, and Europe, and it was first introduced to North America in 1999 [<xref rid="B235" ref-type="bibr">235</xref>]. Since then, the virus has spread rapidly throughout the United States and has been associated with over 21,000 encephalitis/meningitis cases and 1,800 deaths [<xref rid="B236" ref-type="bibr">236</xref>]. However, no effective prophylactic or therapeutic measures are currently available [<xref rid="B234" ref-type="bibr">234</xref>]. Infection with WNV in humans remains asymptomatic and/or subclinical in most cases and causes symptoms in 20-30% of WNV-infected individuals. The clinical manifestations range from a mild flu-like illness to more severe neuroinvasive disease, associated with significant morbidity and mortality [<xref rid="B234" ref-type="bibr">234</xref>, <xref rid="B237" ref-type="bibr">237</xref>].</p><p>The protective role of IFN-I after WNV infection has been extensively demonstrated in mice by the marked increase in mortality in infected IFN-<italic>&#x003b1;</italic>/<italic>&#x003b2;</italic> receptor-deficient mice [<xref rid="B166" ref-type="bibr">166</xref>]. The studies of IFN-I protection after WNV infection are more limited in human cells. Recently, the PI3K, which play an important role in the induction of IFN-I antiviral responses, have been shown to control West Nile virus infection in human and mouse cells [<xref rid="B238" ref-type="bibr">238</xref>]. The presence of PI3K inhibitors blocked the translocation of IRF-7 from the cytosol to the nuclei, reduced IFN-I mRNA and protein expression, and decreased the secretion of IFN-I. Recently, in human monocyte-derived DCs early activation of RLR or IFN-I signaling could block WNV infection [<xref rid="B239" ref-type="bibr">239</xref>]. Furthermore, in human glioblastoma cells, WNV replication was regulated by early IFN-<italic>&#x003b2;</italic> induction, while in human neuroblastoma cells, a delayed IFN-<italic>&#x003b2;</italic> response, due to the concealing of viral dsRNA in intracellular membranes, resulted in efficient WNV replication [<xref rid="B240" ref-type="bibr">240</xref>]. In addition, differences in replication and induction of IFN-I responses between attenuated and virulent WNV strains in human monocyte-derived DCs accounted for the differing virulence in humans [<xref rid="B241" ref-type="bibr">241</xref>].</p><p>WNV NS4B and NS5 have been reported as important IFN-I antagonists [<xref rid="B178" ref-type="bibr">178</xref>, <xref rid="B242" ref-type="bibr">242</xref>]. Similar to DENV, NS4B inhibited the JAK/STAT signaling pathway by decreasing STAT1 phosphorylation [<xref rid="B178" ref-type="bibr">178</xref>]. The NS5 of WNV strain NY99 blocked IFN-I responses by inhibition of STAT1 phosphorylation [<xref rid="B242" ref-type="bibr">242</xref>]. The helicase domain of WNV NS3 has been reported to inhibit IFN-I signaling and differences in virulence between the NY99 and NSW2011 strains of WNV have been attributed to differential inhibition of the helicase domain of NS3 [<xref rid="B243" ref-type="bibr">243</xref>]. Furthermore, WNV NS1 has been demonstrated to antagonize IFN-<italic>&#x003b2;</italic> production by suppressing RLR activation [<xref rid="B244" ref-type="bibr">244</xref>].</p><p>The human studies evaluating the IFN-I response to WNV infection and its relationship with disease severity are scarce [<xref rid="B245" ref-type="bibr">245</xref>]. Recently, a study with WNV-infected blood donors revealed that symptom development was positively correlated with early, potent IFN-<italic>&#x003b1;</italic> production [<xref rid="B246" ref-type="bibr">246</xref>]. However, this robust IFN-I response was associated with an inability to maintain continuing immunity during WNV infection, suggesting that an increased initial inflammation may negatively impact the adaptive-T cell responses.</p></sec><sec id="sec2.2.4"><title>2.2.4. Yellow Fever Virus (YFV)</title><p>YFV, the causative agent of yellow fever, is endemic in the tropical regions of Africa and the Americas and is transmitted to humans and nonhuman primates by <italic>Aedes</italic> spp. mosquitoes, including <italic>Aedes aegypti</italic> [<xref rid="B150" ref-type="bibr">150</xref>]. Despite the presence of an effective vaccine YF17D [<xref rid="B247" ref-type="bibr">247</xref>], YFV infection has remained a public health concern in restricted parts of the world, with an incidence of 200,000 cases per year, leading to about 30,000 deaths [<xref rid="B150" ref-type="bibr">150</xref>]. In humans, YFV infection produces variable clinical manifestations, ranging from asymptomatic infection to mild febrile illness and to a possibly fatal disease characterized by severe hepatitis, renal failure, hemorrhage, and shock [<xref rid="B248" ref-type="bibr">248</xref>].</p><p>IFN-I induction has been shown in YF17D-vaccinated human subjects [<xref rid="B249" ref-type="bibr">249</xref>, <xref rid="B250" ref-type="bibr">250</xref>] and combined IFN-I and -III are crucial for controlling YFV infection in mice [<xref rid="B251" ref-type="bibr">251</xref>]. Recently, it has been reported that cells infected with YFV stimulated pDCs to produce IFN-I in a TLR7- and cell contact-dependent manner. Cells producing immature particles as well as capsid-free viral RNA participated in pDC stimulation [<xref rid="B252" ref-type="bibr">252</xref>].</p><p>NS4B and NS5 of YFV have been reported as IFN-I antagonists. YFV NS4B interacts with STING, blocking IFN-I stimulation [<xref rid="B253" ref-type="bibr">253</xref>]. Moreover, YFV NS5 inhibits IFN-I signaling via binding and inhibition of STAT2 following IFN-I-induced phosphorylation of STAT1 and requires K6 ubiquitination [<xref rid="B254" ref-type="bibr">254</xref>]. This IFN-induced ubiquitination of YFV NS5 is absent in murine cells resulting in a lack of binding of YFV NS5 and human STAT2 in murine cells, highlighting the importance of YFV ubiquitination in determining the host cell range for YFV [<xref rid="B255" ref-type="bibr">255</xref>, <xref rid="B256" ref-type="bibr">256</xref>].</p><p>Gene expression microarray analysis in PBMCs from YF17D-vaccinated humans revealed an immune profile related to antiviral IFN-I responses [<xref rid="B249" ref-type="bibr">249</xref>], suggesting that IFN-I may play a role in effective protection in vaccinated subjects. Moreover, human DCs infected with vaccine virus YF17D and a chimeric YF17D/DENV2 produced higher levels of IFN-<italic>&#x003b1;</italic> than those infected with DENV-2 [<xref rid="B193" ref-type="bibr">193</xref>], also indicating an induction of IFN-I production by YF17D vaccine virus. Recently, it has been reported that an inherited IFNAR1 deficiency resulted in life-threatening complications of vaccination with the YF vaccine in a previously healthy individual [<xref rid="B257" ref-type="bibr">257</xref>].</p><p>The dual role of IFNs in protection against and pathogenesis of viral infections was suggested using a gene overexpression screening approach in human cells [<xref rid="B258" ref-type="bibr">258</xref>]. In this study, several ISGs (ADAR, FAM46C, LY6E, and MCOLN2) were identified as inhibitors of YFV, WNV, HCV, HIV, chikungunya virus (CHIKV), and Venezuelan equine encephalitis virus (VEEV) replication. Conversely, several ISGs were found to enhance the replication of YFV, WNV, CHIKV, and VEEV, highlighting the complexity of the IFN-I system.</p></sec><sec id="sec2.2.5"><title>2.2.5. Japanese Encephalitis Virus (JEV)</title><p>JEV is a mosquito-borne flavivirus causing severe neurologic disease, characterized by flaccid paralysis, meningitis, and encephalitis [<xref rid="B150" ref-type="bibr">150</xref>]. JEV is transmitted to humans by <italic>Culex</italic> spp. mosquitoes and is maintained in a zoonotic cycle involving pigs as the major reservoir and water birds as carriers [<xref rid="B259" ref-type="bibr">259</xref>]. JEV infections primarily occur in Asia, where 35,000-50,000 cases and 10,000-15,000 deaths are reported annually [<xref rid="B150" ref-type="bibr">150</xref>].</p><p>JEV infection of human microglial cells has been shown to induce an innate immune response characterized by the production of IFN-<italic>&#x003b2;</italic> via IRF-3 activation and phosphorylation. The overexpression of the ubiquitin ligase TRIM21, which interacts with IRF-3 negatively, regulated this innate immune response by targeting IRF-3-mediated IFN-<italic>&#x003b2;</italic> production [<xref rid="B260" ref-type="bibr">260</xref>]. Recently, neuronal transcriptomic responses to JEV infection showed the upregulation of RIG-I and MDA5, suggesting that neuronal cells play a significant role in immunity against JEV [<xref rid="B261" ref-type="bibr">261</xref>].</p><p>The antagonist activity of JEV NS5 in IFN-I responses has been reported. The JEV NS5 has been shown to block IFN-I signaling by reducing the phosphorylation of TYK2 and STAT1 and subsequently inhibiting STAT1 nuclear localization [<xref rid="B262" ref-type="bibr">262</xref>, <xref rid="B263" ref-type="bibr">263</xref>]. Furthermore, JEV NS5 inhibited the nuclear translocation of IRF-3 and NF-<italic>&#x003ba;</italic>B by binding to nuclear transport proteins KPNA3 and KPNA4, impairing the production of IFN-<italic>&#x003b2;</italic> [<xref rid="B264" ref-type="bibr">264</xref>].</p><p>The IFN-I response during JEV infection in humans has not been fully characterized. A study of proinflammatory profile in humans with JE revealed that nonsurviving patients with JE showed higher levels of IFN-<italic>&#x003b1;</italic> in cerebrospinal fluid than those from survivors during the first days of illness, suggesting that it may be associated with higher viral load [<xref rid="B265" ref-type="bibr">265</xref>].</p></sec><sec id="sec2.2.6"><title>2.2.6. Saint Louis Encephalitis Virus (SLEV)</title><p>SLEV is a mosquito-borne flavivirus transmitted to humans by <italic>Culex</italic> spp. mosquitoes, first discovered in 1933 when a large epidemic of encephalitis occurred in St. Louis, Missouri [<xref rid="B150" ref-type="bibr">150</xref>]. SLEV distribution ranges from Canada to Argentina and across North America [<xref rid="B266" ref-type="bibr">266</xref>]. SLEV produces a mild febrile disease in children and young adults and severe neurologic manifestations that are more frequently observed in elderly and immunocompromised patients.</p><p>Information about IFN-I induction and signaling as well as IFN-I evasion by viral proteins after SLEV infection in human cells is currently very limited. Former studies have shown a variable effect of human IFN in primary human fetal glial cell cultures [<xref rid="B267" ref-type="bibr">267</xref>]. Similar to DENV, ZIKV, and WNV, the protective role of IFN-I against SLEV has been demonstrated in mice since IFN signaling-deficient mice are more susceptible to infection by SLEV than in immunocompetent mice [<xref rid="B268" ref-type="bibr">268</xref>]. Specifically, the protective effects of IFN-<italic>&#x003b1;</italic> have been shown in mice by reducing mortality from SLEV delivered by the aerosol and subcutaneous routes [<xref rid="B269" ref-type="bibr">269</xref>].</p></sec></sec></sec><sec id="sec3"><title>3. IFN-I Therapy and Pathogenic Effects</title><p>IFNs are increasingly recognized as therapeutic agents. Three different types of human IFN (<italic>&#x003b1;</italic>, <italic>&#x003b2;</italic>, and <italic>&#x003b3;</italic>) are widely used for the treatment of various diseases due to their immunomodulating, antiviral, and antiproliferative properties [<xref rid="B270" ref-type="bibr">270</xref>, <xref rid="B271" ref-type="bibr">271</xref>]. However, the optimal dose and duration of IFNs as therapeutic agents have not been established [<xref rid="B272" ref-type="bibr">272</xref>]. This is important since IFNs administered in pharmacological doses produce considerable toxicity that is dose-related and that may require cessation of therapy. Common side effects due to IFN-<italic>&#x003b1;</italic> include flu-like symptoms (fatigue, fever, myalgias, and headaches), pulmonary toxicity, gastrointestinal symptoms, neurotoxicity, and depression [<xref rid="B273" ref-type="bibr">273</xref>&#x02013;<xref rid="B275" ref-type="bibr">275</xref>]. Lethal toxicity associated with IFN-<italic>&#x003b1;</italic> regimen is rare and severe toxicity due to IFN-<italic>&#x003b1;</italic> is manageable if recognized expeditiously [<xref rid="B276" ref-type="bibr">276</xref>, <xref rid="B277" ref-type="bibr">277</xref>].</p><p>The role of endogenous and/or exogenous IFN in the viral infections discussed in this review has been partially explored in human cell lines, animal models, and clinical studies. Depending on the virus, the model used, and the time of infection, IFNs can be either beneficial or deleterious (<xref rid="tab1" ref-type="table">Table 1</xref>).</p><p>Regarding influenza disease, a pathogenic role for endogenous IFN-I has been suggested in children with influenza infection, in whom clinical disease severity was associated with an increased level of IFN-<italic>&#x003b1;</italic> [<xref rid="B278" ref-type="bibr">278</xref>]. In agreement with this, another study associated severity with epithelial cell damage mediated by TNF-<italic>&#x003b1;</italic> related apoptosis-inducing ligand (TRAIL) [<xref rid="B279" ref-type="bibr">279</xref>] whose expression can be induced by IFN-<italic>&#x003b1;</italic> and IFN-<italic>&#x003b2;</italic> [<xref rid="B280" ref-type="bibr">280</xref>]. Moreover, recent evidence showed that the upregulation of TRAIL expression by monocytes and death receptor 5 (DR5) expression by epithelial cells contributed to the pathogenic mechanism induced by IFN-<italic>&#x003b1;</italic>/<italic>&#x003b2;</italic>, where enhanced production of this molecule can contribute to immunopathology in severe infections [<xref rid="B64" ref-type="bibr">64</xref>].</p><p>Concerning RSV infections, intranasal administration of recombinant IFN to infants with RSV infection has shown to be safe and to decrease the duration of symptoms without affecting the time of viral shedding [<xref rid="B281" ref-type="bibr">281</xref>&#x02013;<xref rid="B283" ref-type="bibr">283</xref>].</p><p>During the 1980s, different studies showed that the use of high doses of intranasal IFN-<italic>&#x003b1;</italic> were useful in the prevention of HRV infection [<xref rid="B284" ref-type="bibr">284</xref>&#x02013;<xref rid="B286" ref-type="bibr">286</xref>]. However, it was also found that the use of this molecule (in high doses) was associated with the occurrence of undesirable effects, as described above. Although low-dose treatment has proven to be better tolerated, it has been ineffective as postexposure prophylaxis [<xref rid="B287" ref-type="bibr">287</xref>]. Further investigation regarding the role of IFN-I during HRV infections needs to be completed.</p><p>Dual effects of IFN-I have been observed in HCoV infections, as mentioned previously. A series of case studies describing moderate and severe MERS-CoV infections in adults found that moderate cases had no IFN-<italic>&#x003b1;</italic> response, while severe cases had variable levels of IFN-<italic>&#x003b1;</italic> [<xref rid="B288" ref-type="bibr">288</xref>]. However, other studies have shown that MERS-CoV and SARS-CoV patients improved with IFN-<italic>&#x003b1;</italic> therapy [<xref rid="B289" ref-type="bibr">289</xref>, <xref rid="B290" ref-type="bibr">290</xref>].</p><p>Regarding DENV infections, the studies evaluating the association of IFN-I response with disease severity in humans have yielded mixed results [<xref rid="B188" ref-type="bibr">188</xref>, <xref rid="B190" ref-type="bibr">190</xref>&#x02013;<xref rid="B192" ref-type="bibr">192</xref>], as described previously. Recent studies in dengue patients in South America have suggested that high levels of IFN- <italic>&#x003b2;</italic> might accompany a worsened progression of the disease [<xref rid="B197" ref-type="bibr">197</xref>, <xref rid="B198" ref-type="bibr">198</xref>]. In addition, monocytes of individuals with past severe dengue (SD) exhibited a significant upregulation of IFNB-1, RIG-I, and NLRP3 genes compared to those with past non-SD that was accompanied with higher viral loads, suggesting that initial innate immune responses may influence disease outcome [<xref rid="B291" ref-type="bibr">291</xref>].</p><p>With regard to ZIKV, IFN-I treatment has not been described in ZIKV patients. A recent murine model of ZIKV infection using dexamethasone-immunosuppressed mice showed that IFN-I treatment improved clinical outcomes, reducing viral load and inflammation in different visceral organs including testicles, suggesting the consideration for evaluating the effects of recombinant IFN treatment in patients at high risk for ZIKV-associated complications [<xref rid="B292" ref-type="bibr">292</xref>].</p><p>Concerning WNV-infected patients, the use of IFN-<italic>&#x003b1;</italic> is limited to case reports of meningoencephalitis, where different outcomes have been described [<xref rid="B293" ref-type="bibr">293</xref>&#x02013;<xref rid="B296" ref-type="bibr">296</xref>]. IFN-<italic>&#x003b1;</italic> treatment was well tolerated and might have potential beneficial effects. However, the dynamic course of WNV neuroinvasive disease prevented the determination of whether the beneficial effects were due to the experimental therapy or to chance. Further randomized, double-blinded, placebo-controlled clinical trials are needed to define the role of IFN-<italic>&#x003b1;</italic> treatment in WNV-infected patients.</p><p>The antiviral effects of IFN-<italic>&#x003b1;</italic> against JEV have been originally described in cell cultures [<xref rid="B297" ref-type="bibr">297</xref>]. In humans, IFN-<italic>&#x003b1;</italic>2a treatment against JE was also evaluated in a randomized double-blind placebo-controlled trial in Vietnamese children with JEV infection [<xref rid="B298" ref-type="bibr">298</xref>]. Intramuscular IFN-<italic>&#x003b1;</italic> administration did not show beneficial effects on hospital death or severe sequelae at discharge, suggesting that higher doses, alternative administration routes, or combination with other antiviral drugs might be needed.</p><p>Similar to WNV and JEV, the use of IFN-<italic>&#x003b1;</italic> was evaluated in human subjects with SLEV severe neurologic disease. A nonrandomized, unblinded, interventional pilot study evaluated IFN-<italic>&#x003b1;</italic>2b therapy for meningoencephalitis produced by SLEV and suggested a beneficial effect on the early neurologic course of the disease, indicating that two weeks of treatment were well tolerated [<xref rid="B299" ref-type="bibr">299</xref>]. A subsequent study in solid organ transplant recipients with SLEV meningoencephalitis showed that even with delayed administration, the combination treatment with IFN-<italic>&#x003b1;</italic>2b and intravenous immunoglobulin G was associated with a potential clinical improvement [<xref rid="B300" ref-type="bibr">300</xref>]. These studies support the conduction of a subsequent randomized, double-blinded, placebo-controlled trial of IFN-<italic>&#x003b1;</italic>2a therapy for SLEV meningoencephalitis.</p></sec><sec id="sec4"><title>4. Therapeutic Potential of ISG Effector Mechanisms in Human Viral Infectious Diseases</title><p>Upon recognition of viral infection, the cell, through PRRs, mediates the production of IFN-I leading to the transcription of hundreds of ISGs by the JAK/STAT pathway [<xref rid="B301" ref-type="bibr">301</xref>]. ISGs are the effectors of cell-autonomous antiviral defense and have been shown to be very effective at resisting and controlling pathogens. ISGs are induced to vastly different levels during viral infection or IFN treatment, and expression levels are often dependent on time, dose, and cell type. They act at different stages of the viral life cycle, from entry, replication, assembly, and release, providing adequate cellular immunity against both RNA and DNA viruses [<xref rid="B302" ref-type="bibr">302</xref>]. Microarray studies have identified between 50&#x02013;1000 ISGs, with 200&#x02013;500 genes typical of many cell types. Representative and well-studied ISG members with specific or broad antiviral activities include IRF1, IRF3, IRF7, IRF9, IFITM3, ISG15, and OASL. The products of these ISGs exert numerous antiviral effector functions, many of which are still not fully described. However, as the mechanisms of more IFN effectors are uncovered, it is likely that their modes of action will collectively span the majority of virus life cycle stages [<xref rid="B303" ref-type="bibr">303</xref>]. In addition to having potent antiviral activity, ISGs also augment the innate immune response to viral infection, thereby strengthening this response [<xref rid="B304" ref-type="bibr">304</xref>]. This has driven special attention in the attempt to advance novel therapeutics to control viral infection and their pathogenesis.</p><p>Currently, there are vaccines for influenza virus, YFV and JEV; however, neither effective vaccines nor specific therapies are available for RSV, hMPV, PIV, HRV, HCoV, DENV, ZIKV, WNV, or SLEV. Although several vaccines are under diverse phases of development for these viruses, there is a need for alternative antiviral therapeutic approaches.</p><p>Several ISGs have been described in the setting of respiratory viruses (<xref rid="tab2" ref-type="table">Table 2</xref>). Recent work has shown that the egress of the influenza virus is also targeted by an ISG. Viperin interacts with the cellular enzyme farnesyl diphosphatesynthase to perturb lipid rafts, resulting in inhibition of influenza and rhinovirus release [<xref rid="B305" ref-type="bibr">305</xref>, <xref rid="B306" ref-type="bibr">306</xref>]. In addition, ZAP, which can be upregulated independently from IFN production, limits influenza virus replication via the enhancement of RIG-I [<xref rid="B307" ref-type="bibr">307</xref>]. TRIM56 is another ISG with broad antiviral activity. Although its upregulation is dependent on IFN-I, it abrogates influenza virus A and B and HCoV infection through STING and TLR-3/TRIF [<xref rid="B308" ref-type="bibr">308</xref>, <xref rid="B309" ref-type="bibr">309</xref>]. TRIM21 has shown activity against rhinovirus by intercepting incoming antibody-opsonized virions during cellular infection, mediating efficient postentry neutralization [<xref rid="B310" ref-type="bibr">310</xref>]. A new human IFN-induced gene that we have termed ISG20 codes for a 3&#x02032; to 5&#x02032; exonuclease with specificity for single-stranded RNA and, to a lesser extent, for DNA. ISG20-overexpressing HeLa cells showed resistance to infections by the influenza virus. The mechanism has been shown to be related to the impairment of the polymerase activity, inhibiting both the replication and transcription [<xref rid="B311" ref-type="bibr">311</xref>, <xref rid="B312" ref-type="bibr">312</xref>]. Finally, TDRD7 (tudor domain containing 7) has shown activity against several paramyxoviruses, such as HPIV3 and RSV by interfering with the activation of AMP-dependent kinase (AMPK). The activation of AMPK is required for efficient replication. TDRD7 interferes with the activation of AMPK, limiting viral replication [<xref rid="B313" ref-type="bibr">313</xref>].</p><p>Several ISGs have been reported to inhibit flavivirus infection through different mechanisms (<xref rid="tab2" ref-type="table">Table 2</xref>). The expression of IFN-I inducible ISGs such as IFITM2/3, viperin, ISG15, ISG20, OAS, BST2, RyDEN, TRIM69, and IFI6 has been shown to block DENV infection [<xref rid="B314" ref-type="bibr">314</xref>&#x02013;<xref rid="B320" ref-type="bibr">320</xref>] at multiple steps of the viral cycle. IFITM2 and IFITM3 disrupted the early steps (entry and/or uncoating) of DENV and WNV infection [<xref rid="B314" ref-type="bibr">314</xref>, <xref rid="B316" ref-type="bibr">316</xref>]. In contrast, three IFN-induced cellular enzymes, viperin, ISG20, and dsRNA-activated protein kinase, inhibited the steps of the DENV and WNV cycle in viral proteins and/or RNA biosynthesis [<xref rid="B314" ref-type="bibr">314</xref>]. DENV infection-induced viperin which has antiviral properties residing in the C-terminal region of the protein that acts to restrict early DENV RNA production/accumulation, potentially via the interaction of viperin with DENV NS3 and replication complexes [<xref rid="B315" ref-type="bibr">315</xref>]. The expression of the Repressor of yield of DENV (RyDEN) conferred resistance to all serotypes of DENV in human cells. RyDEN is likely to interfere with the translation of DENV via interaction with viral RNA and cellular mRNA-binding proteins, resulting in the inhibition of virus replication in infected cells [<xref rid="B317" ref-type="bibr">317</xref>]. OAS and its downstream effector RNase L have been reported to block DENV replication and likely contributed to host defense against DENV infection playing a role in determining the outcomes of DENV disease severity [<xref rid="B318" ref-type="bibr">318</xref>]. ZIKV has been reported to induce the expression of ISG15 in primary human corneal epithelial cells, and the silencing of ISG15 increased ZIKV infectivity [<xref rid="B321" ref-type="bibr">321</xref>]. ISG15 has also inhibited the replication of several flaviviruses, including DENV, WNV, and JEV [<xref rid="B322" ref-type="bibr">322</xref>&#x02013;<xref rid="B324" ref-type="bibr">324</xref>]. IFN-<italic>&#x003b1;</italic>-inducible protein 6 (IFI6), an endoplasmic reticulum- (ER-) localized integral membrane effector, prophylactically protected uninfected cells by preventing the formation of virus-induced ER membrane invaginations that house flavivirus (YFV, WNV, and DENV) replication machinery [<xref rid="B320" ref-type="bibr">320</xref>]. TRIM69 interacts with DENV NS3 directly and mediates its ubiquitination and degradation, thus, interrupting DENV replication [<xref rid="B319" ref-type="bibr">319</xref>]. Recently, Schlafen 11, an ISG that controls the synthesis of proteins by regulating tRNA abundance, has been reported to restrict WNV, DENV, and ZIKV replication by impairing viral infectivity [<xref rid="B325" ref-type="bibr">325</xref>].</p></sec><sec id="sec5"><title>5. Conclusions</title><p>After 60 years of research, the protective role of IFN-I has been demonstrated from cell culture to animal models and in human subjects. More recently, pathogenic effects of IFN-I have been described during viral infections highlighting the vast and intricate interactions of IFN-I in the immune response. Further insights into the effector mechanisms of individual ISGs in the complex signaling networks in human viral diseases are needed in order to design more specific and effective therapeutic strategies.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors apologize to colleagues whose work could not be cited due to space constraints. This work was supported by Agencia Nacional de Promoci&#x000f3;n Cient&#x000ed;fica y Tecnol&#x000f3;gica (Grant PICT 2015 N&#x000b0;0076) and CONICET. PLA and LBT are career researchers from CONICET and ABB is a fellow from the same institution.</p></ack><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that there is no conflict of interest regarding the publication of this paper.</p></sec><sec><title>Authors' Contributions</title><p>PLA, ABB, DRH, and LBT contributed to the literature search and paper preparation.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isaacs</surname><given-names>A.</given-names></name><name><surname>Lindenmann</surname><given-names>J.</given-names></name></person-group><article-title>Virus interference. I. The interferon</article-title><source><italic toggle="yes">Journal of Interferon Research</italic></source><year>1957</year><volume>7</volume><issue>5</issue><fpage>429</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1089/jir.1987.7.429</pub-id><pub-id pub-id-type="other">2-s2.0-0023423794</pub-id><?supplied-pmid 2445832?><pub-id pub-id-type="pmid">2445832</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilcek</surname><given-names>J.</given-names></name></person-group><article-title>Fifty years of interferon research: aiming at a moving target</article-title><source><italic toggle="yes">Immunity</italic></source><year>2006</year><volume>25</volume><issue>3</issue><fpage>343</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2006.08.008</pub-id><pub-id pub-id-type="other">2-s2.0-33748470359</pub-id><?supplied-pmid 16979566?><pub-id pub-id-type="pmid">16979566</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isaacs</surname><given-names>A.</given-names></name><name><surname>Lindenmann</surname><given-names>J.</given-names></name><name><surname>Valentine</surname><given-names>R. C.</given-names></name></person-group><article-title>Virus interference. II. Some properties of interferon</article-title><source><italic toggle="yes">Proceedings of the Royal Society of London-Series B: Biological Sciences</italic></source><year>1957</year><volume>147</volume><issue>927</issue><fpage>268</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1098/rspb.1957.0049</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pestka</surname><given-names>S.</given-names></name><name><surname>Krause</surname><given-names>C. D.</given-names></name><name><surname>Walter</surname><given-names>M. R.</given-names></name></person-group><article-title>Interferons, interferon-like cytokines, and their receptors</article-title><source><italic toggle="yes">Immunological Reviews</italic></source><year>2004</year><volume>202</volume><fpage>8</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1111/j.0105-2896.2004.00204.x</pub-id><pub-id pub-id-type="other">2-s2.0-9644262469</pub-id><?supplied-pmid 15546383?><pub-id pub-id-type="pmid">15546383</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theofilopoulos</surname><given-names>A. N.</given-names></name><name><surname>Baccala</surname><given-names>R.</given-names></name><name><surname>Beutler</surname><given-names>B.</given-names></name><name><surname>Kono</surname><given-names>D. H.</given-names></name></person-group><article-title>Type I interferons (alpha/beta) in immunity and autoimmunity</article-title><source><italic toggle="yes">Annual Review of Immunology</italic></source><year>2005</year><volume>23</volume><fpage>307</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.23.021704.115843</pub-id><pub-id pub-id-type="other">2-s2.0-17644402442</pub-id><?supplied-pmid 15771573?><pub-id pub-id-type="pmid">15771573</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>T.</given-names></name><name><surname>Akira</surname><given-names>S.</given-names></name></person-group><article-title>Toll-like receptors and their crosstalk with other innate receptors in infection and immunity</article-title><source><italic toggle="yes">Immunity</italic></source><year>2011</year><volume>34</volume><issue>5</issue><fpage>637</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.05.006</pub-id><pub-id pub-id-type="other">2-s2.0-79956300649</pub-id><?supplied-pmid 21616434?><pub-id pub-id-type="pmid">21616434</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durbin</surname><given-names>R. K.</given-names></name><name><surname>Kotenko</surname><given-names>S. V.</given-names></name><name><surname>Durbin</surname><given-names>J. E.</given-names></name></person-group><article-title>Interferon induction and function at the mucosal surface</article-title><source><italic toggle="yes">Immunological Reviews</italic></source><year>2013</year><volume>255</volume><issue>1</issue><fpage>25</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1111/imr.12101</pub-id><pub-id pub-id-type="other">2-s2.0-84881658991</pub-id><?supplied-pmid 23947345?><pub-id pub-id-type="pmid">23947345</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ioannidis</surname><given-names>I.</given-names></name><name><surname>McNally</surname><given-names>B.</given-names></name><name><surname>Willette</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Plasticity and virus specificity of the airway epithelial cell immune response during respiratory virus infection</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2012</year><volume>86</volume><issue>10</issue><fpage>5422</fpage><lpage>5436</lpage><pub-id pub-id-type="doi">10.1128/JVI.06757-11</pub-id><pub-id pub-id-type="other">2-s2.0-84861321791</pub-id><?supplied-pmid 22398282?><pub-id pub-id-type="pmid">22398282</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwasaki</surname><given-names>A.</given-names></name><name><surname>Medzhitov</surname><given-names>R.</given-names></name></person-group><article-title>Toll-like receptor control of the adaptive immune responses</article-title><source><italic toggle="yes">Nature Immunology</italic></source><year>2004</year><volume>5</volume><issue>10</issue><fpage>987</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1038/ni1112</pub-id><pub-id pub-id-type="other">2-s2.0-5444262511</pub-id><?supplied-pmid 15454922?><pub-id pub-id-type="pmid">15454922</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beutler</surname><given-names>B.</given-names></name></person-group><article-title>Inferences, questions and possibilities in toll-like receptor signalling</article-title><source><italic toggle="yes">Nature</italic></source><year>2004</year><volume>430</volume><issue>6996</issue><fpage>257</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1038/nature02761</pub-id><pub-id pub-id-type="other">2-s2.0-3142654210</pub-id><?supplied-pmid 15241424?><pub-id pub-id-type="pmid">15241424</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moynagh</surname><given-names>P. N.</given-names></name></person-group><article-title>The NF-B pathway</article-title><source><italic toggle="yes">Journal of Cell Science</italic></source><year>2005</year><volume>118</volume><issue>20</issue><fpage>4589</fpage><lpage>4592</lpage><pub-id pub-id-type="doi">10.1242/jcs.02579</pub-id><pub-id pub-id-type="other">2-s2.0-27844487939</pub-id><pub-id pub-id-type="pmid">16219681</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>K.</given-names></name><name><surname>Takaoka</surname><given-names>A.</given-names></name><name><surname>Taniguchi</surname><given-names>T.</given-names></name></person-group><article-title>Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors</article-title><source><italic toggle="yes">Immunity</italic></source><year>2006</year><volume>25</volume><issue>3</issue><fpage>349</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2006.08.009</pub-id><pub-id pub-id-type="other">2-s2.0-33748475531</pub-id><?supplied-pmid 16979567?><pub-id pub-id-type="pmid">16979567</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malmgaard</surname><given-names>L.</given-names></name></person-group><article-title>Induction and regulation of IFNs during viral infections</article-title><source><italic toggle="yes">Journal of Interferon &#x00026; Cytokine Research</italic></source><year>2004</year><volume>24</volume><issue>8</issue><fpage>439</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1089/1079990041689665</pub-id><pub-id pub-id-type="other">2-s2.0-4344658402</pub-id><?supplied-pmid 15320958?><pub-id pub-id-type="pmid">15320958</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>T.</given-names></name><name><surname>Takaoka</surname><given-names>A.</given-names></name></person-group><article-title>The interferon-<italic>&#x003b1;</italic>/<italic>&#x003b2;</italic> system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors</article-title><source><italic toggle="yes">Current Opinion in Immunology</italic></source><year>2002</year><volume>14</volume><issue>1</issue><fpage>111</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/S0952-7915(01)00305-3</pub-id><pub-id pub-id-type="other">2-s2.0-0036467492</pub-id><?supplied-pmid 11790540?><pub-id pub-id-type="pmid">11790540</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivashkiv</surname><given-names>L. B.</given-names></name><name><surname>Donlin</surname><given-names>L. T.</given-names></name></person-group><article-title>Regulation of type I interferon responses</article-title><source><italic toggle="yes">Nature Reviews Immunology</italic></source><year>2014</year><volume>14</volume><issue>1</issue><fpage>36</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1038/nri3581</pub-id><pub-id pub-id-type="other">2-s2.0-84893075305</pub-id><?supplied-pmid 24362405?><pub-id pub-id-type="pmid">24362405</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samuel</surname><given-names>C. E.</given-names></name></person-group><article-title>Antiviral actions of interferons</article-title><source><italic toggle="yes">Clinical Microbiology Reviews</italic></source><year>2001</year><volume>14</volume><issue>4</issue><fpage>778</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1128/CMR.14.4.778-809.2001</pub-id><pub-id pub-id-type="other">2-s2.0-0034767753</pub-id><?supplied-pmid 11585785?><pub-id pub-id-type="pmid">11585785</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>N.</given-names></name><name><surname>Chen</surname><given-names>Z. J.</given-names></name></person-group><article-title>Intrinsic antiviral immunity</article-title><source><italic toggle="yes">Nature Immunology</italic></source><year>2012</year><volume>13</volume><issue>3</issue><fpage>214</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1038/ni.2229</pub-id><pub-id pub-id-type="other">2-s2.0-84863115198</pub-id><?supplied-pmid 22344284?><pub-id pub-id-type="pmid">22344284</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pindel</surname><given-names>A.</given-names></name><name><surname>Sadler</surname><given-names>A.</given-names></name></person-group><article-title>The role of protein kinase R in the interferon response</article-title><source><italic toggle="yes">Journal of Interferon &#x00026; Cytokine Research</italic></source><year>2011</year><volume>31</volume><issue>1</issue><fpage>59</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1089/jir.2010.0099</pub-id><pub-id pub-id-type="other">2-s2.0-78651488459</pub-id><?supplied-pmid 21166592?><pub-id pub-id-type="pmid">21166592</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gebauer</surname><given-names>F.</given-names></name><name><surname>Hentze</surname><given-names>M. W.</given-names></name></person-group><article-title>Molecular mechanisms of translational control</article-title><source><italic toggle="yes">Nature Reviews Molecular Cell Biology</italic></source><year>2004</year><volume>5</volume><issue>10</issue><fpage>827</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1038/nrm1488</pub-id><pub-id pub-id-type="other">2-s2.0-5044229348</pub-id><?supplied-pmid 15459663?><pub-id pub-id-type="pmid">15459663</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>R. H.</given-names></name></person-group><article-title>Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2007</year><volume>81</volume><issue>23</issue><fpage>12720</fpage><lpage>12729</lpage><pub-id pub-id-type="doi">10.1128/JVI.01471-07</pub-id><pub-id pub-id-type="other">2-s2.0-36348987303</pub-id><?supplied-pmid 17804500?><pub-id pub-id-type="pmid">17804500</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>I. C.</given-names></name><name><surname>Bailey</surname><given-names>C. C.</given-names></name><name><surname>Weyer</surname><given-names>J. L.</given-names></name><etal/></person-group><article-title>Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus</article-title><source><italic toggle="yes">PLoS Pathogens</italic></source><year>2011</year><volume>7</volume><issue>1, article e1001258</issue><pub-id pub-id-type="doi">10.1371/journal.ppat.1001258</pub-id><pub-id pub-id-type="other">2-s2.0-79551532447</pub-id><?supplied-pmid 21253575?><pub-id pub-id-type="pmid">21253575</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>D. G.</given-names></name><name><surname>Dimock</surname><given-names>K.</given-names></name><name><surname>Kang</surname><given-names>C. Y.</given-names></name></person-group><article-title>Numerous transitions in human parainfluenza virus 3 RNA recovered from persistently infected cells</article-title><source><italic toggle="yes">Virology</italic></source><year>1991</year><volume>181</volume><issue>2</issue><fpage>760</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(91)90913-v</pub-id><pub-id pub-id-type="other">2-s2.0-0025848735</pub-id><?supplied-pmid 1849685?><pub-id pub-id-type="pmid">1849685</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haller</surname><given-names>O.</given-names></name><name><surname>Kochs</surname><given-names>G.</given-names></name></person-group><article-title>Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity</article-title><source><italic toggle="yes">Journal of Interferon &#x00026; Cytokine Research</italic></source><year>2011</year><volume>31</volume><issue>1</issue><fpage>79</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1089/jir.2010.0076</pub-id><pub-id pub-id-type="other">2-s2.0-78651515640</pub-id><?supplied-pmid 21166595?><pub-id pub-id-type="pmid">21166595</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>R. Y.</given-names></name><name><surname>Hsu</surname><given-names>T. W.</given-names></name><name><surname>Chen</surname><given-names>Y. L.</given-names></name><etal/></person-group><article-title>Japanese encephalitis virus non-coding RNA inhibits activation of interferon by blocking nuclear translocation of interferon regulatory factor 3</article-title><source><italic toggle="yes">Veterinary Microbiology</italic></source><year>2013</year><volume>166</volume><issue>1-2</issue><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2013.04.026</pub-id><pub-id pub-id-type="other">2-s2.0-84880506768</pub-id><pub-id pub-id-type="pmid">23755934</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tailor</surname><given-names>P.</given-names></name><name><surname>Tamura</surname><given-names>T.</given-names></name><name><surname>Ozato</surname><given-names>K.</given-names></name></person-group><article-title>IRF family proteins and type I interferon induction in dendritic cells</article-title><source><italic toggle="yes">Cell Research</italic></source><year>2006</year><volume>16</volume><issue>2</issue><fpage>134</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1038/sj.cr.7310018</pub-id><pub-id pub-id-type="other">2-s2.0-32644464262</pub-id><?supplied-pmid 16474425?><pub-id pub-id-type="pmid">16474425</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>A. P.</given-names></name><name><surname>Salajegheh</surname><given-names>M.</given-names></name><name><surname>Morehouse</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Human plasmacytoid dendritic cell accumulation amplifies their type 1 interferon production</article-title><source><italic toggle="yes">Clinical Immunology</italic></source><year>2010</year><volume>136</volume><issue>1</issue><fpage>130</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2010.02.014</pub-id><pub-id pub-id-type="other">2-s2.0-77953025081</pub-id><?supplied-pmid 20346735?><pub-id pub-id-type="pmid">20346735</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegal</surname><given-names>F. P.</given-names></name><name><surname>Kadowaki</surname><given-names>N.</given-names></name><name><surname>Shodell</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The nature of the principal type 1 interferon-producing cells in human blood</article-title><source><italic toggle="yes">Science</italic></source><year>1999</year><volume>284</volume><issue>5421</issue><fpage>1835</fpage><lpage>1837</lpage><pub-id pub-id-type="doi">10.1126/science.284.5421.1835</pub-id><pub-id pub-id-type="other">2-s2.0-0033546053</pub-id><?supplied-pmid 10364556?><pub-id pub-id-type="pmid">10364556</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald-Bocarsly</surname><given-names>P.</given-names></name><name><surname>Feng</surname><given-names>D.</given-names></name></person-group><article-title>The role of type I interferon production by dendritic cells in host defense</article-title><source><italic toggle="yes">Biochimie</italic></source><year>2007</year><volume>89</volume><issue>6-7</issue><fpage>843</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1016/j.biochi.2007.04.018</pub-id><pub-id pub-id-type="other">2-s2.0-34347250432</pub-id><?supplied-pmid 17544561?><pub-id pub-id-type="pmid">17544561</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brinkmann</surname><given-names>V.</given-names></name><name><surname>Geiger</surname><given-names>T.</given-names></name><name><surname>Alkan</surname><given-names>S.</given-names></name><name><surname>Heusser</surname><given-names>C. H.</given-names></name></person-group><article-title>Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells</article-title><source><italic toggle="yes">The Journal of Experimental Medicine</italic></source><year>1993</year><volume>178</volume><issue>5</issue><fpage>1655</fpage><lpage>1663</lpage><pub-id pub-id-type="doi">10.1084/jem.178.5.1655</pub-id><pub-id pub-id-type="other">2-s2.0-0027433104</pub-id><?supplied-pmid 8228812?><pub-id pub-id-type="pmid">8228812</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marrack</surname><given-names>P.</given-names></name><name><surname>Kappler</surname><given-names>J.</given-names></name><name><surname>Mitchell</surname><given-names>T.</given-names></name></person-group><article-title>Type I interferons keep activated T cells alive</article-title><source><italic toggle="yes">The Journal of Experimental Medicine</italic></source><year>1999</year><volume>189</volume><issue>3</issue><fpage>521</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1084/jem.189.3.521</pub-id><pub-id pub-id-type="other">2-s2.0-0033081259</pub-id><?supplied-pmid 9927514?><pub-id pub-id-type="pmid">9927514</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curtsinger</surname><given-names>J. M.</given-names></name><name><surname>Valenzuela</surname><given-names>J. O.</given-names></name><name><surname>Agarwal</surname><given-names>P.</given-names></name><name><surname>Lins</surname><given-names>D.</given-names></name><name><surname>Mescher</surname><given-names>M. F.</given-names></name></person-group><article-title>Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2005</year><volume>174</volume><issue>8</issue><fpage>4465</fpage><lpage>4469</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.174.8.4465</pub-id><pub-id pub-id-type="other">2-s2.0-18344362061</pub-id><?supplied-pmid 15814665?><pub-id pub-id-type="pmid">15814665</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name></person-group><article-title>Direct action of type I IFN on NK cells is required for their activation in response to vaccinia viral infection in vivo</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2008</year><volume>180</volume><issue>3</issue><fpage>1592</fpage><lpage>1597</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.180.3.1592</pub-id><pub-id pub-id-type="other">2-s2.0-40749093670</pub-id><?supplied-pmid 18209055?><pub-id pub-id-type="pmid">18209055</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Bon</surname><given-names>A.</given-names></name><name><surname>Tough</surname><given-names>D. F.</given-names></name></person-group><article-title>Links between innate and adaptive immunity via type I interferon</article-title><source><italic toggle="yes">Current Opinion in Immunology</italic></source><year>2002</year><volume>14</volume><issue>4</issue><fpage>432</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1016/s0952-7915(02)00354-0</pub-id><pub-id pub-id-type="other">2-s2.0-0036668242</pub-id><?supplied-pmid 12088676?><pub-id pub-id-type="pmid">12088676</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaunt</surname><given-names>E. R.</given-names></name><name><surname>Harvala</surname><given-names>H.</given-names></name><name><surname>McIntyre</surname><given-names>C.</given-names></name><name><surname>Templeton</surname><given-names>K. E.</given-names></name><name><surname>Simmonds</surname><given-names>P.</given-names></name></person-group><article-title>Disease burden of the most commonly detected respiratory viruses in hospitalized patients calculated using the disability adjusted life year (DALY) model</article-title><source><italic toggle="yes">Journal of Clinical Virology</italic></source><year>2011</year><volume>52</volume><issue>3</issue><fpage>215</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2011.07.017</pub-id><pub-id pub-id-type="other">2-s2.0-80054684521</pub-id><?supplied-pmid 21880543?><pub-id pub-id-type="pmid">21880543</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tregoning</surname><given-names>J. S.</given-names></name><name><surname>Schwarze</surname><given-names>J.</given-names></name></person-group><article-title>Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology</article-title><source><italic toggle="yes">Clinical Microbiology Reviews</italic></source><year>2010</year><volume>23</volume><issue>1</issue><fpage>74</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1128/CMR.00032-09</pub-id><pub-id pub-id-type="other">2-s2.0-74249116206</pub-id><?supplied-pmid 20065326?><pub-id pub-id-type="pmid">20065326</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeo</surname><given-names>K. T.</given-names></name><name><surname>de la Puerta</surname><given-names>R.</given-names></name><name><surname>Tee</surname><given-names>N. W. S.</given-names></name><name><surname>Thoon</surname><given-names>K. C.</given-names></name><name><surname>Rajadurai</surname><given-names>V. S.</given-names></name><name><surname>Yung</surname><given-names>C. F.</given-names></name></person-group><article-title>Burden, etiology, and risk factors of respiratory virus infections among symptomatic preterm infants in the tropics: a retrospective single-center cohort study</article-title><source><italic toggle="yes">Clinical Infectious Diseases</italic></source><year>2018</year><volume>67</volume><issue>10</issue><fpage>1603</fpage><lpage>1609</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy311</pub-id><pub-id pub-id-type="other">2-s2.0-85055656569</pub-id><?supplied-pmid 29659748?><pub-id pub-id-type="pmid">29659748</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>Y. B.</given-names></name><name><surname>Song</surname><given-names>J. Y.</given-names></name><name><surname>Choi</surname><given-names>M. J.</given-names></name><etal/></person-group><article-title>Etiology and clinical outcomes of acute respiratory virus infection in hospitalized adults</article-title><source><italic toggle="yes">Infection &#x00026; Chemotherapy</italic></source><year>2014</year><volume>46</volume><issue>2</issue><fpage>67</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.3947/ic.2014.46.2.67</pub-id><pub-id pub-id-type="other">2-s2.0-84903838164</pub-id><?supplied-pmid 25024868?><pub-id pub-id-type="pmid">25024868</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caballero</surname><given-names>M. T.</given-names></name><name><surname>Serra</surname><given-names>M. E.</given-names></name><name><surname>Acosta</surname><given-names>P. L.</given-names></name><etal/></person-group><article-title>TLR4 genotype and environmental LPS mediate RSV bronchiolitis through Th2 polarization</article-title><source><italic toggle="yes">The Journal of Clinical Investigation</italic></source><year>2015</year><volume>125</volume><issue>2</issue><fpage>571</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1172/JCI75183</pub-id><pub-id pub-id-type="other">2-s2.0-84926427192</pub-id><?supplied-pmid 25555213?><pub-id pub-id-type="pmid">25555213</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loo</surname><given-names>Y. M.</given-names></name><name><surname>Fornek</surname><given-names>J.</given-names></name><name><surname>Crochet</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2008</year><volume>82</volume><issue>1</issue><fpage>335</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1128/JVI.01080-07</pub-id><pub-id pub-id-type="other">2-s2.0-37349052379</pub-id><?supplied-pmid 17942531?><pub-id pub-id-type="pmid">17942531</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blasius</surname><given-names>A. L.</given-names></name><name><surname>Beutler</surname><given-names>B.</given-names></name></person-group><article-title>Intracellular toll-like receptors</article-title><source><italic toggle="yes">Immunity</italic></source><year>2010</year><volume>32</volume><issue>3</issue><fpage>305</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.03.012</pub-id><pub-id pub-id-type="other">2-s2.0-77949940198</pub-id><?supplied-pmid 20346772?><pub-id pub-id-type="pmid">20346772</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jewell</surname><given-names>N. A.</given-names></name><name><surname>Vaghefi</surname><given-names>N.</given-names></name><name><surname>Mertz</surname><given-names>S. E.</given-names></name><etal/></person-group><article-title>Differential type I interferon induction by respiratory syncytial virus and influenza a virus in vivo</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2007</year><volume>81</volume><issue>18</issue><fpage>9790</fpage><lpage>9800</lpage><pub-id pub-id-type="doi">10.1128/JVI.00530-07</pub-id><pub-id pub-id-type="other">2-s2.0-35348882688</pub-id><?supplied-pmid 17626092?><pub-id pub-id-type="pmid">17626092</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soto</surname><given-names>J. A.</given-names></name><name><surname>G&#x000e1;lvez</surname><given-names>N. M. S.</given-names></name><name><surname>Benavente</surname><given-names>F. M.</given-names></name><etal/></person-group><article-title>Human metapneumovirus: mechanisms and molecular targets used by the virus to avoid the immune system</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2018</year><volume>9</volume><fpage>p. 2466</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.02466</pub-id><pub-id pub-id-type="other">2-s2.0-85055781521</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name></person-group><article-title>Induction and evasion of type I interferon responses by influenza viruses</article-title><source><italic toggle="yes">Virus Research</italic></source><year>2011</year><volume>162</volume><issue>1-2</issue><fpage>12</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2011.10.017</pub-id><pub-id pub-id-type="other">2-s2.0-81555200097</pub-id><?supplied-pmid 22027189?><pub-id pub-id-type="pmid">22027189</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Te Velthuis</surname><given-names>A. J. W.</given-names></name><name><surname>Fodor</surname><given-names>E.</given-names></name></person-group><article-title>Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis</article-title><source><italic toggle="yes">Nature Reviews Microbiology</italic></source><year>2016</year><volume>14</volume><issue>8</issue><fpage>479</fpage><lpage>493</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2016.87</pub-id><pub-id pub-id-type="other">2-s2.0-84978162055</pub-id><?supplied-pmid 27396566?><pub-id pub-id-type="pmid">27396566</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoneyama</surname><given-names>M.</given-names></name><name><surname>Kikuchi</surname><given-names>M.</given-names></name><name><surname>Natsukawa</surname><given-names>T.</given-names></name><etal/></person-group><article-title>The RNA helicase RIG-I has an essential function in double-stranded RNA- induced innate antiviral responses</article-title><source><italic toggle="yes">Nature Immunology</italic></source><year>2004</year><volume>5</volume><issue>7</issue><fpage>730</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1038/ni1087</pub-id><pub-id pub-id-type="other">2-s2.0-3242813113</pub-id><?supplied-pmid 15208624?><pub-id pub-id-type="pmid">15208624</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>H.</given-names></name><name><surname>Takeuchi</surname><given-names>O.</given-names></name><name><surname>Sato</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses</article-title><source><italic toggle="yes">Nature</italic></source><year>2006</year><volume>441</volume><issue>7089</issue><fpage>101</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1038/nature04734</pub-id><pub-id pub-id-type="other">2-s2.0-33646342149</pub-id><?supplied-pmid 16625202?><pub-id pub-id-type="pmid">16625202</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>H.</given-names></name><name><surname>Takeuchi</surname><given-names>O.</given-names></name><name><surname>Mikamo-Satoh</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5</article-title><source><italic toggle="yes">The Journal of Experimental Medicine</italic></source><year>2008</year><volume>205</volume><issue>7</issue><fpage>1601</fpage><lpage>1610</lpage><pub-id pub-id-type="doi">10.1084/jem.20080091</pub-id><pub-id pub-id-type="other">2-s2.0-46949097299</pub-id><?supplied-pmid 18591409?><pub-id pub-id-type="pmid">18591409</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Childs</surname><given-names>K. S.</given-names></name><name><surname>Randall</surname><given-names>R. E.</given-names></name><name><surname>Goodbourn</surname><given-names>S.</given-names></name></person-group><article-title>LGP2 plays a critical role in sensitizing mda-5 to activation by double-stranded RNA</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2013</year><volume>8</volume><issue>5, article e64202</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0064202</pub-id><pub-id pub-id-type="other">2-s2.0-84877326407</pub-id><?supplied-pmid 23671710?><pub-id pub-id-type="pmid">23671710</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le Goffic</surname><given-names>R.</given-names></name><name><surname>Pothlichet</surname><given-names>J.</given-names></name><name><surname>Vitour</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Cutting edge: influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2007</year><volume>178</volume><issue>6</issue><fpage>3368</fpage><lpage>3372</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.6.3368</pub-id><pub-id pub-id-type="other">2-s2.0-33947206046</pub-id><?supplied-pmid 17339430?><pub-id pub-id-type="pmid">17339430</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lund</surname><given-names>J. M.</given-names></name><name><surname>Alexopoulou</surname><given-names>L.</given-names></name><name><surname>Sato</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Recognition of single-stranded RNA viruses by toll-like receptor 7</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2004</year><volume>101</volume><issue>15</issue><fpage>5598</fpage><lpage>5603</lpage><pub-id pub-id-type="doi">10.1073/pnas.0400937101</pub-id><pub-id pub-id-type="other">2-s2.0-1842631428</pub-id><?supplied-pmid 15034168?><pub-id pub-id-type="pmid">15034168</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hale</surname><given-names>B. G.</given-names></name><name><surname>Randall</surname><given-names>R. E.</given-names></name><name><surname>Ort&#x000ed;n</surname><given-names>J.</given-names></name><name><surname>Jackson</surname><given-names>D.</given-names></name></person-group><article-title>The multifunctional NS1 protein of influenza A viruses</article-title><source><italic toggle="yes">The Journal of General Virology</italic></source><year>2008</year><volume>89, Part 10</volume><fpage>2359</fpage><lpage>2376</lpage><pub-id pub-id-type="doi">10.1099/vir.0.2008/004606-0</pub-id><pub-id pub-id-type="other">2-s2.0-54449099369</pub-id><?supplied-pmid 18796704?><pub-id pub-id-type="pmid">18796704</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hale</surname><given-names>B. G.</given-names></name><name><surname>Steel</surname><given-names>J.</given-names></name><name><surname>Medina</surname><given-names>R. A.</given-names></name><etal/></person-group><article-title>Inefficient control of host gene expression by the 2009 pandemic H1N1 influenza A virus NS1 protein</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2010</year><volume>84</volume><issue>14</issue><fpage>6909</fpage><lpage>6922</lpage><pub-id pub-id-type="doi">10.1128/JVI.00081-10</pub-id><pub-id pub-id-type="other">2-s2.0-77953784997</pub-id><?supplied-pmid 20444891?><pub-id pub-id-type="pmid">20444891</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales</surname><given-names>A.</given-names></name><name><surname>Martinez-Sobrido</surname><given-names>L.</given-names></name><name><surname>Topham</surname><given-names>D.</given-names></name><name><surname>DeDiego</surname><given-names>M.</given-names></name></person-group><article-title>Modulation of innate immune responses by the influenza A NS1 and PA-X proteins</article-title><source><italic toggle="yes">Viruses</italic></source><year>2018</year><volume>10</volume><issue>12</issue><fpage>p. 708</fpage><pub-id pub-id-type="doi">10.3390/v10120708</pub-id><pub-id pub-id-type="other">2-s2.0-85058692793</pub-id><?supplied-pmid 30545063?><pub-id pub-id-type="pmid">30545063</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krug</surname><given-names>R. M.</given-names></name></person-group><article-title>Functions of the influenza A virus NS1 protein in antiviral defense</article-title><source><italic toggle="yes">Current Opinion in Virology</italic></source><year>2015</year><volume>12</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2015.01.007</pub-id><pub-id pub-id-type="other">2-s2.0-84921960062</pub-id><?supplied-pmid 25638592?><pub-id pub-id-type="pmid">25638592</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloom</surname><given-names>J. D.</given-names></name><name><surname>Gong</surname><given-names>L. I.</given-names></name><name><surname>Baltimore</surname><given-names>D.</given-names></name></person-group><article-title>Permissive secondary mutations enable the evolution of influenza oseltamivir resistance</article-title><source><italic toggle="yes">Science</italic></source><year>2010</year><volume>328</volume><issue>5983</issue><fpage>1272</fpage><lpage>1275</lpage><pub-id pub-id-type="doi">10.1126/science.1187816</pub-id><pub-id pub-id-type="other">2-s2.0-77953262416</pub-id><?supplied-pmid 20522774?><pub-id pub-id-type="pmid">20522774</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pichlmair</surname><given-names>A.</given-names></name><name><surname>Schulz</surname><given-names>O.</given-names></name><name><surname>Tan</surname><given-names>C. P.</given-names></name><etal/></person-group><article-title>RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates</article-title><source><italic toggle="yes">Science</italic></source><year>2006</year><volume>314</volume><issue>5801</issue><fpage>997</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1126/science.1132998</pub-id><pub-id pub-id-type="other">2-s2.0-33750984771</pub-id><?supplied-pmid 17038589?><pub-id pub-id-type="pmid">17038589</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergmann</surname><given-names>M.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name><name><surname>Carnero</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2000</year><volume>74</volume><issue>13</issue><fpage>6203</fpage><lpage>6206</lpage><pub-id pub-id-type="doi">10.1128/jvi.74.13.6203-6206.2000</pub-id><pub-id pub-id-type="other">2-s2.0-0034044065</pub-id><?supplied-pmid 10846107?><pub-id pub-id-type="pmid">10846107</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schierhorn</surname><given-names>K. L.</given-names></name><name><surname>Jolmes</surname><given-names>F.</given-names></name><name><surname>Bespalowa</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Influenza A virus virulence depends on two amino acids in the N-terminal domain of its NS1 protein to facilitate inhibition of the RNA-dependent protein kinase PKR</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2017</year><volume>91</volume><issue>10</issue><pub-id pub-id-type="doi">10.1128/JVI.00198-17</pub-id><pub-id pub-id-type="other">2-s2.0-85018279836</pub-id><?supplied-pmid 28250123?><pub-id pub-id-type="pmid">28250123</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Knipe</surname><given-names>D. M.</given-names></name><name><surname>Howley</surname><given-names>P. M.</given-names></name></person-group><source><italic toggle="yes">Fields Virology</italic></source><year>2013</year><edition>6th</edition><publisher-loc>Philadelphia, PA</publisher-loc><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehrhardt</surname><given-names>C.</given-names></name><name><surname>Ludwig</surname><given-names>S.</given-names></name></person-group><article-title>A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway</article-title><source><italic toggle="yes">Cellular Microbiology</italic></source><year>2009</year><volume>11</volume><issue>6</issue><fpage>863</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2009.01309.x</pub-id><pub-id pub-id-type="other">2-s2.0-65549130101</pub-id><?supplied-pmid 19290913?><pub-id pub-id-type="pmid">19290913</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koerner</surname><given-names>I.</given-names></name><name><surname>Kochs</surname><given-names>G.</given-names></name><name><surname>Kalinke</surname><given-names>U.</given-names></name><name><surname>Weiss</surname><given-names>S.</given-names></name><name><surname>Staeheli</surname><given-names>P.</given-names></name></person-group><article-title>Protective role of beta interferon in host defense against influenza A virus</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2007</year><volume>81</volume><issue>4</issue><fpage>2025</fpage><lpage>2030</lpage><pub-id pub-id-type="doi">10.1128/JVI.01718-06</pub-id><pub-id pub-id-type="other">2-s2.0-33846796382</pub-id><?supplied-pmid 17151098?><pub-id pub-id-type="pmid">17151098</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szretter</surname><given-names>K. J.</given-names></name><name><surname>Gangappa</surname><given-names>S.</given-names></name><name><surname>Belser</surname><given-names>J. A.</given-names></name><etal/></person-group><article-title>Early control of H5N1 influenza virus replication by the type I interferon response in mice</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2009</year><volume>83</volume><issue>11</issue><fpage>5825</fpage><lpage>5834</lpage><pub-id pub-id-type="doi">10.1128/JVI.02144-08</pub-id><pub-id pub-id-type="other">2-s2.0-66149154715</pub-id><?supplied-pmid 19297490?><pub-id pub-id-type="pmid">19297490</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>G. E.</given-names></name><name><surname>Gaszewska-Mastarlarz</surname><given-names>A.</given-names></name><name><surname>Moskophidis</surname><given-names>D.</given-names></name></person-group><article-title>The role of alpha/beta and gamma interferons in development of immunity to influenza A virus in mice</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2000</year><volume>74</volume><issue>9</issue><fpage>3996</fpage><lpage>4003</lpage><pub-id pub-id-type="doi">10.1128/JVI.74.9.3996-4003.2000</pub-id><pub-id pub-id-type="other">2-s2.0-0034003375</pub-id><?supplied-pmid 10756011?><pub-id pub-id-type="pmid">10756011</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>S.</given-names></name><name><surname>Crotta</surname><given-names>S.</given-names></name><name><surname>McCabe</surname><given-names>T. M.</given-names></name><name><surname>Wack</surname><given-names>A.</given-names></name></person-group><article-title>Pathogenic potential of interferon <italic>&#x003b1;&#x003b2;</italic> in acute influenza infection</article-title><source><italic toggle="yes">Nature Communications</italic></source><year>2014</year><volume>5</volume><issue>1</issue><fpage>p. 3864</fpage><pub-id pub-id-type="doi">10.1038/ncomms4864</pub-id><pub-id pub-id-type="other">2-s2.0-84901358668</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>C. B.</given-names></name><name><surname>Douglas</surname><given-names>R. G.</given-names><suffix>Jr.</suffix></name><name><surname>Simons</surname><given-names>R. L.</given-names></name><name><surname>Geiman</surname><given-names>J. M.</given-names></name></person-group><article-title>Interferon production in children with respiratory syncytial, influenza, and parainfluenza virus infections</article-title><source><italic toggle="yes">The Journal of Pediatrics</italic></source><year>1978</year><volume>93</volume><issue>1</issue><fpage>28</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/S0022-3476(78)80594-0</pub-id><pub-id pub-id-type="other">2-s2.0-0017855442</pub-id><pub-id pub-id-type="pmid">206677</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melendi</surname><given-names>G. A.</given-names></name><name><surname>Coviello</surname><given-names>S.</given-names></name><name><surname>Bhat</surname><given-names>N.</given-names></name><name><surname>Zea-Hernandez</surname><given-names>J.</given-names></name><name><surname>Ferolla</surname><given-names>F. M.</given-names></name><name><surname>Polack</surname><given-names>F. P.</given-names></name></person-group><article-title>Breastfeeding is associated with the production of type I interferon in infants infected with influenza virus</article-title><source><italic toggle="yes">Acta Paediatrica</italic></source><year>2010</year><volume>99</volume><issue>10</issue><fpage>1517</fpage><lpage>1521</lpage><pub-id pub-id-type="doi">10.1111/j.1651-2227.2010.01862.x</pub-id><pub-id pub-id-type="other">2-s2.0-77956360519</pub-id><?supplied-pmid 20456265?><pub-id pub-id-type="pmid">20456265</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>M. I.</given-names></name><name><surname>Bergel</surname><given-names>E.</given-names></name><name><surname>Gibbons</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Differential gender response to respiratory infections and to the protective effect of breast milk in preterm infants</article-title><source><italic toggle="yes">Pediatrics</italic></source><year>2008</year><volume>121</volume><issue>6</issue><fpage>e1510</fpage><lpage>e1516</lpage><pub-id pub-id-type="doi">10.1542/peds.2007-1757</pub-id><pub-id pub-id-type="other">2-s2.0-48949088392</pub-id><?supplied-pmid 18519454?><pub-id pub-id-type="pmid">18519454</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canaday</surname><given-names>D. H.</given-names></name><name><surname>Amponsah</surname><given-names>N. A.</given-names></name><name><surname>Jones</surname><given-names>L.</given-names></name><name><surname>Tisch</surname><given-names>D. J.</given-names></name><name><surname>Hornick</surname><given-names>T. R.</given-names></name><name><surname>Ramachandra</surname><given-names>L.</given-names></name></person-group><article-title>Influenza-induced production of interferon-alpha is defective in geriatric individuals</article-title><source><italic toggle="yes">Journal of Clinical Immunology</italic></source><year>2010</year><volume>30</volume><issue>3</issue><fpage>373</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1007/s10875-010-9374-9</pub-id><pub-id pub-id-type="other">2-s2.0-77953289128</pub-id><?supplied-pmid 20182777?><pub-id pub-id-type="pmid">20182777</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forbes</surname><given-names>R. L.</given-names></name><name><surname>Wark</surname><given-names>P. A.</given-names></name><name><surname>Murphy</surname><given-names>V. E.</given-names></name><name><surname>Gibson</surname><given-names>P. G.</given-names></name></person-group><article-title>Pregnant women have attenuated innate interferon responses to 2009 pandemic influenza A virus subtype H1N1</article-title><source><italic toggle="yes">The Journal of Infectious Diseases</italic></source><year>2012</year><volume>206</volume><issue>5</issue><fpage>646</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis377</pub-id><pub-id pub-id-type="other">2-s2.0-84864934698</pub-id><?supplied-pmid 22693225?><pub-id pub-id-type="pmid">22693225</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everitt</surname><given-names>A. R.</given-names></name><name><surname>Clare</surname><given-names>S.</given-names></name><name><surname>Pertel</surname><given-names>T.</given-names></name><etal/></person-group><article-title>IFITM3 restricts the morbidity and mortality associated with influenza</article-title><source><italic toggle="yes">Nature</italic></source><year>2012</year><volume>484</volume><issue>7395</issue><fpage>519</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1038/nature10921</pub-id><pub-id pub-id-type="other">2-s2.0-84862777209</pub-id><?supplied-pmid 22446628?><pub-id pub-id-type="pmid">22446628</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Hepatitis B virus spliced variants are associated with an impaired response to interferon therapy</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2015</year><volume>5</volume><issue>1</issue><fpage>p. 16459</fpage><pub-id pub-id-type="doi">10.1038/srep16459</pub-id><pub-id pub-id-type="other">2-s2.0-84947814463</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>C. B.</given-names></name><name><surname>Weinberg</surname><given-names>G. A.</given-names></name><name><surname>Iwane</surname><given-names>M. K.</given-names></name><etal/></person-group><article-title>The burden of respiratory syncytial virus infection in young children</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>2009</year><volume>360</volume><issue>6</issue><fpage>588</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0804877</pub-id><pub-id pub-id-type="other">2-s2.0-59749095702</pub-id><?supplied-pmid 19196675?><pub-id pub-id-type="pmid">19196675</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falsey</surname><given-names>A. R.</given-names></name><name><surname>Hennessey</surname><given-names>P. A.</given-names></name><name><surname>Formica</surname><given-names>M. A.</given-names></name><name><surname>Cox</surname><given-names>C.</given-names></name><name><surname>Walsh</surname><given-names>E. E.</given-names></name></person-group><article-title>Respiratory syncytial virus infection in elderly and high-risk adults</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>2005</year><volume>352</volume><issue>17</issue><fpage>1749</fpage><lpage>1759</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa043951</pub-id><pub-id pub-id-type="other">2-s2.0-17644392071</pub-id><?supplied-pmid 15858184?><pub-id pub-id-type="pmid">15858184</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bermejo-Martin</surname><given-names>J. F.</given-names></name><name><surname>Garcia-Arevalo</surname><given-names>M. C.</given-names></name><name><surname>de Lejarazu</surname><given-names>R. O.</given-names></name><etal/></person-group><article-title>Predominance of Th2 cytokines, CXC chemokines and innate immunity mediators at the mucosal level during severe respiratory syncytial virus infection in children</article-title><source><italic toggle="yes">European Cytokine Network</italic></source><year>2007</year><volume>18</volume><issue>3</issue><fpage>162</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1684/ecn.2007.0096</pub-id><pub-id pub-id-type="other">2-s2.0-35348879131</pub-id><?supplied-pmid 17823085?><pub-id pub-id-type="pmid">17823085</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goutagny</surname><given-names>N.</given-names></name><name><surname>Jiang</surname><given-names>Z.</given-names></name><name><surname>Tian</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Cell type-specific recognition of human metapneumoviruses (HMPVs) by retinoic acid-inducible gene I (RIG-I) and TLR7 and viral interference of RIG-I ligand recognition by HMPV-B1 phosphoprotein</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2010</year><volume>184</volume><issue>3</issue><fpage>1168</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0902750</pub-id><pub-id pub-id-type="other">2-s2.0-77949313642</pub-id><?supplied-pmid 20042593?><pub-id pub-id-type="pmid">20042593</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belgnaoui</surname><given-names>S. M.</given-names></name><name><surname>Paz</surname><given-names>S.</given-names></name><name><surname>Hiscott</surname><given-names>J.</given-names></name></person-group><article-title>Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS) adapter</article-title><source><italic toggle="yes">Current Opinion in Immunology</italic></source><year>2011</year><volume>23</volume><issue>5</issue><fpage>564</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2011.08.001</pub-id><pub-id pub-id-type="other">2-s2.0-80053590435</pub-id><?supplied-pmid 21865020?><pub-id pub-id-type="pmid">21865020</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R. F.</given-names></name><name><surname>Yang</surname><given-names>K. D.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>J. W.</given-names></name><name><surname>Chiu</surname><given-names>C. C.</given-names></name><name><surname>Cheng</surname><given-names>J. T.</given-names></name></person-group><article-title>Different clinical and laboratory manifestations between dengue haemorrhagic fever and dengue fever with bleeding tendency</article-title><source><italic toggle="yes">Transactions of the Royal Society of Tropical Medicine and Hygiene</italic></source><year>2007</year><volume>101</volume><issue>11</issue><fpage>1106</fpage><lpage>1113</lpage><pub-id pub-id-type="doi">10.1016/j.trstmh.2007.06.019</pub-id><pub-id pub-id-type="other">2-s2.0-34548859536</pub-id><?supplied-pmid 17764712?><pub-id pub-id-type="pmid">17764712</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabbah</surname><given-names>A.</given-names></name><name><surname>Chang</surname><given-names>T. H.</given-names></name><name><surname>Harnack</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Activation of innate immune antiviral responses by Nod2</article-title><source><italic toggle="yes">Nature Immunology</italic></source><year>2009</year><volume>10</volume><issue>10</issue><fpage>1073</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1038/ni.1782</pub-id><pub-id pub-id-type="other">2-s2.0-70349459620</pub-id><?supplied-pmid 19701189?><pub-id pub-id-type="pmid">19701189</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>N. J.</given-names><suffix>Jr.</suffix></name><name><surname>Hiscott</surname><given-names>J.</given-names></name><name><surname>Signs</surname><given-names>D. J.</given-names></name></person-group><article-title>The limited role of the human interferon system response to respiratory syncytial virus challenge: analysis and comparison to influenza virus challenge</article-title><source><italic toggle="yes">Microbial Pathogenesis</italic></source><year>1992</year><volume>12</volume><issue>6</issue><fpage>409</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/0882-4010(92)90003-7</pub-id><pub-id pub-id-type="other">2-s2.0-0026874239</pub-id><?supplied-pmid 1522795?><pub-id pub-id-type="pmid">1522795</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIntosh</surname><given-names>K.</given-names></name></person-group><article-title>Interferon in nasal secretions from infants with viral respiratory tract infections</article-title><source><italic toggle="yes">The Journal of Pediatrics</italic></source><year>1978</year><volume>93</volume><issue>1</issue><fpage>33</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/S0022-3476(78)80595-2</pub-id><pub-id pub-id-type="other">2-s2.0-0017864677</pub-id><?supplied-pmid 650342?><pub-id pub-id-type="pmid">650342</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>J.</given-names></name><name><surname>Lynch</surname><given-names>O. T.</given-names></name><name><surname>Suessmuth</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ligase</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2007</year><volume>81</volume><issue>7</issue><fpage>3428</fpage><lpage>3436</lpage><pub-id pub-id-type="doi">10.1128/JVI.02303-06</pub-id><pub-id pub-id-type="other">2-s2.0-33947399733</pub-id><?supplied-pmid 17251292?><pub-id pub-id-type="pmid">17251292</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramaswamy</surname><given-names>M.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Varga</surname><given-names>S. M.</given-names></name><name><surname>Barik</surname><given-names>S.</given-names></name><name><surname>Behlke</surname><given-names>M. A.</given-names></name><name><surname>Look</surname><given-names>D. C.</given-names></name></person-group><article-title>Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction</article-title><source><italic toggle="yes">Virology</italic></source><year>2006</year><volume>344</volume><issue>2</issue><fpage>328</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2005.09.009</pub-id><pub-id pub-id-type="other">2-s2.0-30044431891</pub-id><?supplied-pmid 16216295?><pub-id pub-id-type="pmid">16216295</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Pang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>A novel mechanism for the inhibition of interferon regulatory factor-3-dependent gene expression by human respiratory syncytial virus NS1 protein</article-title><source><italic toggle="yes">The Journal of General Virology</italic></source><year>2011</year><volume>92, Part 9</volume><fpage>2153</fpage><lpage>2159</lpage><pub-id pub-id-type="doi">10.1099/vir.0.032987-0</pub-id><pub-id pub-id-type="other">2-s2.0-80051706667</pub-id><?supplied-pmid 21632562?><pub-id pub-id-type="pmid">21632562</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>Z.</given-names></name><name><surname>Tran</surname><given-names>K. C.</given-names></name><name><surname>Teng</surname><given-names>M. N.</given-names></name></person-group><article-title>Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-I</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2009</year><volume>83</volume><issue>8</issue><fpage>3734</fpage><lpage>3742</lpage><pub-id pub-id-type="doi">10.1128/JVI.02434-08</pub-id><pub-id pub-id-type="other">2-s2.0-64049090424</pub-id><?supplied-pmid 19193793?><pub-id pub-id-type="pmid">19193793</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Cheng</surname><given-names>X.</given-names></name><name><surname>Tang</surname><given-names>R.</given-names></name><name><surname>Munoz</surname><given-names>M.</given-names></name><name><surname>Nguyen</surname><given-names>N.</given-names></name></person-group><article-title>Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo</article-title><source><italic toggle="yes">Virology</italic></source><year>2000</year><volume>273</volume><issue>1</issue><fpage>210</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1006/viro.2000.0393</pub-id><pub-id pub-id-type="other">2-s2.0-0034691566</pub-id><?supplied-pmid 10891423?><pub-id pub-id-type="pmid">10891423</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Kong</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene</article-title><source><italic toggle="yes">Nature Medicine</italic></source><year>2005</year><volume>11</volume><issue>1</issue><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1038/nm1174</pub-id><pub-id pub-id-type="other">2-s2.0-13444252624</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramaswamy</surname><given-names>M.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Monick</surname><given-names>M. M.</given-names></name><name><surname>Hunninghake</surname><given-names>G. W.</given-names></name><name><surname>Look</surname><given-names>D. C.</given-names></name></person-group><article-title>Specific inhibition of type I interferon signal transduction by respiratory syncytial virus</article-title><source><italic toggle="yes">American Journal of Respiratory Cell and Molecular Biology</italic></source><year>2004</year><volume>30</volume><issue>6</issue><fpage>893</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2003-0410OC</pub-id><pub-id pub-id-type="other">2-s2.0-1642431694</pub-id><?supplied-pmid 14722224?><pub-id pub-id-type="pmid">14722224</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>M. S.</given-names></name><name><surname>Brazas</surname><given-names>R. M.</given-names></name><name><surname>Holtzman</surname><given-names>M. J.</given-names></name></person-group><article-title>Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2005</year><volume>79</volume><issue>14</issue><fpage>9315</fpage><lpage>9319</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.14.9315-9319.2005</pub-id><pub-id pub-id-type="other">2-s2.0-20044387307</pub-id><?supplied-pmid 15994826?><pub-id pub-id-type="pmid">15994826</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marr</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>T. I.</given-names></name><name><surname>Kam</surname><given-names>S. H. Y.</given-names></name><etal/></person-group><article-title>Attenuation of respiratory syncytial virus-induced and RIG-I-dependent type I IFN responses in human neonates and very young children</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2014</year><volume>192</volume><issue>3</issue><fpage>948</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1302007</pub-id><pub-id pub-id-type="other">2-s2.0-84893365419</pub-id><?supplied-pmid 24391215?><pub-id pub-id-type="pmid">24391215</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thwaites</surname><given-names>R. S.</given-names></name><name><surname>Coates</surname><given-names>M.</given-names></name><name><surname>Ito</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Reduced nasal viral load and IFN responses in infants with respiratory syncytial virus bronchiolitis and respiratory failure</article-title><source><italic toggle="yes">American Journal of Respiratory and Critical Care Medicine</italic></source><year>2018</year><volume>198</volume><issue>8</issue><fpage>1074</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1164/rccm.201712-2567OC</pub-id><pub-id pub-id-type="other">2-s2.0-85054888822</pub-id><?supplied-pmid 29688024?><pub-id pub-id-type="pmid">29688024</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Hoogen</surname><given-names>B. G.</given-names></name><name><surname>de Jong</surname><given-names>J. C.</given-names></name><name><surname>Groen</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A newly discovered human pneumovirus isolated from young children with respiratory tract disease</article-title><source><italic toggle="yes">Nature Medicine</italic></source><year>2001</year><volume>7</volume><issue>6</issue><fpage>719</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1038/89098</pub-id><pub-id pub-id-type="other">2-s2.0-0034953901</pub-id><?supplied-pmid 11385510?><pub-id pub-id-type="pmid">11385510</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shafagati</surname><given-names>N.</given-names></name><name><surname>Williams</surname><given-names>J.</given-names></name></person-group><article-title>Human metapneumovirus - what we know now</article-title><source><italic toggle="yes">F1000Research</italic></source><year>2018</year><volume>7</volume><fpage>p. 135</fpage><pub-id pub-id-type="doi">10.12688/f1000research.12625.1</pub-id><pub-id pub-id-type="other">2-s2.0-85041736377</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feuillet</surname><given-names>F.</given-names></name><name><surname>Lina</surname><given-names>B.</given-names></name><name><surname>Rosa-Calatrava</surname><given-names>M.</given-names></name><name><surname>Boivin</surname><given-names>G.</given-names></name></person-group><article-title>Ten years of human metapneumovirus research</article-title><source><italic toggle="yes">Journal of Clinical Virology</italic></source><year>2012</year><volume>53</volume><issue>2</issue><fpage>97</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2011.10.002</pub-id><pub-id pub-id-type="other">2-s2.0-84855539522</pub-id><?supplied-pmid 22074934?><pub-id pub-id-type="pmid">22074934</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>J. S.</given-names></name></person-group><article-title>Epidemiology of human metapneumovirus</article-title><source><italic toggle="yes">Clinical Microbiology Reviews</italic></source><year>2006</year><volume>19</volume><issue>3</issue><fpage>546</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1128/CMR.00014-06</pub-id><pub-id pub-id-type="other">2-s2.0-33746473500</pub-id><?supplied-pmid 16847085?><pub-id pub-id-type="pmid">16847085</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>S.</given-names></name><name><surname>Bao</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Role of retinoic acid inducible gene-I in human metapneumovirus-induced cellular signalling</article-title><source><italic toggle="yes">The Journal of General Virology</italic></source><year>2008</year><volume>89, Part 8</volume><fpage>1978</fpage><lpage>1986</lpage><pub-id pub-id-type="doi">10.1099/vir.0.2008/000778-0</pub-id><pub-id pub-id-type="other">2-s2.0-50549095789</pub-id><?supplied-pmid 18632970?><pub-id pub-id-type="pmid">18632970</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>J.</given-names></name><name><surname>Kolli</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Human metapneumovirus inhibits IFN-<italic>&#x003b2;</italic> signaling by downregulating Jak1 and Tyk2 cellular levels</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2011</year><volume>6</volume><issue>9, article e24496</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0024496</pub-id><pub-id pub-id-type="other">2-s2.0-80052898726</pub-id><?supplied-pmid 21949722?><pub-id pub-id-type="pmid">21949722</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinwiddie</surname><given-names>D. L.</given-names></name><name><surname>Harrod</surname><given-names>K. S.</given-names></name></person-group><article-title>Human metapneumovirus inhibits IFN-<italic>&#x003b1;</italic> signaling through inhibition of STAT1 phosphorylation</article-title><source><italic toggle="yes">American Journal of Respiratory Cell and Molecular Biology</italic></source><year>2008</year><volume>38</volume><issue>6</issue><fpage>661</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2007-0285OC</pub-id><pub-id pub-id-type="other">2-s2.0-45249091224</pub-id><pub-id pub-id-type="pmid">18218993</pub-id></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Kolli</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Human metapneumovirus M2-2 protein inhibits innate cellular signaling by targeting MAVS</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2012</year><volume>86</volume><issue>23</issue><fpage>13049</fpage><lpage>13061</lpage><pub-id pub-id-type="doi">10.1128/JVI.01248-12</pub-id><pub-id pub-id-type="other">2-s2.0-84869223930</pub-id><?supplied-pmid 23015697?><pub-id pub-id-type="pmid">23015697</pub-id></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>X.</given-names></name><name><surname>Deng</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Functional motifs responsible for human metapneumovirus M2-2-mediated innate immune evasion</article-title><source><italic toggle="yes">Virology</italic></source><year>2016</year><volume>499</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2016.09.026</pub-id><pub-id pub-id-type="other">2-s2.0-84991650760</pub-id><?supplied-pmid 27743962?><pub-id pub-id-type="pmid">27743962</pub-id></element-citation></ref><ref id="B100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>X.</given-names></name><name><surname>Kolli</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Shan</surname><given-names>Y.</given-names></name><name><surname>Garofalo</surname><given-names>R. P.</given-names></name><name><surname>Casola</surname><given-names>A.</given-names></name></person-group><article-title>Human metapneumovirus small hydrophobic protein inhibits NF-kappaB transcriptional activity</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2008</year><volume>82</volume><issue>16</issue><fpage>8224</fpage><lpage>8229</lpage><pub-id pub-id-type="doi">10.1128/JVI.02584-07</pub-id><pub-id pub-id-type="other">2-s2.0-49149103623</pub-id><?supplied-pmid 18550666?><pub-id pub-id-type="pmid">18550666</pub-id></element-citation></ref><ref id="B101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malmo</surname><given-names>J.</given-names></name><name><surname>Moe</surname><given-names>N.</given-names></name><name><surname>Krokstad</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Cytokine profiles in human metapneumovirus infected children: identification of genes involved in the antiviral response and pathogenesis</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2016</year><volume>11</volume><issue>5, article e0155484</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0155484</pub-id><pub-id pub-id-type="other">2-s2.0-84969921523</pub-id><?supplied-pmid 27171557?><pub-id pub-id-type="pmid">27171557</pub-id></element-citation></ref><ref id="B102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hastings</surname><given-names>A. K.</given-names></name><name><surname>Erickson</surname><given-names>J. J.</given-names></name><name><surname>Schuster</surname><given-names>J. E.</given-names></name><etal/></person-group><article-title>Role of type I interferon signaling in human metapneumovirus pathogenesis and control of viral replication</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2015</year><volume>89</volume><issue>8</issue><fpage>4405</fpage><lpage>4420</lpage><pub-id pub-id-type="doi">10.1128/JVI.03275-14</pub-id><pub-id pub-id-type="other">2-s2.0-84925427995</pub-id><?supplied-pmid 25653440?><pub-id pub-id-type="pmid">25653440</pub-id></element-citation></ref><ref id="B103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komada</surname><given-names>H.</given-names></name><name><surname>Tsurudome</surname><given-names>M.</given-names></name><name><surname>Ueda</surname><given-names>M.</given-names></name><name><surname>Nishio</surname><given-names>M.</given-names></name><name><surname>Bando</surname><given-names>H.</given-names></name><name><surname>Ito</surname><given-names>Y.</given-names></name></person-group><article-title>Isolation and characterization of monoclonal antibodies to human parainfluenza virus type 4 and their use in revealing antigenic relation between subtypes 4A and 413</article-title><source><italic toggle="yes">Virology</italic></source><year>1989</year><volume>171</volume><issue>1</issue><fpage>28</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(89)90507-2</pub-id><pub-id pub-id-type="other">2-s2.0-0024372213</pub-id><?supplied-pmid 2472703?><pub-id pub-id-type="pmid">2472703</pub-id></element-citation></ref><ref id="B104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinberg</surname><given-names>G. A.</given-names></name><name><surname>Hall</surname><given-names>C. B.</given-names></name><name><surname>Iwane</surname><given-names>M. K.</given-names></name><etal/></person-group><article-title>Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization</article-title><source><italic toggle="yes">The Journal of Pediatrics</italic></source><year>2009</year><volume>154</volume><issue>5</issue><fpage>694</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2008.11.034</pub-id><pub-id pub-id-type="other">2-s2.0-64149119175</pub-id><?supplied-pmid 19159905?><pub-id pub-id-type="pmid">19159905</pub-id></element-citation></ref><ref id="B105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabbah</surname><given-names>A.</given-names></name><name><surname>Bose</surname><given-names>S.</given-names></name></person-group><article-title>Retinoic acid inducible gene I activates innate antiviral response against human parainfluenza virus type 3</article-title><source><italic toggle="yes">Virology Journal</italic></source><year>2009</year><volume>6</volume><issue>1</issue><fpage>p. 200</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-6-200</pub-id><pub-id pub-id-type="other">2-s2.0-73349112516</pub-id></element-citation></ref><ref id="B106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luthra</surname><given-names>P.</given-names></name><name><surname>Sun</surname><given-names>D.</given-names></name><name><surname>Silverman</surname><given-names>R. H.</given-names></name><name><surname>He</surname><given-names>B.</given-names></name></person-group><article-title>Activation of IFN-<italic>&#x003b2;</italic> expression by a viral mRNA through RNase L and MDA5</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2011</year><volume>108</volume><issue>5</issue><fpage>2118</fpage><lpage>2123</lpage><pub-id pub-id-type="doi">10.1073/pnas.1012409108</pub-id><pub-id pub-id-type="other">2-s2.0-79952125382</pub-id><?supplied-pmid 21245317?><pub-id pub-id-type="pmid">21245317</pub-id></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaap-Nutt</surname><given-names>A.</given-names></name><name><surname>D'Angelo</surname><given-names>C.</given-names></name><name><surname>Scull</surname><given-names>M. A.</given-names></name><etal/></person-group><article-title>Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates</article-title><source><italic toggle="yes">Virology</italic></source><year>2010</year><volume>397</volume><issue>2</issue><fpage>285</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2009.11.018</pub-id><pub-id pub-id-type="other">2-s2.0-75949087764</pub-id><?supplied-pmid 19969320?><pub-id pub-id-type="pmid">19969320</pub-id></element-citation></ref><ref id="B108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boonyaratanakornkit</surname><given-names>J. B.</given-names></name><name><surname>Bartlett</surname><given-names>E. J.</given-names></name><name><surname>Amaro-Carambot</surname><given-names>E.</given-names></name><name><surname>Collins</surname><given-names>P. L.</given-names></name><name><surname>Murphy</surname><given-names>B. R.</given-names></name><name><surname>Schmidt</surname><given-names>A. C.</given-names></name></person-group><article-title>The C proteins of human parainfluenza virus type 1 (HPIV1) control the transcription of a broad array of cellular genes that would otherwise respond to HPIV1 infection</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2009</year><volume>83</volume><issue>4</issue><fpage>1892</fpage><lpage>1910</lpage><pub-id pub-id-type="doi">10.1128/JVI.01373-08</pub-id><pub-id pub-id-type="other">2-s2.0-59649088310</pub-id><?supplied-pmid 19052086?><pub-id pub-id-type="pmid">19052086</pub-id></element-citation></ref><ref id="B109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boonyaratanakornkit</surname><given-names>J.</given-names></name><name><surname>Bartlett</surname><given-names>E.</given-names></name><name><surname>Schomacker</surname><given-names>H.</given-names></name><etal/></person-group><article-title>The C proteins of human parainfluenza virus type 1 limit double-stranded RNA accumulation that would otherwise trigger activation of MDA5 and protein kinase R</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2011</year><volume>85</volume><issue>4</issue><fpage>1495</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.1128/JVI.01297-10</pub-id><pub-id pub-id-type="other">2-s2.0-78951490665</pub-id><?supplied-pmid 21123378?><pub-id pub-id-type="pmid">21123378</pub-id></element-citation></ref><ref id="B110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cleve</surname><given-names>W.</given-names></name><name><surname>Amaro-Carambot</surname><given-names>E.</given-names></name><name><surname>Surman</surname><given-names>S. R.</given-names></name><etal/></person-group><article-title>Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1</article-title><source><italic toggle="yes">Virology</italic></source><year>2006</year><volume>352</volume><issue>1</issue><fpage>61</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2006.04.011</pub-id><pub-id pub-id-type="other">2-s2.0-33746714414</pub-id><?supplied-pmid 16750233?><pub-id pub-id-type="pmid">16750233</pub-id></element-citation></ref><ref id="B111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malur</surname><given-names>A. G.</given-names></name><name><surname>Hoffman</surname><given-names>M. A.</given-names></name><name><surname>Banerjee</surname><given-names>A. K.</given-names></name></person-group><article-title>The human parainfluenza virus type 3 (HPIV 3) C protein inhibits viral transcription</article-title><source><italic toggle="yes">Virus Research</italic></source><year>2004</year><volume>99</volume><issue>2</issue><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2003.11.009</pub-id><pub-id pub-id-type="other">2-s2.0-1642471882</pub-id><?supplied-pmid 14749186?><pub-id pub-id-type="pmid">14749186</pub-id></element-citation></ref><ref id="B112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schomacker</surname><given-names>H.</given-names></name><name><surname>Hebner</surname><given-names>R. M.</given-names></name><name><surname>Boonyaratanakornkit</surname><given-names>J.</given-names></name><etal/></person-group><article-title>The C proteins of human parainfluenza virus type 1 block IFN signaling by binding and retaining Stat1 in perinuclear aggregates at the late endosome</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2012</year><volume>7</volume><issue>2, article e28382</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0028382</pub-id><pub-id pub-id-type="other">2-s2.0-84857088880</pub-id><?supplied-pmid 22355301?><pub-id pub-id-type="pmid">22355301</pub-id></element-citation></ref><ref id="B113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Childs</surname><given-names>K.</given-names></name><name><surname>Stock</surname><given-names>N.</given-names></name><name><surname>Ross</surname><given-names>C.</given-names></name><etal/></person-group><article-title>mda-5, but not RIG-I, is a common target for paramyxovirus V proteins</article-title><source><italic toggle="yes">Virology</italic></source><year>2007</year><volume>359</volume><issue>1</issue><fpage>190</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2006.09.023</pub-id><pub-id pub-id-type="other">2-s2.0-33846863325</pub-id><?supplied-pmid 17049367?><pub-id pub-id-type="pmid">17049367</pub-id></element-citation></ref><ref id="B114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrejeva</surname><given-names>J.</given-names></name><name><surname>Childs</surname><given-names>K. S.</given-names></name><name><surname>Young</surname><given-names>D. F.</given-names></name><etal/></person-group><article-title>The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>2004</year><volume>101</volume><issue>49</issue><fpage>17264</fpage><lpage>17269</lpage><pub-id pub-id-type="doi">10.1073/pnas.0407639101</pub-id><pub-id pub-id-type="other">2-s2.0-10344259136</pub-id><?supplied-pmid 15563593?><pub-id pub-id-type="pmid">15563593</pub-id></element-citation></ref><ref id="B115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrejeva</surname><given-names>J.</given-names></name><name><surname>Young</surname><given-names>D. F.</given-names></name><name><surname>Goodbourn</surname><given-names>S.</given-names></name><name><surname>Randall</surname><given-names>R. E.</given-names></name></person-group><article-title>Degradation of STAT1 and STAT2 by the V proteins of simian virus 5 and human parainfluenza virus type 2, respectively: consequences for virus replication in the presence of alpha/beta and gamma interferons</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2002</year><volume>76</volume><issue>5</issue><fpage>2159</fpage><lpage>2167</lpage><pub-id pub-id-type="doi">10.1128/jvi.76.5.2159-2167.2002</pub-id><pub-id pub-id-type="other">2-s2.0-0036168735</pub-id><?supplied-pmid 11836393?><pub-id pub-id-type="pmid">11836393</pub-id></element-citation></ref><ref id="B116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>D. R.</given-names></name><name><surname>Zhu</surname><given-names>H. Z.</given-names></name></person-group><article-title>Hepatitis C virus and antiviral innate immunity: who wins at tug-of-war?</article-title><source><italic toggle="yes">World Journal of Gastroenterology</italic></source><year>2015</year><volume>21</volume><issue>13</issue><fpage>3786</fpage><lpage>3800</lpage><pub-id pub-id-type="doi">10.3748/wjg.v21.i13.3786</pub-id><pub-id pub-id-type="other">2-s2.0-84926650523</pub-id><?supplied-pmid 25852264?><pub-id pub-id-type="pmid">25852264</pub-id></element-citation></ref><ref id="B117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaap-Nutt</surname><given-names>A.</given-names></name><name><surname>Liesman</surname><given-names>R.</given-names></name><name><surname>Bartlett</surname><given-names>E. J.</given-names></name><etal/></person-group><article-title>Human parainfluenza virus serotypes differ in their kinetics of replication and cytokine secretion in human tracheobronchial airway epithelium</article-title><source><italic toggle="yes">Virology</italic></source><year>2012</year><volume>433</volume><issue>2</issue><fpage>320</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2012.08.027</pub-id><pub-id pub-id-type="other">2-s2.0-84867220341</pub-id><?supplied-pmid 22959894?><pub-id pub-id-type="pmid">22959894</pub-id></element-citation></ref><ref id="B118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gern</surname><given-names>J. E.</given-names></name></person-group><article-title>The ABCs of rhinoviruses, wheezing, and asthma</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2010</year><volume>84</volume><issue>15</issue><fpage>7418</fpage><lpage>7426</lpage><pub-id pub-id-type="doi">10.1128/JVI.02290-09</pub-id><pub-id pub-id-type="other">2-s2.0-77954524570</pub-id><?supplied-pmid 20375160?><pub-id pub-id-type="pmid">20375160</pub-id></element-citation></ref><ref id="B119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fendrick</surname><given-names>A. M.</given-names></name></person-group><article-title>Viral respiratory infections due to rhinoviruses: current knowledge, new developments</article-title><source><italic toggle="yes">American Journal of Therapeutics</italic></source><year>2003</year><volume>10</volume><issue>3</issue><fpage>193</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1097/00045391-200305000-00006</pub-id><pub-id pub-id-type="other">2-s2.0-0141430913</pub-id><?supplied-pmid 12756426?><pub-id pub-id-type="pmid">12756426</pub-id></element-citation></ref><ref id="B120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Triantafilou</surname><given-names>K.</given-names></name><name><surname>Vakakis</surname><given-names>E.</given-names></name><name><surname>Richer</surname><given-names>E. A. J.</given-names></name><name><surname>Evans</surname><given-names>G. L.</given-names></name><name><surname>Villiers</surname><given-names>J. P.</given-names></name><name><surname>Triantafilou</surname><given-names>M.</given-names></name></person-group><article-title>Human rhinovirus recognition in non-immune cells is mediated by toll-like receptors and MDA-5, which trigger a synergetic pro-inflammatory immune response</article-title><source><italic toggle="yes">Virulence</italic></source><year>2011</year><volume>2</volume><issue>1</issue><fpage>22</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.4161/viru.2.1.13807</pub-id><pub-id pub-id-type="other">2-s2.0-79951494075</pub-id><?supplied-pmid 21224721?><pub-id pub-id-type="pmid">21224721</pub-id></element-citation></ref><ref id="B121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hewson</surname><given-names>C. A.</given-names></name><name><surname>Jardine</surname><given-names>A.</given-names></name><name><surname>Edwards</surname><given-names>M. R.</given-names></name><name><surname>Laza-Stanca</surname><given-names>V.</given-names></name><name><surname>Johnston</surname><given-names>S. L.</given-names></name></person-group><article-title>Toll-like receptor 3 is induced by and mediates antiviral activity against rhinovirus infection of human bronchial epithelial cells</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2005</year><volume>79</volume><issue>19</issue><fpage>12273</fpage><lpage>12279</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.19.12273-12279.2005</pub-id><pub-id pub-id-type="other">2-s2.0-25144439512</pub-id><?supplied-pmid 16160153?><pub-id pub-id-type="pmid">16160153</pub-id></element-citation></ref><ref id="B122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Miller</surname><given-names>D. J.</given-names></name><name><surname>Bowman</surname><given-names>E. R.</given-names></name><etal/></person-group><article-title>MDA5 and TLR3 initiate pro-inflammatory signaling pathways leading to rhinovirus-induced airways inflammation and hyperresponsiveness</article-title><source><italic toggle="yes">PLoS Pathogens</italic></source><year>2011</year><volume>7</volume><issue>5, article e1002070</issue><pub-id pub-id-type="doi">10.1371/journal.ppat.1002070</pub-id><pub-id pub-id-type="other">2-s2.0-79958062793</pub-id><?supplied-pmid 21637773?><pub-id pub-id-type="pmid">21637773</pub-id></element-citation></ref><ref id="B123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slater</surname><given-names>L.</given-names></name><name><surname>Bartlett</surname><given-names>N. W.</given-names></name><name><surname>Haas</surname><given-names>J. J.</given-names></name><etal/></person-group><article-title>Co-ordinated role of TLR3, RIG-I and MDA5 in the innate response to rhinovirus in bronchial epithelium</article-title><source><italic toggle="yes">PLoS Pathogens</italic></source><year>2010</year><volume>6</volume><issue>11, article e1001178</issue><pub-id pub-id-type="doi">10.1371/journal.ppat.1001178</pub-id><pub-id pub-id-type="other">2-s2.0-79251492014</pub-id><?supplied-pmid 21079690?><pub-id pub-id-type="pmid">21079690</pub-id></element-citation></ref><ref id="B124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartlett</surname><given-names>N. W.</given-names></name><name><surname>Slater</surname><given-names>L.</given-names></name><name><surname>Glanville</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Defining critical roles for NF&#x02010;<italic>&#x003ba;</italic>B p65 and type I interferon in innate immunity to rhinovirus</article-title><source><italic toggle="yes">EMBO Molecular Medicine</italic></source><year>2012</year><volume>4</volume><issue>12</issue><fpage>1244</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1002/emmm.201201650</pub-id><pub-id pub-id-type="other">2-s2.0-84872375201</pub-id><pub-id pub-id-type="pmid">23165884</pub-id></element-citation></ref><ref id="B125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drahos</surname><given-names>J.</given-names></name><name><surname>Racaniello</surname><given-names>V. R.</given-names></name></person-group><article-title>Cleavage of IPS-1 in cells infected with human rhinovirus</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2009</year><volume>83</volume><issue>22</issue><fpage>11581</fpage><lpage>11587</lpage><pub-id pub-id-type="doi">10.1128/JVI.01490-09</pub-id><pub-id pub-id-type="other">2-s2.0-70350625078</pub-id><?supplied-pmid 19740998?><pub-id pub-id-type="pmid">19740998</pub-id></element-citation></ref><ref id="B126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barral</surname><given-names>P. M.</given-names></name><name><surname>Sarkar</surname><given-names>D.</given-names></name><name><surname>Fisher</surname><given-names>P. B.</given-names></name><name><surname>Racaniello</surname><given-names>V. R.</given-names></name></person-group><article-title>RIG-I is cleaved during picornavirus infection</article-title><source><italic toggle="yes">Virology</italic></source><year>2009</year><volume>391</volume><issue>2</issue><fpage>171</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2009.06.045</pub-id><pub-id pub-id-type="other">2-s2.0-68649098926</pub-id><?supplied-pmid 19628239?><pub-id pub-id-type="pmid">19628239</pub-id></element-citation></ref><ref id="B127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>M. R.</given-names></name><name><surname>Regamey</surname><given-names>N.</given-names></name><name><surname>Vareille</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Impaired innate interferon induction in severe therapy resistant atopic asthmatic children</article-title><source><italic toggle="yes">Mucosal Immunology</italic></source><year>2013</year><volume>6</volume><issue>4</issue><fpage>797</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1038/mi.2012.118</pub-id><pub-id pub-id-type="other">2-s2.0-84879400685</pub-id><?supplied-pmid 23212197?><pub-id pub-id-type="pmid">23212197</pub-id></element-citation></ref><ref id="B128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname><given-names>Y.</given-names></name><name><surname>Finlayson</surname><given-names>A.</given-names></name><name><surname>White</surname><given-names>O. J.</given-names></name><name><surname>Carroll</surname><given-names>M. L.</given-names></name><name><surname>Upham</surname><given-names>J. W.</given-names></name></person-group><article-title>Rhinovirus stimulated IFN-<italic>&#x003b1;</italic> production: how important are plasmacytoid DCs, monocytes and endosomal pH?</article-title><source><italic toggle="yes">Clin Transl Immunology</italic></source><year>2015</year><volume>4</volume><issue>10, article e46</issue><pub-id pub-id-type="doi">10.1038/cti.2015.27</pub-id><?supplied-pmid 26682054?><pub-id pub-id-type="pmid">26682054</pub-id></element-citation></ref><ref id="B129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sykes</surname><given-names>A.</given-names></name><name><surname>Edwards</surname><given-names>M. R.</given-names></name><name><surname>Macintyre</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Rhinovirus 16-induced IFN-<italic>&#x003b1;</italic> and IFN-<italic>&#x003b2;</italic> are deficient in bronchoalveolar lavage cells in asthmatic patients</article-title><source><italic toggle="yes">The Journal of Allergy and Clinical Immunology</italic></source><year>2012</year><volume>129</volume><issue>6</issue><fpage>1506</fpage><lpage>1514.e6</lpage><comment>e6</comment><pub-id pub-id-type="doi">10.1016/j.jaci.2012.03.044</pub-id><pub-id pub-id-type="other">2-s2.0-84861654883</pub-id><?supplied-pmid 22657407?><pub-id pub-id-type="pmid">22657407</pub-id></element-citation></ref><ref id="B130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>T. M.</given-names></name><name><surname>Durrani</surname><given-names>S. R.</given-names></name><name><surname>Bochkov</surname><given-names>Y. A.</given-names></name><name><surname>Devries</surname><given-names>M. K.</given-names></name><name><surname>Rajamanickam</surname><given-names>V.</given-names></name><name><surname>Jackson</surname><given-names>D. J.</given-names></name></person-group><article-title>Effect of exogenous interferons on rhinovirus replication and airway inflammatory responses</article-title><source><italic toggle="yes">Annals of Allergy, Asthma &#x00026; Immunology</italic></source><year>2013</year><volume>111</volume><issue>5</issue><fpage>397</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1016/j.anai.2013.07.029</pub-id><pub-id pub-id-type="other">2-s2.0-84885958643</pub-id><?supplied-pmid 24125148?><pub-id pub-id-type="pmid">24125148</pub-id></element-citation></ref><ref id="B131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cakebread</surname><given-names>J. A.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Grainge</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Exogenous IFN-<italic>&#x003b2;</italic> has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus</article-title><source><italic toggle="yes">The Journal of Allergy and Clinical Immunology</italic></source><year>2011</year><volume>127</volume><issue>5</issue><fpage>1148</fpage><lpage>1154.e9</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2011.01.023</pub-id><pub-id pub-id-type="other">2-s2.0-79955634439</pub-id><?supplied-pmid 21329968?><pub-id pub-id-type="pmid">21329968</pub-id></element-citation></ref><ref id="B132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>J. L.</given-names></name><name><surname>Shaker</surname><given-names>M.</given-names></name><name><surname>McMeen</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Comparison of viral load in individuals with and without asthma during infections with rhinovirus</article-title><source><italic toggle="yes">American Journal of Respiratory and Critical Care Medicine</italic></source><year>2014</year><volume>189</volume><issue>5</issue><fpage>532</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1164/rccm.201310-1767OC</pub-id><pub-id pub-id-type="other">2-s2.0-84895538373</pub-id><?supplied-pmid 24471509?><pub-id pub-id-type="pmid">24471509</pub-id></element-citation></ref><ref id="B133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Hoek</surname><given-names>L.</given-names></name></person-group><article-title>Human coronaviruses: what do they cause?</article-title><source><italic toggle="yes">Antiviral Therapy</italic></source><year>2007</year><volume>12</volume><issue>4 Part B</issue><fpage>651</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">17944272</pub-id></element-citation></ref><ref id="B134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masters</surname><given-names>P. S.</given-names></name></person-group><article-title>The molecular biology of coronaviruses</article-title><source><italic toggle="yes">Advances in Virus Research</italic></source><year>2006</year><volume>66</volume><fpage>193</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/S0065-3527(06)66005-3</pub-id><pub-id pub-id-type="other">2-s2.0-33746317830</pub-id><?supplied-pmid 16877062?><pub-id pub-id-type="pmid">16877062</pub-id></element-citation></ref><ref id="B135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorbalenya</surname><given-names>A. E.</given-names></name><name><surname>Snijder</surname><given-names>E. J.</given-names></name><name><surname>Spaan</surname><given-names>W. J.</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus phylogeny: toward consensus</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2004</year><volume>78</volume><issue>15</issue><fpage>7863</fpage><lpage>7866</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.15.7863-7866.2004</pub-id><pub-id pub-id-type="other">2-s2.0-3242695128</pub-id><?supplied-pmid 15254158?><pub-id pub-id-type="pmid">15254158</pub-id></element-citation></ref><ref id="B136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Guo</surname><given-names>D.</given-names></name></person-group><article-title>Emerging coronaviruses: genome structure, replication, and pathogenesis</article-title><source><italic toggle="yes">Journal of Medical Virology</italic></source><year>2020</year><volume>92</volume><issue>4</issue><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1002/jmv.25681</pub-id><?supplied-pmid 31967327?><pub-id pub-id-type="pmid">31967327</pub-id></element-citation></ref><ref id="B137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>S.</given-names></name><name><surname>Thomsen</surname><given-names>A. R.</given-names></name></person-group><article-title>Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2012</year><volume>86</volume><issue>6</issue><fpage>2900</fpage><lpage>2910</lpage><pub-id pub-id-type="doi">10.1128/JVI.05738-11</pub-id><pub-id pub-id-type="other">2-s2.0-84857969026</pub-id><?supplied-pmid 22258243?><pub-id pub-id-type="pmid">22258243</pub-id></element-citation></ref><ref id="B138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>D. E.</given-names></name><name><surname>Marie</surname><given-names>I. J.</given-names></name><name><surname>Durbin</surname><given-names>J. E.</given-names></name></person-group><article-title>Induction and function of type I and III interferon in response to viral infection</article-title><source><italic toggle="yes">Current Opinion in Virology</italic></source><year>2011</year><volume>1</volume><issue>6</issue><fpage>476</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2011.11.001</pub-id><pub-id pub-id-type="other">2-s2.0-82955163285</pub-id><?supplied-pmid 22323926?><pub-id pub-id-type="pmid">22323926</pub-id></element-citation></ref><ref id="B139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNab</surname><given-names>F.</given-names></name><name><surname>Mayer-Barber</surname><given-names>K.</given-names></name><name><surname>Sher</surname><given-names>A.</given-names></name><name><surname>Wack</surname><given-names>A.</given-names></name><name><surname>O'Garra</surname><given-names>A.</given-names></name></person-group><article-title>Type I interferons in infectious disease</article-title><source><italic toggle="yes">Nature Reviews Immunology</italic></source><year>2015</year><volume>15</volume><issue>2</issue><fpage>87</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1038/nri3787</pub-id><pub-id pub-id-type="other">2-s2.0-84923000335</pub-id><?supplied-pmid 25614319?><pub-id pub-id-type="pmid">25614319</pub-id></element-citation></ref><ref id="B140"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menachery</surname><given-names>V. D.</given-names></name><name><surname>Eisfeld</surname><given-names>A. J.</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses</article-title><source><italic toggle="yes">MBio</italic></source><year>2014</year><volume>5</volume><issue>3</issue><fpage>p. e01174</fpage><pub-id pub-id-type="doi">10.1128/mBio.01174-14</pub-id><pub-id pub-id-type="other">2-s2.0-84904015653</pub-id><?supplied-pmid 24846384?><pub-id pub-id-type="pmid">24846384</pub-id></element-citation></ref><ref id="B141"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Z&#x000fc;st</surname><given-names>R.</given-names></name><name><surname>Cervantes-Barragan</surname><given-names>L.</given-names></name><name><surname>Habjan</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Ribose 2&#x02019;- _O_ -methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5</article-title><source><italic toggle="yes">Nature Immunology</italic></source><year>2011</year><volume>12</volume><issue>2</issue><fpage>137</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1038/ni.1979</pub-id><pub-id pub-id-type="other">2-s2.0-78751637122</pub-id><?supplied-pmid 21217758?><pub-id pub-id-type="pmid">21217758</pub-id></element-citation></ref><ref id="B142"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frieman</surname><given-names>M.</given-names></name><name><surname>Ratia</surname><given-names>K.</given-names></name><name><surname>Johnston</surname><given-names>R. E.</given-names></name><name><surname>Mesecar</surname><given-names>A. D.</given-names></name><name><surname>Baric</surname><given-names>R. S.</given-names></name></person-group><article-title>Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2009</year><volume>83</volume><issue>13</issue><fpage>6689</fpage><lpage>6705</lpage><pub-id pub-id-type="doi">10.1128/JVI.02220-08</pub-id><pub-id pub-id-type="other">2-s2.0-67449088510</pub-id><?supplied-pmid 19369340?><pub-id pub-id-type="pmid">19369340</pub-id></element-citation></ref><ref id="B143"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devaraj</surname><given-names>S. G.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus</article-title><source><italic toggle="yes">The Journal of Biological Chemistry</italic></source><year>2007</year><volume>282</volume><issue>44</issue><fpage>32208</fpage><lpage>32221</lpage><pub-id pub-id-type="doi">10.1074/jbc.M704870200</pub-id><pub-id pub-id-type="other">2-s2.0-36148979683</pub-id><?supplied-pmid 17761676?><pub-id pub-id-type="pmid">17761676</pub-id></element-citation></ref><ref id="B144"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mielech</surname><given-names>A. M.</given-names></name><name><surname>Kilianski</surname><given-names>A.</given-names></name><name><surname>Baez-Santos</surname><given-names>Y. M.</given-names></name><name><surname>Mesecar</surname><given-names>A. D.</given-names></name><name><surname>Baker</surname><given-names>S. C.</given-names></name></person-group><article-title>MERS-CoV papain-like protease has deISGylating and deubiquitinating activities</article-title><source><italic toggle="yes">Virology</italic></source><year>2014</year><volume>450-451</volume><fpage>64</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2013.11.040</pub-id><pub-id pub-id-type="other">2-s2.0-84890863276</pub-id><?supplied-pmid 24503068?><pub-id pub-id-type="pmid">24503068</pub-id></element-citation></ref><ref id="B145"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siu</surname><given-names>K. L.</given-names></name><name><surname>Kok</surname><given-names>K. H.</given-names></name><name><surname>Ng</surname><given-names>M. H.</given-names></name><etal/></person-group><article-title>Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex</article-title><source><italic toggle="yes">The Journal of Biological Chemistry</italic></source><year>2009</year><volume>284</volume><issue>24</issue><fpage>16202</fpage><lpage>16209</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.008227</pub-id><pub-id pub-id-type="other">2-s2.0-67650230347</pub-id><?supplied-pmid 19380580?><pub-id pub-id-type="pmid">19380580</pub-id></element-citation></ref><ref id="B146"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>C. S.</given-names></name><name><surname>Qi</surname><given-names>H. Y.</given-names></name><name><surname>Boularan</surname><given-names>C.</given-names></name><etal/></person-group><article-title>SARS-coronavirus open reading frame-9b suppresses innate immunity by targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2014</year><volume>193</volume><issue>6</issue><fpage>3080</fpage><lpage>3089</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1303196</pub-id><pub-id pub-id-type="other">2-s2.0-84921664520</pub-id><?supplied-pmid 25135833?><pub-id pub-id-type="pmid">25135833</pub-id></element-citation></ref><ref id="B147"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheuplein</surname><given-names>V. A.</given-names></name><name><surname>Seifried</surname><given-names>J.</given-names></name><name><surname>Malczyk</surname><given-names>A. H.</given-names></name><etal/></person-group><article-title>High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2015</year><volume>89</volume><issue>7</issue><fpage>3859</fpage><lpage>3869</lpage><pub-id pub-id-type="doi">10.1128/JVI.03607-14</pub-id><pub-id pub-id-type="other">2-s2.0-84924787740</pub-id><?supplied-pmid 25609809?><pub-id pub-id-type="pmid">25609809</pub-id></element-citation></ref><ref id="B148"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>M. J.</given-names></name><name><surname>Ran</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2007</year><volume>81</volume><issue>16</issue><fpage>8692</fpage><lpage>8706</lpage><pub-id pub-id-type="doi">10.1128/JVI.00527-07</pub-id><pub-id pub-id-type="other">2-s2.0-34547814128</pub-id><?supplied-pmid 17537853?><pub-id pub-id-type="pmid">17537853</pub-id></element-citation></ref><ref id="B149"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gould</surname><given-names>E.</given-names></name><name><surname>Pettersson</surname><given-names>J.</given-names></name><name><surname>Higgs</surname><given-names>S.</given-names></name><name><surname>Charrel</surname><given-names>R.</given-names></name><name><surname>de Lamballerie</surname><given-names>X.</given-names></name></person-group><article-title>Emerging arboviruses: why today?</article-title><source><italic toggle="yes">One Health</italic></source><year>2017</year><volume>4</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.onehlt.2017.06.001</pub-id><pub-id pub-id-type="other">2-s2.0-85021734175</pub-id><?supplied-pmid 28785601?><pub-id pub-id-type="pmid">28785601</pub-id></element-citation></ref><ref id="B150"><label>150</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pierson</surname><given-names>C. P.</given-names></name><name><surname>Diamond</surname><given-names>M. S.</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Knipe</surname><given-names>D. M.</given-names></name><name><surname>Howley</surname><given-names>P. M.</given-names></name></person-group><article-title>Flaviviruses</article-title><source><italic toggle="yes">Fields Virology</italic></source><year>2013</year><publisher-loc>Philadelphia</publisher-loc><publisher-name>Lippincott-Raven</publisher-name><fpage>747</fpage><lpage>794</lpage></element-citation></ref><ref id="B151"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gack</surname><given-names>M. U.</given-names></name><name><surname>Diamond</surname><given-names>M. S.</given-names></name></person-group><article-title>Innate immune escape by dengue and West Nile viruses</article-title><source><italic toggle="yes">Current Opinion in Virology</italic></source><year>2016</year><volume>20</volume><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2016.09.013</pub-id><pub-id pub-id-type="other">2-s2.0-84992512259</pub-id><?supplied-pmid 27792906?><pub-id pub-id-type="pmid">27792906</pub-id></element-citation></ref><ref id="B152"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cumberworth</surname><given-names>S. L.</given-names></name><name><surname>Clark</surname><given-names>J. J.</given-names></name><name><surname>Kohl</surname><given-names>A.</given-names></name><name><surname>Donald</surname><given-names>C. L.</given-names></name></person-group><article-title>Inhibition of type I interferon induction and signalling by mosquito-borne flaviviruses</article-title><source><italic toggle="yes">Cellular Microbiology</italic></source><year>2017</year><volume>19</volume><issue>5</issue><fpage>p. e12737</fpage><pub-id pub-id-type="doi">10.1111/cmi.12737</pub-id><pub-id pub-id-type="other">2-s2.0-85016225932</pub-id><?supplied-pmid 28273394?><pub-id pub-id-type="pmid">28273394</pub-id></element-citation></ref><ref id="B153"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>M. S.</given-names></name></person-group><article-title>Mechanisms of evasion of the type I interferon antiviral response by flaviviruses</article-title><source><italic toggle="yes">Journal of Interferon &#x00026; Cytokine Research</italic></source><year>2009</year><volume>29</volume><issue>9</issue><fpage>521</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1089/jir.2009.0069</pub-id><pub-id pub-id-type="other">2-s2.0-70349263719</pub-id><?supplied-pmid 19694536?><pub-id pub-id-type="pmid">19694536</pub-id></element-citation></ref><ref id="B154"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>J. H.</given-names></name><name><surname>Wang</surname><given-names>M. Y.</given-names></name><name><surname>Huang</surname><given-names>C. Y.</given-names></name><etal/></person-group><article-title>Infection with the dengue RNA virus activates TLR9 signaling in human dendritic cells</article-title><source><italic toggle="yes">EMBO Reports</italic></source><year>2018</year><volume>19</volume><issue>8</issue><pub-id pub-id-type="doi">10.15252/embr.201846182</pub-id><pub-id pub-id-type="other">2-s2.0-85051069987</pub-id><?supplied-pmid 29880709?><pub-id pub-id-type="pmid">29880709</pub-id></element-citation></ref><ref id="B155"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoggins</surname><given-names>J. W.</given-names></name><name><surname>MacDuff</surname><given-names>D.</given-names></name><name><surname>Imanaka</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity</article-title><source><italic toggle="yes">Nature</italic></source><year>2014</year><volume>505</volume><issue>7485</issue><fpage>691</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1038/nature12862</pub-id><pub-id pub-id-type="other">2-s2.0-84895904323</pub-id><?supplied-pmid 24284630?><pub-id pub-id-type="pmid">24284630</pub-id></element-citation></ref><ref id="B156"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assil</surname><given-names>S.</given-names></name><name><surname>Col&#x000e9;on</surname><given-names>S.</given-names></name><name><surname>Dong</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Plasmacytoid dendritic cells and infected cells form an interferogenic synapse required for antiviral responses</article-title><source><italic toggle="yes">Cell Host &#x00026; Microbe</italic></source><year>2019</year><volume>25</volume><issue>5</issue><fpage>730</fpage><lpage>745.e6</lpage><comment>e6</comment><pub-id pub-id-type="doi">10.1016/j.chom.2019.03.005</pub-id><pub-id pub-id-type="other">2-s2.0-85064972022</pub-id><?supplied-pmid 31003939?><pub-id pub-id-type="pmid">31003939</pub-id></element-citation></ref><ref id="B157"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castillo Ramirez</surname><given-names>J. A.</given-names></name><name><surname>Urcuqui-Inchima</surname><given-names>S.</given-names></name></person-group><article-title>Dengue virus control of Type I IFN responses: a history of manipulation and control</article-title><source><italic toggle="yes">Journal of Interferon &#x00026; Cytokine Research</italic></source><year>2015</year><volume>35</volume><issue>6</issue><fpage>421</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1089/jir.2014.0129</pub-id><pub-id pub-id-type="other">2-s2.0-84931058316</pub-id><?supplied-pmid 25629430?><pub-id pub-id-type="pmid">25629430</pub-id></element-citation></ref><ref id="B158"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Best</surname><given-names>S. M.</given-names></name></person-group><article-title>The many faces of the flavivirus NS5 protein in antagonism of type I interferon signaling</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2017</year><volume>91</volume><issue>3</issue><pub-id pub-id-type="doi">10.1128/JVI.01970-16</pub-id><pub-id pub-id-type="other">2-s2.0-85010876906</pub-id><?supplied-pmid 27881649?><pub-id pub-id-type="pmid">27881649</pub-id></element-citation></ref><ref id="B159"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Zika virus evades interferon-mediated antiviral response through the co- operation of multiple nonstructural proteins <italic>in vitro</italic></article-title><source><italic toggle="yes">Cell Discovery</italic></source><year>2017</year><volume>3</volume><issue>1</issue><fpage>p. 17006</fpage><pub-id pub-id-type="doi">10.1038/celldisc.2017.6</pub-id><pub-id pub-id-type="other">2-s2.0-85021049648</pub-id></element-citation></ref><ref id="B160"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnettler</surname><given-names>E.</given-names></name><name><surname>Sterken</surname><given-names>M. G.</given-names></name><name><surname>Leung</surname><given-names>J. Y.</given-names></name><etal/></person-group><article-title>Noncoding flavivirus RNA displays RNA interference suppressor activity in insect and Mammalian cells</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2012</year><volume>86</volume><issue>24</issue><fpage>13486</fpage><lpage>13500</lpage><pub-id pub-id-type="doi">10.1128/JVI.01104-12</pub-id><pub-id pub-id-type="other">2-s2.0-84870716729</pub-id><?supplied-pmid 23035235?><pub-id pub-id-type="pmid">23035235</pub-id></element-citation></ref><ref id="B161"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donald</surname><given-names>C. L.</given-names></name><name><surname>Brennan</surname><given-names>B.</given-names></name><name><surname>Cumberworth</surname><given-names>S. L.</given-names></name><etal/></person-group><article-title>Full genome sequence and sfRNA interferon antagonist activity of Zika virus from Recife, Brazil</article-title><source><italic toggle="yes">PLoS Neglected Tropical Diseases</italic></source><year>2016</year><volume>10</volume><issue>10, article e0005048</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0005048</pub-id><pub-id pub-id-type="other">2-s2.0-84994245990</pub-id><?supplied-pmid 27706161?><pub-id pub-id-type="pmid">27706161</pub-id></element-citation></ref><ref id="B162"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manokaran</surname><given-names>G.</given-names></name><name><surname>Finol</surname><given-names>E.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness</article-title><source><italic toggle="yes">Science</italic></source><year>2015</year><volume>350</volume><issue>6257</issue><fpage>217</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1126/science.aab3369</pub-id><pub-id pub-id-type="other">2-s2.0-84943577112</pub-id><?supplied-pmid 26138103?><pub-id pub-id-type="pmid">26138103</pub-id></element-citation></ref><ref id="B163"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orozco</surname><given-names>S.</given-names></name><name><surname>Schmid</surname><given-names>M. A.</given-names></name><name><surname>Parameswaran</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor</article-title><source><italic toggle="yes">The Journal of General Virology</italic></source><year>2012</year><volume>93, Part 10</volume><fpage>2152</fpage><lpage>2157</lpage><pub-id pub-id-type="doi">10.1099/vir.0.045088-0</pub-id><pub-id pub-id-type="other">2-s2.0-84866318086</pub-id><?supplied-pmid 22815273?><pub-id pub-id-type="pmid">22815273</pub-id></element-citation></ref><ref id="B164"><label>164</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zellweger</surname><given-names>R. M.</given-names></name><name><surname>Prestwood</surname><given-names>T. R.</given-names></name><name><surname>Shresta</surname><given-names>S.</given-names></name></person-group><article-title>Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease</article-title><source><italic toggle="yes">Cell Host &#x00026; Microbe</italic></source><year>2010</year><volume>7</volume><issue>2</issue><fpage>128</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2010.01.004</pub-id><pub-id pub-id-type="other">2-s2.0-76249103868</pub-id><?supplied-pmid 20153282?><pub-id pub-id-type="pmid">20153282</pub-id></element-citation></ref><ref id="B165"><label>165</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazear</surname><given-names>H. M.</given-names></name><name><surname>Govero</surname><given-names>J.</given-names></name><name><surname>Smith</surname><given-names>A. M.</given-names></name><etal/></person-group><article-title>A mouse model of Zika virus pathogenesis</article-title><source><italic toggle="yes">Cell Host &#x00026; Microbe</italic></source><year>2016</year><volume>19</volume><issue>5</issue><fpage>720</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.03.010</pub-id><pub-id pub-id-type="other">2-s2.0-84962438993</pub-id><?supplied-pmid 27066744?><pub-id pub-id-type="pmid">27066744</pub-id></element-citation></ref><ref id="B166"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samuel</surname><given-names>M. A.</given-names></name><name><surname>Diamond</surname><given-names>M. S.</given-names></name></person-group><article-title>Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2005</year><volume>79</volume><issue>21</issue><fpage>13350</fpage><lpage>13361</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.21.13350-13361.2005</pub-id><pub-id pub-id-type="other">2-s2.0-27144486896</pub-id><?supplied-pmid 16227257?><pub-id pub-id-type="pmid">16227257</pub-id></element-citation></ref><ref id="B167"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzman</surname><given-names>M. G.</given-names></name><name><surname>Harris</surname><given-names>E.</given-names></name></person-group><article-title>Dengue</article-title><source><italic toggle="yes">Lancet</italic></source><year>2015</year><volume>385</volume><issue>9966</issue><fpage>453</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)60572-9</pub-id><pub-id pub-id-type="other">2-s2.0-84923306752</pub-id><?supplied-pmid 25230594?><pub-id pub-id-type="pmid">25230594</pub-id></element-citation></ref><ref id="B168"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>S.</given-names></name><name><surname>Gething</surname><given-names>P. W.</given-names></name><name><surname>Brady</surname><given-names>O. J.</given-names></name><etal/></person-group><article-title>The global distribution and burden of dengue</article-title><source><italic toggle="yes">Nature</italic></source><year>2013</year><volume>496</volume><issue>7446</issue><fpage>504</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1038/nature12060</pub-id><pub-id pub-id-type="other">2-s2.0-84876804736</pub-id><?supplied-pmid 23563266?><pub-id pub-id-type="pmid">23563266</pub-id></element-citation></ref><ref id="B169"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martina</surname><given-names>B. E.</given-names></name><name><surname>Koraka</surname><given-names>P.</given-names></name><name><surname>Osterhaus</surname><given-names>A. D.</given-names></name></person-group><article-title>Dengue virus pathogenesis: an integrated view</article-title><source><italic toggle="yes">Clinical Microbiology Reviews</italic></source><year>2009</year><volume>22</volume><issue>4</issue><fpage>564</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1128/CMR.00035-09</pub-id><pub-id pub-id-type="other">2-s2.0-70449094069</pub-id><?supplied-pmid 19822889?><pub-id pub-id-type="pmid">19822889</pub-id></element-citation></ref><ref id="B170"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzman</surname><given-names>M. G.</given-names></name><name><surname>Gubler</surname><given-names>D. J.</given-names></name><name><surname>Izquierdo</surname><given-names>A.</given-names></name><name><surname>Martinez</surname><given-names>E.</given-names></name><name><surname>Halstead</surname><given-names>S. B.</given-names></name></person-group><article-title>Dengue infection</article-title><source><italic toggle="yes">Nature Reviews Disease Primers</italic></source><year>2016</year><volume>2</volume><issue>1</issue><fpage>p. 16055</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2016.55</pub-id><pub-id pub-id-type="other">2-s2.0-85006210691</pub-id></element-citation></ref><ref id="B171"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngono</surname><given-names>A. E.</given-names></name><name><surname>Shresta</surname><given-names>S.</given-names></name></person-group><article-title>Immune response to dengue and Zika</article-title><source><italic toggle="yes">Annual Review of Immunology</italic></source><year>2018</year><volume>36</volume><fpage>279</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-042617-053142</pub-id><pub-id pub-id-type="other">2-s2.0-85045086099</pub-id><?supplied-pmid 29345964?><pub-id pub-id-type="pmid">29345964</pub-id></element-citation></ref><ref id="B172"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>M. S.</given-names></name><name><surname>Harris</surname><given-names>E.</given-names></name></person-group><article-title>Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism</article-title><source><italic toggle="yes">Virology</italic></source><year>2001</year><volume>289</volume><issue>2</issue><fpage>297</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1006/viro.2001.1114</pub-id><pub-id pub-id-type="other">2-s2.0-0035950611</pub-id><?supplied-pmid 11689052?><pub-id pub-id-type="pmid">11689052</pub-id></element-citation></ref><ref id="B173"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>M. S.</given-names></name><name><surname>Roberts</surname><given-names>T. G.</given-names></name><name><surname>Edgil</surname><given-names>D.</given-names></name><name><surname>Lu</surname><given-names>B.</given-names></name><name><surname>Ernst</surname><given-names>J.</given-names></name><name><surname>Harris</surname><given-names>E.</given-names></name></person-group><article-title>Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2000</year><volume>74</volume><issue>11</issue><fpage>4957</fpage><lpage>4966</lpage><pub-id pub-id-type="doi">10.1128/jvi.74.11.4957-4966.2000</pub-id><pub-id pub-id-type="other">2-s2.0-0034101043</pub-id><?supplied-pmid 10799569?><pub-id pub-id-type="pmid">10799569</pub-id></element-citation></ref><ref id="B174"><label>174</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasirudeen</surname><given-names>A. M.</given-names></name><name><surname>Wong</surname><given-names>H. H.</given-names></name><name><surname>Thien</surname><given-names>P.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><name><surname>Lam</surname><given-names>K. P.</given-names></name><name><surname>Liu</surname><given-names>D. X.</given-names></name></person-group><article-title>RIG-I, MDA5 and TLR3 synergistically play an important role in restriction of dengue virus infection</article-title><source><italic toggle="yes">PLoS Neglected Tropical Diseases</italic></source><year>2011</year><volume>5</volume><issue>1, article e926</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0000926</pub-id><pub-id pub-id-type="other">2-s2.0-79851492362</pub-id><?supplied-pmid 21245912?><pub-id pub-id-type="pmid">21245912</pub-id></element-citation></ref><ref id="B175"><label>175</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Ng</surname><given-names>M. M.</given-names></name><name><surname>Chu</surname><given-names>J. J.</given-names></name></person-group><article-title>Activation of TLR2 and TLR6 by dengue NS1 protein and its implications in the immunopathogenesis of dengue virus infection</article-title><source><italic toggle="yes">PLoS Pathogens</italic></source><year>2015</year><volume>11</volume><issue>7, article e1005053</issue><pub-id pub-id-type="doi">10.1371/journal.ppat.1005053</pub-id><pub-id pub-id-type="other">2-s2.0-84938796594</pub-id><?supplied-pmid 26226614?><pub-id pub-id-type="pmid">26226614</pub-id></element-citation></ref><ref id="B176"><label>176</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suthar</surname><given-names>M. S.</given-names></name><name><surname>Diamond</surname><given-names>M. S.</given-names></name><name><surname>Gale</surname><given-names>M.</given-names><suffix>Jr.</suffix></name></person-group><article-title>West Nile virus infection and immunity</article-title><source><italic toggle="yes">Nature Reviews Microbiology</italic></source><year>2013</year><volume>11</volume><issue>2</issue><fpage>115</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2950</pub-id><pub-id pub-id-type="other">2-s2.0-84872436774</pub-id><?supplied-pmid 23321534?><pub-id pub-id-type="pmid">23321534</pub-id></element-citation></ref><ref id="B177"><label>177</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagni</surname><given-names>S.</given-names></name><name><surname>Fernandez-Sesma</surname><given-names>A.</given-names></name></person-group><article-title>Evasion of the human innate immune system by dengue virus</article-title><source><italic toggle="yes">Immunologic Research</italic></source><year>2012</year><volume>54</volume><issue>1-3</issue><fpage>152</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1007/s12026-012-8334-2</pub-id><pub-id pub-id-type="other">2-s2.0-84867859813</pub-id><?supplied-pmid 22569913?><pub-id pub-id-type="pmid">22569913</pub-id></element-citation></ref><ref id="B178"><label>178</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munoz-Jordan</surname><given-names>J. L.</given-names></name><name><surname>Sanchez-Burgos</surname><given-names>G. G.</given-names></name><name><surname>Laurent-Rolle</surname><given-names>M.</given-names></name><name><surname>Garcia-Sastre</surname><given-names>A.</given-names></name></person-group><article-title>Inhibition of interferon signaling by dengue virus</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>2003</year><volume>100</volume><issue>24</issue><fpage>14333</fpage><lpage>14338</lpage><pub-id pub-id-type="doi">10.1073/pnas.2335168100</pub-id><pub-id pub-id-type="other">2-s2.0-0344630221</pub-id><?supplied-pmid 14612562?><pub-id pub-id-type="pmid">14612562</pub-id></element-citation></ref><ref id="B179"><label>179</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>C. Y.</given-names></name><name><surname>Chang</surname><given-names>T. H.</given-names></name><name><surname>Liang</surname><given-names>J. J.</given-names></name><etal/></person-group><article-title>Dengue virus targets the adaptor protein MITA to subvert host innate immunity</article-title><source><italic toggle="yes">PLoS Pathogens</italic></source><year>2012</year><volume>8</volume><issue>6, article e1002780</issue><pub-id pub-id-type="doi">10.1371/journal.ppat.1002780</pub-id><pub-id pub-id-type="other">2-s2.0-84864036246</pub-id><?supplied-pmid 22761576?><pub-id pub-id-type="pmid">22761576</pub-id></element-citation></ref><ref id="B180"><label>180</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguirre</surname><given-names>S.</given-names></name><name><surname>Maestre</surname><given-names>A. M.</given-names></name><name><surname>Pagni</surname><given-names>S.</given-names></name><etal/></person-group><article-title>DENV inhibits type I IFN production in infected cells by cleaving human STING</article-title><source><italic toggle="yes">PLoS Pathogens</italic></source><year>2012</year><volume>8</volume><issue>10, article e1002934</issue><pub-id pub-id-type="doi">10.1371/journal.ppat.1002934</pub-id><pub-id pub-id-type="other">2-s2.0-84868102239</pub-id><?supplied-pmid 23055924?><pub-id pub-id-type="pmid">23055924</pub-id></element-citation></ref><ref id="B181"><label>181</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stabell</surname><given-names>A. C.</given-names></name><name><surname>Meyerson</surname><given-names>N. R.</given-names></name><name><surname>Gullberg</surname><given-names>R. C.</given-names></name><etal/></person-group><article-title>Dengue viruses cleave STING in humans but not in nonhuman primates, their presumed natural reservoir</article-title><source><italic toggle="yes">eLife</italic></source><year>2018</year><volume>7</volume><pub-id pub-id-type="doi">10.7554/eLife.31919</pub-id><pub-id pub-id-type="other">2-s2.0-85045690360</pub-id></element-citation></ref><ref id="B182"><label>182</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anglero-Rodriguez</surname><given-names>Y. I.</given-names></name><name><surname>Pantoja</surname><given-names>P.</given-names></name><name><surname>Sariol</surname><given-names>C. A.</given-names></name></person-group><article-title>Dengue virus subverts the interferon induction pathway via NS2B/3 protease-I<italic>&#x003ba;</italic>B kinase epsilon interaction</article-title><source><italic toggle="yes">Clinical and Vaccine Immunology</italic></source><year>2014</year><volume>21</volume><issue>1</issue><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1128/CVI.00500-13</pub-id><pub-id pub-id-type="other">2-s2.0-84892164414</pub-id><?supplied-pmid 24173023?><pub-id pub-id-type="pmid">24173023</pub-id></element-citation></ref><ref id="B183"><label>183</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashour</surname><given-names>J.</given-names></name><name><surname>Laurent-Rolle</surname><given-names>M.</given-names></name><name><surname>Shi</surname><given-names>P. Y.</given-names></name><name><surname>Garc&#x000ed;a-Sastre</surname><given-names>A.</given-names></name></person-group><article-title>NS5 of dengue virus mediates STAT2 binding and degradation</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2009</year><volume>83</volume><issue>11</issue><fpage>5408</fpage><lpage>5418</lpage><pub-id pub-id-type="doi">10.1128/JVI.02188-08</pub-id><pub-id pub-id-type="other">2-s2.0-66149146738</pub-id><?supplied-pmid 19279106?><pub-id pub-id-type="pmid">19279106</pub-id></element-citation></ref><ref id="B184"><label>184</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzon</surname><given-names>M.</given-names></name><name><surname>Jones</surname><given-names>M.</given-names></name><name><surname>Davidson</surname><given-names>A.</given-names></name><name><surname>Chain</surname><given-names>B.</given-names></name><name><surname>Jacobs</surname><given-names>M.</given-names></name></person-group><article-title>Dengue virus NS5 inhibits interferon&#x02010;<italic>&#x003b1;</italic> signaling by blocking signal transducer and activator of transcription 2 phosphorylation</article-title><source><italic toggle="yes">The Journal of Infectious Diseases</italic></source><year>2009</year><volume>200</volume><issue>8</issue><fpage>1261</fpage><lpage>1270</lpage><pub-id pub-id-type="doi">10.1086/605847</pub-id><pub-id pub-id-type="other">2-s2.0-70349432365</pub-id><pub-id pub-id-type="pmid">19754307</pub-id></element-citation></ref><ref id="B185"><label>185</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashour</surname><given-names>J.</given-names></name><name><surname>Morrison</surname><given-names>J.</given-names></name><name><surname>Laurent-Rolle</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Mouse STAT2 restricts early dengue virus replication</article-title><source><italic toggle="yes">Cell Host &#x00026; Microbe</italic></source><year>2010</year><volume>8</volume><issue>5</issue><fpage>410</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2010.10.007</pub-id><pub-id pub-id-type="other">2-s2.0-78349248232</pub-id><?supplied-pmid 21075352?><pub-id pub-id-type="pmid">21075352</pub-id></element-citation></ref><ref id="B186"><label>186</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Virulence difference of five type I dengue viruses and the intrinsic molecular mechanism</article-title><source><italic toggle="yes">PLoS Neglected Tropical Diseases</italic></source><year>2019</year><volume>13</volume><issue>3, article e0007202</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0007202</pub-id><pub-id pub-id-type="other">2-s2.0-85062996404</pub-id><?supplied-pmid 30830907?><pub-id pub-id-type="pmid">30830907</pub-id></element-citation></ref><ref id="B187"><label>187</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Madoz</surname><given-names>J. R.</given-names></name><name><surname>Bernal-Rubio</surname><given-names>D.</given-names></name><name><surname>Kaminski</surname><given-names>D.</given-names></name><name><surname>Boyd</surname><given-names>K.</given-names></name><name><surname>Fernandez-Sesma</surname><given-names>A.</given-names></name></person-group><article-title>Dengue virus inhibits the production of type I interferon in primary human dendritic cells</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2010</year><volume>84</volume><issue>9</issue><fpage>4845</fpage><lpage>4850</lpage><pub-id pub-id-type="doi">10.1128/JVI.02514-09</pub-id><pub-id pub-id-type="other">2-s2.0-77950824984</pub-id><?supplied-pmid 20164230?><pub-id pub-id-type="pmid">20164230</pub-id></element-citation></ref><ref id="B188"><label>188</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurane</surname><given-names>I.</given-names></name><name><surname>Innis</surname><given-names>B. L.</given-names></name><name><surname>Nimmannitya</surname><given-names>S.</given-names></name><name><surname>Nisalak</surname><given-names>A.</given-names></name><name><surname>Ennis</surname><given-names>F. A.</given-names></name><name><surname>Meager</surname><given-names>A.</given-names></name></person-group><article-title>High levels of interferon alpha in the sera of children with dengue virus infection</article-title><source><italic toggle="yes">The American Journal of Tropical Medicine and Hygiene</italic></source><year>1993</year><volume>48</volume><issue>2</issue><fpage>222</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1993.48.222</pub-id><pub-id pub-id-type="other">2-s2.0-0027466321</pub-id><?supplied-pmid 8447527?><pub-id pub-id-type="pmid">8447527</pub-id></element-citation></ref><ref id="B189"><label>189</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becquart</surname><given-names>P.</given-names></name><name><surname>Wauquier</surname><given-names>N.</given-names></name><name><surname>Nkoghe</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Acute dengue virus 2 infection in Gabonese patients is associated with an early innate immune response, including strong interferon alpha production</article-title><source><italic toggle="yes">BMC Infectious Diseases</italic></source><year>2010</year><volume>10</volume><issue>1</issue><fpage>p. 356</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-10-356</pub-id><pub-id pub-id-type="other">2-s2.0-78650087190</pub-id></element-citation></ref><ref id="B190"><label>190</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hern&#x000e1;ndez</surname><given-names>S. I. D. L. C.</given-names></name><name><surname>Puerta-Guardo</surname><given-names>H.</given-names></name><name><surname>Flores-Aguilar</surname><given-names>H.</given-names></name><etal/></person-group><article-title>A strong interferon response correlates with a milder dengue clinical condition</article-title><source><italic toggle="yes">Journal of Clinical Virology</italic></source><year>2014</year><volume>60</volume><issue>3</issue><fpage>196</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2014.04.002</pub-id><pub-id pub-id-type="other">2-s2.0-84902180563</pub-id><?supplied-pmid 24793964?><pub-id pub-id-type="pmid">24793964</pub-id></element-citation></ref><ref id="B191"><label>191</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pech Torres</surname><given-names>R. E.</given-names></name><name><surname>Cedillo Rivera</surname><given-names>R. M.</given-names></name><name><surname>Loro&#x000f1;o Pino</surname><given-names>M. A.</given-names></name><name><surname>S&#x000e1;nchez Burgos</surname><given-names>G. G.</given-names></name></person-group><article-title>Serum levels of IFN-<italic>&#x003b2;</italic> are associated with days of evolution but not with severity of dengue</article-title><source><italic toggle="yes">Journal of Medical Virology</italic></source><year>2016</year><volume>88</volume><issue>3</issue><fpage>395</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1002/jmv.24343</pub-id><pub-id pub-id-type="other">2-s2.0-84955172450</pub-id><?supplied-pmid 26252251?><pub-id pub-id-type="pmid">26252251</pub-id></element-citation></ref><ref id="B192"><label>192</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>Kou</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Both viremia and cytokine levels associate with the lack of severe disease in secondary dengue 1 infection among adult Chinese patients</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2010</year><volume>5</volume><issue>12, article e15631</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0015631</pub-id><pub-id pub-id-type="other">2-s2.0-78650927402</pub-id><?supplied-pmid 21206915?><pub-id pub-id-type="pmid">21206915</pub-id></element-citation></ref><ref id="B193"><label>193</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandini</surname><given-names>M.</given-names></name><name><surname>Reis</surname><given-names>S. R.</given-names></name><name><surname>Torrentes-Carvalho</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Dengue-2 and yellow fever 17DD viruses infect human dendritic cells, resulting in an induction of activation markers, cytokines and chemokines and secretion of different TNF-<italic>&#x003b1;</italic> and IFN-<italic>&#x003b1;</italic> profiles</article-title><source><italic toggle="yes">Mem&#x000f3;rias do Instituto Oswaldo Cruz</italic></source><year>2011</year><volume>106</volume><issue>5</issue><fpage>594</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1590/s0074-02762011000500012</pub-id><pub-id pub-id-type="other">2-s2.0-80052703435</pub-id><?supplied-pmid 21894381?><pub-id pub-id-type="pmid">21894381</pub-id></element-citation></ref><ref id="B194"><label>194</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libraty</surname><given-names>D. H.</given-names></name><name><surname>Endy</surname><given-names>T. P.</given-names></name><name><surname>Houng</surname><given-names>H. S.</given-names></name><etal/></person-group><article-title>Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections</article-title><source><italic toggle="yes">The Journal of Infectious Diseases</italic></source><year>2002</year><volume>185</volume><issue>9</issue><fpage>1213</fpage><lpage>1221</lpage><pub-id pub-id-type="doi">10.1086/340365</pub-id><pub-id pub-id-type="other">2-s2.0-0036569001</pub-id><?supplied-pmid 12001037?><pub-id pub-id-type="pmid">12001037</pub-id></element-citation></ref><ref id="B195"><label>195</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singla</surname><given-names>M.</given-names></name><name><surname>Kar</surname><given-names>M.</given-names></name><name><surname>Sethi</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Immune response to dengue virus infection in pediatric patients in New Delhi, India--association of viremia, inflammatory mediators and monocytes with disease severity</article-title><source><italic toggle="yes">PLoS Neglected Tropical Diseases</italic></source><year>2016</year><volume>10</volume><issue>3, article e0004497</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0004497</pub-id><pub-id pub-id-type="other">2-s2.0-84962425384</pub-id><?supplied-pmid 26982706?><pub-id pub-id-type="pmid">26982706</pub-id></element-citation></ref><ref id="B196"><label>196</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perdomo-Celis</surname><given-names>F.</given-names></name><name><surname>Salgado</surname><given-names>D. M.</given-names></name><name><surname>Narvaez</surname><given-names>C. F.</given-names></name></person-group><article-title>Selective dysfunction of subsets of peripheral blood mononuclear cells during pediatric dengue and its relationship with clinical outcome</article-title><source><italic toggle="yes">Virology</italic></source><year>2017</year><volume>507</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2017.04.004</pub-id><pub-id pub-id-type="other">2-s2.0-85017184828</pub-id><?supplied-pmid 28395181?><pub-id pub-id-type="pmid">28395181</pub-id></element-citation></ref><ref id="B197"><label>197</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talarico</surname><given-names>L. B.</given-names></name><name><surname>Byrne</surname><given-names>A. B.</given-names></name><name><surname>Amarilla</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Characterization of type I interferon responses in dengue and severe dengue in children in Paraguay</article-title><source><italic toggle="yes">Journal of Clinical Virology</italic></source><year>2017</year><volume>97</volume><fpage>10</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.jcv.2017.10.010</pub-id><pub-id pub-id-type="other">2-s2.0-85032003270</pub-id><?supplied-pmid 29078078?><pub-id pub-id-type="pmid">29078078</pub-id></element-citation></ref><ref id="B198"><label>198</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>R. A.</given-names></name><name><surname>Silva</surname><given-names>M. M.</given-names></name><name><surname>Calzavara-Silva</surname><given-names>C. E.</given-names></name><etal/></person-group><article-title>Primary dengue haemorrhagic fever in patients from northeast of Brazil is associated with high levels of interferon-<italic>&#x003b2;</italic> during acute phase</article-title><source><italic toggle="yes">Mem&#x000f3;rias do Instituto Oswaldo Cruz</italic></source><year>2016</year><volume>111</volume><issue>6</issue><fpage>378</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1590/0074-02760150453</pub-id><pub-id pub-id-type="other">2-s2.0-84971430839</pub-id><?supplied-pmid 27223651?><pub-id pub-id-type="pmid">27223651</pub-id></element-citation></ref><ref id="B199"><label>199</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>T. H.</given-names></name><name><surname>Liao</surname><given-names>C. L.</given-names></name><name><surname>Lin</surname><given-names>Y. L.</given-names></name></person-group><article-title>Flavivirus induces interferon-beta gene expression through a pathway involving RIG-I-dependent IRF-3 and PI3K-dependent NF-kappaB activation</article-title><source><italic toggle="yes">Microbes and Infection</italic></source><year>2006</year><volume>8</volume><issue>1</issue><fpage>157</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2005.06.014</pub-id><pub-id pub-id-type="other">2-s2.0-31344477977</pub-id><?supplied-pmid 16182584?><pub-id pub-id-type="pmid">16182584</pub-id></element-citation></ref><ref id="B200"><label>200</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurane</surname><given-names>I.</given-names></name><name><surname>Ennis</surname><given-names>F. A.</given-names></name></person-group><article-title>Production of interferon alpha by dengue virus-infected human monocytes</article-title><source><italic toggle="yes">The Journal of General Virology</italic></source><year>1988</year><volume>69</volume><issue>2</issue><fpage>445</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-69-2-445</pub-id><pub-id pub-id-type="other">2-s2.0-0023830792</pub-id><pub-id pub-id-type="pmid">3339332</pub-id></element-citation></ref><ref id="B201"><label>201</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M. I.</given-names></name><name><surname>Wong</surname><given-names>P. S.</given-names></name><name><surname>Ng</surname><given-names>L. C.</given-names></name><name><surname>Tan</surname><given-names>C. H.</given-names></name></person-group><article-title>Oral susceptibility of Singapore Aedes (Stegomyia) aegypti (Linnaeus) to Zika virus</article-title><source><italic toggle="yes">PLoS Neglected Tropical Diseases</italic></source><year>2012</year><volume>6</volume><issue>8, article e1792</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0001792</pub-id><pub-id pub-id-type="other">2-s2.0-84865973831</pub-id><?supplied-pmid 22953014?><pub-id pub-id-type="pmid">22953014</pub-id></element-citation></ref><ref id="B202"><label>202</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>D. I.</given-names></name></person-group><article-title>Zika virus infection in man</article-title><source><italic toggle="yes">Transactions of the Royal Society of Tropical Medicine and Hygiene</italic></source><year>1964</year><volume>58</volume><fpage>335</fpage><lpage>338</lpage><?supplied-pmid 14175744?><pub-id pub-id-type="pmid">14175744</pub-id></element-citation></ref><ref id="B203"><label>203</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddow</surname><given-names>A. D.</given-names></name><name><surname>Schuh</surname><given-names>A. J.</given-names></name><name><surname>Yasuda</surname><given-names>C. Y.</given-names></name><etal/></person-group><article-title>Genetic characterization of Zika virus strains: geographic expansion of the Asian lineage</article-title><source><italic toggle="yes">PLoS Neglected Tropical Diseases</italic></source><year>2012</year><volume>6</volume><issue>2, article e1477</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0001477</pub-id><pub-id pub-id-type="other">2-s2.0-84857819894</pub-id><?supplied-pmid 22389730?><pub-id pub-id-type="pmid">22389730</pub-id></element-citation></ref><ref id="B204"><label>204</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>E. B.</given-names></name></person-group><article-title>Zika virus outside Africa</article-title><source><italic toggle="yes">Emerging Infectious Diseases</italic></source><year>2009</year><volume>15</volume><issue>9</issue><fpage>1347</fpage><lpage>1350</lpage><pub-id pub-id-type="doi">10.3201/eid1509.090442</pub-id><pub-id pub-id-type="other">2-s2.0-70249130933</pub-id><?supplied-pmid 19788800?><pub-id pub-id-type="pmid">19788800</pub-id></element-citation></ref><ref id="B205"><label>205</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffy</surname><given-names>M. R.</given-names></name><name><surname>Chen</surname><given-names>T. H.</given-names></name><name><surname>Hancock</surname><given-names>W. T.</given-names></name><etal/></person-group><article-title>Zika virus outbreak on Yap Island, Federated States of Micronesia</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>2009</year><volume>360</volume><issue>24</issue><fpage>2536</fpage><lpage>2543</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0805715</pub-id><pub-id pub-id-type="other">2-s2.0-67149088928</pub-id><pub-id pub-id-type="pmid">19516034</pub-id></element-citation></ref><ref id="B206"><label>206</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hancock</surname><given-names>W. T.</given-names></name><name><surname>Marfel</surname><given-names>M.</given-names></name><name><surname>Bel</surname><given-names>M.</given-names></name></person-group><article-title>Zika virus, French Polynesia, South Pacific, 2013</article-title><source><italic toggle="yes">Emerging Infectious Diseases</italic></source><year>2014</year><volume>20</volume><issue>11</issue><fpage>p. 1960</fpage><pub-id pub-id-type="doi">10.3201/eid2011.141380</pub-id><pub-id pub-id-type="other">2-s2.0-84949131429</pub-id><?supplied-pmid 25341051?><pub-id pub-id-type="pmid">25341051</pub-id></element-citation></ref><ref id="B207"><label>207</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanluca</surname><given-names>C.</given-names></name><name><surname>Melo</surname><given-names>V. C. A.</given-names></name><name><surname>Mosimann</surname><given-names>A. L. P.</given-names></name><name><surname>Santos</surname><given-names>G. I. V.</given-names></name><name><surname>Santos</surname><given-names>C. N. D.</given-names></name><name><surname>Luz</surname><given-names>K.</given-names></name></person-group><article-title>First report of autochthonous transmission of Zika virus in Brazil</article-title><source><italic toggle="yes">Mem&#x000f3;rias do Instituto Oswaldo Cruz</italic></source><year>2015</year><volume>110</volume><issue>4</issue><fpage>569</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1590/0074-02760150192</pub-id><pub-id pub-id-type="other">2-s2.0-84930857012</pub-id><?supplied-pmid 26061233?><pub-id pub-id-type="pmid">26061233</pub-id></element-citation></ref><ref id="B208"><label>208</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enfissi</surname><given-names>A.</given-names></name><name><surname>Codrington</surname><given-names>J.</given-names></name><name><surname>Roosblad</surname><given-names>J.</given-names></name><name><surname>Kazanji</surname><given-names>M.</given-names></name><name><surname>Rousset</surname><given-names>D.</given-names></name></person-group><article-title>Zika virus genome from the Americas</article-title><source><italic toggle="yes">Lancet</italic></source><year>2016</year><volume>387</volume><issue>10015</issue><fpage>227</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)00003-9</pub-id><pub-id pub-id-type="other">2-s2.0-84954375368</pub-id><?supplied-pmid 26775124?><pub-id pub-id-type="pmid">26775124</pub-id></element-citation></ref><ref id="B209"><label>209</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campos</surname><given-names>G. S.</given-names></name><name><surname>Bandeira</surname><given-names>A. C.</given-names></name><name><surname>Sardi</surname><given-names>S. I.</given-names></name></person-group><article-title>Zika virus outbreak, Bahia, Brazil</article-title><source><italic toggle="yes">Emerging Infectious Diseases</italic></source><year>2015</year><volume>21</volume><issue>10</issue><fpage>1885</fpage><lpage>1886</lpage><pub-id pub-id-type="doi">10.3201/eid2110.150847</pub-id><pub-id pub-id-type="other">2-s2.0-84942163282</pub-id><?supplied-pmid 26401719?><pub-id pub-id-type="pmid">26401719</pub-id></element-citation></ref><ref id="B210"><label>210</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyer</surname><given-names>O.</given-names></name></person-group><article-title>Zika virus spreads across Americas as concerns mount over birth defects</article-title><source><italic toggle="yes">BMJ</italic></source><year>2015</year><volume>351</volume><fpage>p. h6983</fpage><pub-id pub-id-type="doi">10.1136/bmj.h6983</pub-id><pub-id pub-id-type="other">2-s2.0-84958998578</pub-id></element-citation></ref><ref id="B211"><label>211</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>L. C.</given-names></name></person-group><article-title>Microcephaly and Zika virus infection</article-title><source><italic toggle="yes">Lancet</italic></source><year>2016</year><volume>387</volume><issue>10033</issue><fpage>2070</fpage><lpage>2072</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)00742-X</pub-id><pub-id pub-id-type="other">2-s2.0-84961113851</pub-id><pub-id pub-id-type="pmid">26993880</pub-id></element-citation></ref><ref id="B212"><label>212</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>D. W.</given-names></name><name><surname>Mackenzie</surname><given-names>J.</given-names></name></person-group><article-title>Zika virus and Guillain-Barr&#x000e9; syndrome: another viral cause to add to the list</article-title><source><italic toggle="yes">Lancet</italic></source><year>2016</year><volume>387</volume><issue>10027</issue><fpage>1486</fpage><lpage>1488</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)00564-X</pub-id><pub-id pub-id-type="other">2-s2.0-84961226193</pub-id><pub-id pub-id-type="pmid">26948432</pub-id></element-citation></ref><ref id="B213"><label>213</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martines</surname><given-names>R. B.</given-names></name><name><surname>Bhatnagar</surname><given-names>J.</given-names></name><name><surname>Keating</surname><given-names>M. K.</given-names></name><etal/></person-group><article-title>Notes from the field: evidence of Zika virus infection in brain and placental tissues from two congenitally infected newborns and two fetal losses--Brazil, 2015</article-title><source><italic toggle="yes">MMWR Morbidity and Mortality Weekly Report</italic></source><year>2016</year><volume>65</volume><issue>6</issue><fpage>159</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm6506e1</pub-id><?supplied-pmid 26890059?><pub-id pub-id-type="pmid">26890059</pub-id></element-citation></ref><ref id="B214"><label>214</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Ortenzio</surname><given-names>E.</given-names></name><name><surname>Matheron</surname><given-names>S.</given-names></name><name><surname>Yazdanpanah</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Evidence of sexual transmission of Zika virus</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>2016</year><volume>374</volume><issue>22</issue><fpage>2195</fpage><lpage>2198</lpage><pub-id pub-id-type="doi">10.1056/NEJMc1604449</pub-id><pub-id pub-id-type="other">2-s2.0-84969559736</pub-id><?supplied-pmid 27074370?><pub-id pub-id-type="pmid">27074370</pub-id></element-citation></ref><ref id="B215"><label>215</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamel</surname><given-names>R.</given-names></name><name><surname>Dejarnac</surname><given-names>O.</given-names></name><name><surname>Wichit</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Biology of Zika virus infection in human skin cells</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2015</year><volume>89</volume><issue>17</issue><fpage>8880</fpage><lpage>8896</lpage><pub-id pub-id-type="doi">10.1128/JVI.00354-15</pub-id><pub-id pub-id-type="other">2-s2.0-84938919218</pub-id><?supplied-pmid 26085147?><pub-id pub-id-type="pmid">26085147</pub-id></element-citation></ref><ref id="B216"><label>216</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagani</surname><given-names>I.</given-names></name><name><surname>Ghezzi</surname><given-names>S.</given-names></name><name><surname>Ulisse</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Human endometrial stromal cells are highly permissive to productive infection by Zika virus</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2017</year><volume>7</volume><issue>1</issue><fpage>p. 44286</fpage><pub-id pub-id-type="doi">10.1038/srep44286</pub-id><pub-id pub-id-type="other">2-s2.0-85014880123</pub-id></element-citation></ref><ref id="B217"><label>217</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frumence</surname><given-names>E.</given-names></name><name><surname>Roche</surname><given-names>M.</given-names></name><name><surname>Krejbich-Trotot</surname><given-names>P.</given-names></name><etal/></person-group><article-title>The South Pacific epidemic strain of Zika virus replicates efficiently in human epithelial A549 cells leading to IFN-<italic>&#x003b2;</italic> production and apoptosis induction</article-title><source><italic toggle="yes">Virology</italic></source><year>2016</year><volume>493</volume><fpage>217</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2016.03.006</pub-id><pub-id pub-id-type="other">2-s2.0-84962436399</pub-id><?supplied-pmid 27060565?><pub-id pub-id-type="pmid">27060565</pub-id></element-citation></ref><ref id="B218"><label>218</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhiman</surname><given-names>G.</given-names></name><name><surname>Abraham</surname><given-names>R.</given-names></name><name><surname>Griffin</surname><given-names>D. E.</given-names></name></person-group><article-title>Human Schwann cells are susceptible to infection with Zika and yellow fever viruses, but not dengue virus</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2019</year><volume>9</volume><issue>1</issue><fpage>p. 9951</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-46389-0</pub-id><pub-id pub-id-type="other">2-s2.0-85068741088</pub-id><?supplied-pmid 31289325?><pub-id pub-id-type="pmid">31289325</pub-id></element-citation></ref><ref id="B219"><label>219</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowen</surname><given-names>J. R.</given-names></name><name><surname>Quicke</surname><given-names>K. M.</given-names></name><name><surname>Maddur</surname><given-names>M. S.</given-names></name><etal/></person-group><article-title>Zika virus antagonizes type I interferon responses during infection of human dendritic cells</article-title><source><italic toggle="yes">PLoS Pathogens</italic></source><year>2017</year><volume>13</volume><issue>2, article e1006164</issue><pub-id pub-id-type="doi">10.1371/journal.ppat.1006164</pub-id><pub-id pub-id-type="other">2-s2.0-85014129552</pub-id><?supplied-pmid 28152048?><pub-id pub-id-type="pmid">28152048</pub-id></element-citation></ref><ref id="B220"><label>220</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khaiboullina</surname><given-names>S. F.</given-names></name><name><surname>Uppal</surname><given-names>T.</given-names></name><name><surname>Sarkar</surname><given-names>R.</given-names></name><name><surname>Gorzalski</surname><given-names>A.</given-names></name><name><surname>St Jeor</surname><given-names>S.</given-names></name><name><surname>Verma</surname><given-names>S. C.</given-names></name></person-group><article-title>ZIKV infection regulates inflammasomes pathway for replication in monocytes</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2017</year><volume>7</volume><issue>1</issue><fpage>p. 16050</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-16072-3</pub-id><pub-id pub-id-type="other">2-s2.0-85034839103</pub-id><?supplied-pmid 29167459?><pub-id pub-id-type="pmid">29167459</pub-id></element-citation></ref><ref id="B221"><label>221</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Hou</surname><given-names>S.</given-names></name><name><surname>Airo</surname><given-names>A. M.</given-names></name><etal/></person-group><article-title>Zika virus inhibits type-I interferon production and downstream signaling</article-title><source><italic toggle="yes">EMBO Reports</italic></source><year>2016</year><volume>17</volume><issue>12</issue><fpage>1766</fpage><lpage>1775</lpage><pub-id pub-id-type="doi">10.15252/embr.201642627</pub-id><pub-id pub-id-type="other">2-s2.0-84996836490</pub-id><?supplied-pmid 27797853?><pub-id pub-id-type="pmid">27797853</pub-id></element-citation></ref><ref id="B222"><label>222</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>A.</given-names></name><name><surname>Ponia</surname><given-names>S. S.</given-names></name><name><surname>Tripathi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Zika virus targets human STAT2 to inhibit type I interferon signaling</article-title><source><italic toggle="yes">Cell Host &#x00026; Microbe</italic></source><year>2016</year><volume>19</volume><issue>6</issue><fpage>882</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.05.009</pub-id><pub-id pub-id-type="other">2-s2.0-84973446526</pub-id><?supplied-pmid 27212660?><pub-id pub-id-type="pmid">27212660</pub-id></element-citation></ref><ref id="B223"><label>223</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez</surname><given-names>J. F. V.</given-names></name><name><surname>Velilla</surname><given-names>P. A.</given-names></name><name><surname>Urcuqui-Inchima</surname><given-names>S.</given-names></name></person-group><article-title>Chikungunya virus and Zika virus, two different viruses examined with a common aim: role of pattern recognition receptors on the inflammatory response</article-title><source><italic toggle="yes">Journal of Interferon &#x00026; Cytokine Research</italic></source><year>2019</year><volume>39</volume><issue>9</issue><fpage>507</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1089/jir.2019.0058</pub-id><pub-id pub-id-type="other">2-s2.0-85071786402</pub-id><?supplied-pmid 31090481?><pub-id pub-id-type="pmid">31090481</pub-id></element-citation></ref><ref id="B224"><label>224</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J. A.</given-names></name><name><surname>Seong</surname><given-names>R. K.</given-names></name><name><surname>Son</surname><given-names>S. W.</given-names></name><name><surname>Shin</surname><given-names>O. S.</given-names></name></person-group><article-title>Insights into ZIKV-mediated innate immune responses in human dermal fibroblasts and epidermal keratinocytes</article-title><source><italic toggle="yes">The Journal of Investigative Dermatology</italic></source><year>2019</year><volume>139</volume><issue>2</issue><fpage>391</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2018.07.038</pub-id><pub-id pub-id-type="other">2-s2.0-85056809368</pub-id><?supplied-pmid 30218650?><pub-id pub-id-type="pmid">30218650</pub-id></element-citation></ref><ref id="B225"><label>225</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Ketkar</surname><given-names>H.</given-names></name><name><surname>Geng</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Zika virus non-structural protein 4A blocks the RLR-MAVS signaling</article-title><source><italic toggle="yes">Frontiers in Microbiology</italic></source><year>2018</year><volume>9</volume><fpage>p. 1350</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.01350</pub-id><pub-id pub-id-type="other">2-s2.0-85049088152</pub-id></element-citation></ref><ref id="B226"><label>226</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>He</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Zika virus antagonizes interferon response in patients and disrupts RIG-I-MAVS interaction through its CARD-TM domains</article-title><source><italic toggle="yes">Cell &#x00026; Bioscience</italic></source><year>2019</year><volume>9</volume><issue>1</issue><fpage>p. 46</fpage><pub-id pub-id-type="doi">10.1186/s13578-019-0308-9</pub-id><pub-id pub-id-type="other">2-s2.0-85066822104</pub-id><pub-id pub-id-type="pmid">31183075</pub-id></element-citation></ref><ref id="B227"><label>227</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riedl</surname><given-names>W.</given-names></name><name><surname>Acharya</surname><given-names>D.</given-names></name><name><surname>Lee</surname><given-names>J. H.</given-names></name><etal/></person-group><article-title>Zika virus NS3 mimics a cellular 14-3-3-binding motif to antagonize RIG-I- and MDA5-mediated innate immunity</article-title><source><italic toggle="yes">Cell Host &#x00026; Microbe</italic></source><year>2019</year><volume>26</volume><issue>4</issue><fpage>493</fpage><lpage>503.e6</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2019.09.012</pub-id><pub-id pub-id-type="other">2-s2.0-85072692599</pub-id><?supplied-pmid 31600501?><pub-id pub-id-type="pmid">31600501</pub-id></element-citation></ref><ref id="B228"><label>228</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>H.</given-names></name><name><surname>Luo</surname><given-names>H.</given-names></name><name><surname>Shan</surname><given-names>C.</given-names></name><etal/></person-group><article-title>An evolutionary NS1 mutation enhances Zika virus evasion of host interferon induction</article-title><source><italic toggle="yes">Nature Communications</italic></source><year>2018</year><volume>9</volume><issue>1</issue><fpage>p. 414</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-02816-2</pub-id><pub-id pub-id-type="other">2-s2.0-85041327442</pub-id><?supplied-pmid 29379028?><pub-id pub-id-type="pmid">29379028</pub-id></element-citation></ref><ref id="B229"><label>229</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tricarico</surname><given-names>P. M.</given-names></name><name><surname>Caracciolo</surname><given-names>I.</given-names></name><name><surname>Crovella</surname><given-names>S.</given-names></name><name><surname>D'Agaro</surname><given-names>P.</given-names></name></person-group><article-title>Zika virus induces inflammasome activation in the glial cell line U87-MG</article-title><source><italic toggle="yes">Biochemical and Biophysical Research Communications</italic></source><year>2017</year><volume>492</volume><issue>4</issue><fpage>597</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2017.01.158</pub-id><pub-id pub-id-type="other">2-s2.0-85012930115</pub-id><?supplied-pmid 28153732?><pub-id pub-id-type="pmid">28153732</pub-id></element-citation></ref><ref id="B230"><label>230</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>de Wu</surname></name><etal/></person-group><article-title>Zika virus infection induces host inflammatory responses by facilitating NLRP3 inflammasome assembly and interleukin-1<italic>&#x003b2;</italic> secretion</article-title><source><italic toggle="yes">Nature Communications</italic></source><year>2018</year><volume>9</volume><issue>1</issue><fpage>p. 106</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-02645-3</pub-id><pub-id pub-id-type="other">2-s2.0-85040609922</pub-id><?supplied-pmid 29317641?><pub-id pub-id-type="pmid">29317641</pub-id></element-citation></ref><ref id="B231"><label>231</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Zika virus elicits inflammation to evade antiviral response by cleaving cGAS via NS1-caspase-1 axis</article-title><source><italic toggle="yes">The EMBO Journal</italic></source><year>2018</year><volume>37</volume><issue>18</issue><pub-id pub-id-type="doi">10.15252/embj.201899347</pub-id><pub-id pub-id-type="other">2-s2.0-85053461266</pub-id><?supplied-pmid 30065070?><pub-id pub-id-type="pmid">30065070</pub-id></element-citation></ref><ref id="B232"><label>232</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>C. N. O.</given-names></name><name><surname>Ribeiro</surname><given-names>D. R.</given-names></name><name><surname>Cardoso Alves</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Association between Zika virus microcephaly in newborns with the rs3775291 variant in toll-like receptor 3 and rs1799964 variant at tumor necrosis factor-<italic>&#x003b1;</italic> gene</article-title><source><italic toggle="yes">The Journal of Infectious Diseases</italic></source><year>2019</year><volume>220</volume><issue>11</issue><fpage>1797</fpage><lpage>1801</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz392</pub-id><pub-id pub-id-type="other">2-s2.0-85073665736</pub-id><?supplied-pmid 31352487?><pub-id pub-id-type="pmid">31352487</pub-id></element-citation></ref><ref id="B233"><label>233</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esser-Nobis</surname><given-names>K.</given-names></name><name><surname>Aarreberg</surname><given-names>L. D.</given-names></name><name><surname>Roby</surname><given-names>J. A.</given-names></name><name><surname>Fairgrieve</surname><given-names>M. R.</given-names></name><name><surname>Green</surname><given-names>R.</given-names></name><name><surname>Gale</surname><given-names>M.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Comparative analysis of African and Asian lineage-derived Zika virus strains reveals differences in activation of and sensitivity to antiviral innate immunity</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2019</year><volume>93</volume><issue>13</issue><pub-id pub-id-type="doi">10.1128/JVI.00640-19</pub-id><pub-id pub-id-type="other">2-s2.0-85068132788</pub-id><?supplied-pmid 31019057?><pub-id pub-id-type="pmid">31019057</pub-id></element-citation></ref><ref id="B234"><label>234</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>T. J.</given-names></name><name><surname>Webb</surname><given-names>C. E.</given-names></name></person-group><article-title>A review of the epidemiological and clinical aspects of West Nile virus</article-title><source><italic toggle="yes">Int J Gen Med</italic></source><year>2014</year><volume>7</volume><fpage>193</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.2147/IJGM.S59902</pub-id><pub-id pub-id-type="other">2-s2.0-84898913236</pub-id><?supplied-pmid 24748813?><pub-id pub-id-type="pmid">24748813</pub-id></element-citation></ref><ref id="B235"><label>235</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostashari</surname><given-names>F.</given-names></name><name><surname>Bunning</surname><given-names>M. L.</given-names></name><name><surname>Kitsutani</surname><given-names>P. T.</given-names></name><etal/></person-group><article-title>Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey</article-title><source><italic toggle="yes">Lancet</italic></source><year>2001</year><volume>358</volume><issue>9278</issue><fpage>261</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(01)05480-0</pub-id><pub-id pub-id-type="other">2-s2.0-0035963919</pub-id><?supplied-pmid 11498211?><pub-id pub-id-type="pmid">11498211</pub-id></element-citation></ref><ref id="B236"><label>236</label><element-citation publication-type="other"><article-title>Centers for Disease Control and Prevention, West Nile Virus, Statistics and Maps</article-title><comment><ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/westnile/statsmaps/index.html">https://www.cdc.gov/westnile/statsmaps/index.html</ext-link></comment></element-citation></ref><ref id="B237"><label>237</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>E. B.</given-names></name><name><surname>Gubler</surname><given-names>D. J.</given-names></name></person-group><article-title>West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States</article-title><source><italic toggle="yes">Annual Review of Medicine</italic></source><year>2006</year><volume>57</volume><issue>1</issue><fpage>181</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1146/annurev.med.57.121304.131418</pub-id><pub-id pub-id-type="other">2-s2.0-32944469306</pub-id></element-citation></ref><ref id="B238"><label>238</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Fikrig</surname><given-names>E.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name></person-group><article-title>An essential role of PI3K in the control of West Nile virus infection</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2017</year><volume>7</volume><issue>1</issue><fpage>p. 3724</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-03912-5</pub-id><pub-id pub-id-type="other">2-s2.0-85020932584</pub-id><?supplied-pmid 28623344?><pub-id pub-id-type="pmid">28623344</pub-id></element-citation></ref><ref id="B239"><label>239</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>M. G.</given-names></name><name><surname>Bowen</surname><given-names>J. R.</given-names></name><name><surname>McDonald</surname><given-names>C. E.</given-names></name><name><surname>Pulendran</surname><given-names>B.</given-names></name><name><surname>Suthar</surname><given-names>M. S.</given-names></name></person-group><article-title>West Nile virus infection blocks inflammatory response and T cell costimulatory capacity of human monocyte-derived dendritic cells</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2019</year><volume>93</volume><issue>23</issue><pub-id pub-id-type="doi">10.1128/JVI.00664-19</pub-id><?supplied-pmid 31534040?><pub-id pub-id-type="pmid">31534040</pub-id></element-citation></ref><ref id="B240"><label>240</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takamatsu</surname><given-names>Y.</given-names></name><name><surname>Uchida</surname><given-names>L.</given-names></name><name><surname>Morita</surname><given-names>K.</given-names></name></person-group><article-title>Delayed IFN response differentiates replication of West Nile virus and Japanese encephalitis virus in human neuroblastoma and glioblastoma cells</article-title><source><italic toggle="yes">The Journal of General Virology</italic></source><year>2015</year><volume>96</volume><issue>8</issue><fpage>2194</fpage><lpage>2199</lpage><pub-id pub-id-type="doi">10.1099/vir.0.000168</pub-id><pub-id pub-id-type="other">2-s2.0-84940197448</pub-id><?supplied-pmid 25920530?><pub-id pub-id-type="pmid">25920530</pub-id></element-citation></ref><ref id="B241"><label>241</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rawle</surname><given-names>D. J.</given-names></name><name><surname>Setoh</surname><given-names>Y. X.</given-names></name><name><surname>Edmonds</surname><given-names>J. H.</given-names></name><name><surname>Khromykh</surname><given-names>A. A.</given-names></name></person-group><article-title>Comparison of attenuated and virulent West Nile virus strains in human monocyte-derived dendritic cells as a model of initial human infection</article-title><source><italic toggle="yes">Virology Journal</italic></source><year>2015</year><volume>12</volume><issue>1</issue><fpage>p. 46</fpage><pub-id pub-id-type="doi">10.1186/s12985-015-0279-3</pub-id><pub-id pub-id-type="other">2-s2.0-84929325410</pub-id></element-citation></ref><ref id="B242"><label>242</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laurent-Rolle</surname><given-names>M.</given-names></name><name><surname>Boer</surname><given-names>E. F.</given-names></name><name><surname>Lubick</surname><given-names>K. J.</given-names></name><etal/></person-group><article-title>The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2010</year><volume>84</volume><issue>7</issue><fpage>3503</fpage><lpage>3515</lpage><pub-id pub-id-type="doi">10.1128/JVI.01161-09</pub-id><pub-id pub-id-type="other">2-s2.0-77949373371</pub-id><?supplied-pmid 20106931?><pub-id pub-id-type="pmid">20106931</pub-id></element-citation></ref><ref id="B243"><label>243</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Setoh</surname><given-names>Y.</given-names></name><name><surname>Periasamy</surname><given-names>P.</given-names></name><name><surname>Peng</surname><given-names>N.</given-names></name><name><surname>Amarilla</surname><given-names>A.</given-names></name><name><surname>Slonchak</surname><given-names>A.</given-names></name><name><surname>Khromykh</surname><given-names>A.</given-names></name></person-group><article-title>Helicase domain of West Nile virus NS3 protein plays a role in inhibition of type I interferon signalling</article-title><source><italic toggle="yes">Viruses</italic></source><year>2017</year><volume>9</volume><issue>11</issue><fpage>p. 326</fpage><pub-id pub-id-type="doi">10.3390/v9110326</pub-id><pub-id pub-id-type="other">2-s2.0-85033489305</pub-id><?supplied-pmid 29099073?><pub-id pub-id-type="pmid">29099073</pub-id></element-citation></ref><ref id="B244"><label>244</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H. L.</given-names></name><name><surname>Ye</surname><given-names>H. Q.</given-names></name><name><surname>Liu</surname><given-names>S. Q.</given-names></name><etal/></person-group><article-title>West Nile virus NS1 antagonizes interferon beta production by targeting RIG-I and MDA5</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2017</year><volume>91</volume><issue>18</issue><pub-id pub-id-type="doi">10.1128/JVI.02396-16</pub-id><pub-id pub-id-type="other">2-s2.0-85028339545</pub-id></element-citation></ref><ref id="B245"><label>245</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobler</surname><given-names>L. H.</given-names></name><name><surname>Cameron</surname><given-names>M. J.</given-names></name><name><surname>Lanteri</surname><given-names>M. C.</given-names></name><etal/></person-group><article-title>Interferon and interferon-induced chemokine expression is associated with control of acute viremia in West Nile virus-infected blood donors</article-title><source><italic toggle="yes">The Journal of Infectious Diseases</italic></source><year>2008</year><volume>198</volume><issue>7</issue><fpage>979</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1086/591466</pub-id><pub-id pub-id-type="other">2-s2.0-51849136166</pub-id><?supplied-pmid 18729779?><pub-id pub-id-type="pmid">18729779</pub-id></element-citation></ref><ref id="B246"><label>246</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>K. W.</given-names></name><name><surname>Sachs</surname><given-names>D.</given-names></name><name><surname>Bardina</surname><given-names>S. V.</given-names></name><etal/></person-group><article-title>Differences in early cytokine production are associated with development of a greater number of symptoms following West Nile virus infection</article-title><source><italic toggle="yes">The Journal of Infectious Diseases</italic></source><year>2016</year><volume>214</volume><issue>4</issue><fpage>634</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiw179</pub-id><pub-id pub-id-type="other">2-s2.0-84988927390</pub-id><?supplied-pmid 27142077?><pub-id pub-id-type="pmid">27142077</pub-id></element-citation></ref><ref id="B247"><label>247</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monath</surname><given-names>T. P.</given-names></name></person-group><article-title>Yellow fever: an update</article-title><source><italic toggle="yes">The Lancet Infectious Diseases</italic></source><year>2001</year><volume>1</volume><issue>1</issue><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(01)00016-0</pub-id><pub-id pub-id-type="other">2-s2.0-0035436653</pub-id><?supplied-pmid 11871403?><pub-id pub-id-type="pmid">11871403</pub-id></element-citation></ref><ref id="B248"><label>248</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monath</surname><given-names>T. P.</given-names></name></person-group><article-title>Treatment of yellow fever</article-title><source><italic toggle="yes">Antiviral Research</italic></source><year>2008</year><volume>78</volume><issue>1</issue><fpage>116</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2007.10.009</pub-id><pub-id pub-id-type="other">2-s2.0-40749108390</pub-id><?supplied-pmid 18061688?><pub-id pub-id-type="pmid">18061688</pub-id></element-citation></ref><ref id="B249"><label>249</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Querec</surname><given-names>T. D.</given-names></name><name><surname>Akondy</surname><given-names>R. S.</given-names></name><name><surname>Lee</surname><given-names>E. K.</given-names></name><etal/></person-group><article-title>Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans</article-title><source><italic toggle="yes">Nature Immunology</italic></source><year>2009</year><volume>10</volume><issue>1</issue><fpage>116</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1038/ni.1688</pub-id><pub-id pub-id-type="other">2-s2.0-57849085182</pub-id><?supplied-pmid 19029902?><pub-id pub-id-type="pmid">19029902</pub-id></element-citation></ref><ref id="B250"><label>250</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaucher</surname><given-names>D.</given-names></name><name><surname>Therrien</surname><given-names>R.</given-names></name><name><surname>Kettaf</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses</article-title><source><italic toggle="yes">The Journal of Experimental Medicine</italic></source><year>2008</year><volume>205</volume><issue>13</issue><fpage>3119</fpage><lpage>3131</lpage><pub-id pub-id-type="doi">10.1084/jem.20082292</pub-id><pub-id pub-id-type="other">2-s2.0-59649129816</pub-id><?supplied-pmid 19047440?><pub-id pub-id-type="pmid">19047440</pub-id></element-citation></ref><ref id="B251"><label>251</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douam</surname><given-names>F.</given-names></name><name><surname>Soto Albrecht</surname><given-names>Y. E.</given-names></name><name><surname>Hrebikova</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Type III interferon-mediated signaling is critical for controlling live attenuated yellow fever virus infection in vivo</article-title><source><italic toggle="yes">MBio</italic></source><year>2017</year><volume>8</volume><issue>4</issue><pub-id pub-id-type="doi">10.1128/mBio.00819-17</pub-id><pub-id pub-id-type="other">2-s2.0-85029171391</pub-id><?supplied-pmid 28811340?><pub-id pub-id-type="pmid">28811340</pub-id></element-citation></ref><ref id="B252"><label>252</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinigaglia</surname><given-names>L.</given-names></name><name><surname>Gracias</surname><given-names>S.</given-names></name><name><surname>D&#x000e9;cembre</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Immature particles and capsid-free viral RNA produced by yellow fever virus- infected cells stimulate plasmacytoid dendritic cells to secrete interferons</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2018</year><volume>8</volume><issue>1</issue><fpage>p. 10889</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-29235-7</pub-id><pub-id pub-id-type="other">2-s2.0-85050345064</pub-id><?supplied-pmid 30022130?><pub-id pub-id-type="pmid">30022130</pub-id></element-citation></ref><ref id="B253"><label>253</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>Z.</given-names></name><name><surname>Barber</surname><given-names>G. N.</given-names></name></person-group><article-title>STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity</article-title><source><italic toggle="yes">Nature</italic></source><year>2009</year><volume>461</volume><issue>7265</issue><fpage>788</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1038/nature08476</pub-id><pub-id pub-id-type="other">2-s2.0-70349943834</pub-id><?supplied-pmid 19776740?><pub-id pub-id-type="pmid">19776740</pub-id></element-citation></ref><ref id="B254"><label>254</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laurent-Rolle</surname><given-names>M.</given-names></name><name><surname>Morrison</surname><given-names>J.</given-names></name><name><surname>Rajsbaum</surname><given-names>R.</given-names></name><etal/></person-group><article-title>The interferon signaling antagonist function of yellow fever virus NS5 protein is activated by type I interferon</article-title><source><italic toggle="yes">Cell Host &#x00026; Microbe</italic></source><year>2014</year><volume>16</volume><issue>3</issue><fpage>314</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2014.07.015</pub-id><pub-id pub-id-type="other">2-s2.0-84907700872</pub-id><?supplied-pmid 25211074?><pub-id pub-id-type="pmid">25211074</pub-id></element-citation></ref><ref id="B255"><label>255</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laurent-Rolle</surname><given-names>M.</given-names></name><name><surname>Morrison</surname><given-names>J.</given-names></name></person-group><article-title>The role of NS5 protein in determination of host cell range for yellow fever virus</article-title><source><italic toggle="yes">DNA and Cell Biology</italic></source><year>2019</year><volume>38</volume><issue>12</issue><fpage>1414</fpage><lpage>1417</lpage><pub-id pub-id-type="doi">10.1089/dna.2019.5115</pub-id><?supplied-pmid 31633391?><pub-id pub-id-type="pmid">31633391</pub-id></element-citation></ref><ref id="B256"><label>256</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miorin</surname><given-names>L.</given-names></name><name><surname>Laurent-Rolle</surname><given-names>M.</given-names></name><name><surname>Pisanelli</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Host-specific NS5 ubiquitination determines yellow fever virus tropism</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2019</year><volume>93</volume><issue>14</issue><pub-id pub-id-type="doi">10.1128/JVI.00151-19</pub-id><pub-id pub-id-type="other">2-s2.0-85068906645</pub-id><?supplied-pmid 31043530?><pub-id pub-id-type="pmid">31043530</pub-id></element-citation></ref><ref id="B257"><label>257</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>N.</given-names></name><name><surname>Bucciol</surname><given-names>G.</given-names></name><name><surname>Moens</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines</article-title><source><italic toggle="yes">The Journal of Experimental Medicine</italic></source><year>2019</year><volume>216</volume><issue>9</issue><fpage>2057</fpage><lpage>2070</lpage><pub-id pub-id-type="doi">10.1084/jem.20182295</pub-id><pub-id pub-id-type="other">2-s2.0-85071786268</pub-id><pub-id pub-id-type="pmid">31270247</pub-id></element-citation></ref><ref id="B258"><label>258</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoggins</surname><given-names>J. W.</given-names></name><name><surname>Wilson</surname><given-names>S. J.</given-names></name><name><surname>Panis</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A diverse range of gene products are effectors of the type I interferon antiviral response</article-title><source><italic toggle="yes">Nature</italic></source><year>2011</year><volume>472</volume><issue>7344</issue><fpage>481</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1038/nature09907</pub-id><pub-id pub-id-type="other">2-s2.0-79955542915</pub-id><?supplied-pmid 21478870?><pub-id pub-id-type="pmid">21478870</pub-id></element-citation></ref><ref id="B259"><label>259</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unni</surname><given-names>S. K.</given-names></name><name><surname>R&#x0016f;&#x0017e;ek</surname><given-names>D.</given-names></name><name><surname>Chhatbar</surname><given-names>C.</given-names></name><name><surname>Mishra</surname><given-names>R.</given-names></name><name><surname>Johri</surname><given-names>M. K.</given-names></name><name><surname>Singh</surname><given-names>S. K.</given-names></name></person-group><article-title>Japanese encephalitis virus: from genome to infectome</article-title><source><italic toggle="yes">Microbes and Infection</italic></source><year>2011</year><volume>13</volume><issue>4</issue><fpage>312</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2011.01.002</pub-id><pub-id pub-id-type="other">2-s2.0-79952442021</pub-id><?supplied-pmid 21238600?><pub-id pub-id-type="pmid">21238600</pub-id></element-citation></ref><ref id="B260"><label>260</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manocha</surname><given-names>G.</given-names></name><name><surname>Mishra</surname><given-names>R.</given-names></name><name><surname>Sharma</surname><given-names>N.</given-names></name><name><surname>Kumawat</surname><given-names>K.</given-names></name><name><surname>Basu</surname><given-names>A.</given-names></name><name><surname>Singh</surname><given-names>S. K.</given-names></name></person-group><article-title>Regulatory role of TRIM21 in the type-I interferon pathway in Japanese encephalitis virus-infected human microglial cells</article-title><source><italic toggle="yes">Journal of Neuroinflammation</italic></source><year>2014</year><volume>11</volume><issue>1</issue><fpage>p. 24</fpage><pub-id pub-id-type="doi">10.1186/1742-2094-11-24</pub-id><pub-id pub-id-type="other">2-s2.0-84896713234</pub-id><pub-id pub-id-type="pmid">24485101</pub-id></element-citation></ref><ref id="B261"><label>261</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>S. P.</given-names></name><name><surname>Ong</surname><given-names>K. C.</given-names></name><name><surname>Perera</surname><given-names>D.</given-names></name><name><surname>Wong</surname><given-names>K. T.</given-names></name></person-group><article-title>Neuronal transcriptomic responses to Japanese encephalitis virus infection with a special focus on chemokine CXCL11 and pattern recognition receptors RIG-1 and MDA5</article-title><source><italic toggle="yes">Virology</italic></source><year>2019</year><volume>527</volume><fpage>107</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2018.10.015</pub-id><pub-id pub-id-type="other">2-s2.0-85057034334</pub-id><?supplied-pmid 30481615?><pub-id pub-id-type="pmid">30481615</pub-id></element-citation></ref><ref id="B262"><label>262</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>R. J.</given-names></name><name><surname>Chang</surname><given-names>B. L.</given-names></name><name><surname>Yu</surname><given-names>H. P.</given-names></name><name><surname>Liao</surname><given-names>C. L.</given-names></name><name><surname>Lin</surname><given-names>Y. L.</given-names></name></person-group><article-title>Blocking of interferon-induced Jak-Stat signaling by Japanese encephalitis virus NS5 through a protein tyrosine phosphatase-mediated mechanism</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2006</year><volume>80</volume><issue>12</issue><fpage>5908</fpage><lpage>5918</lpage><pub-id pub-id-type="doi">10.1128/JVI.02714-05</pub-id><pub-id pub-id-type="other">2-s2.0-33744943788</pub-id><?supplied-pmid 16731929?><pub-id pub-id-type="pmid">16731929</pub-id></element-citation></ref><ref id="B263"><label>263</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>R. J.</given-names></name><name><surname>Liao</surname><given-names>C. L.</given-names></name><name><surname>Lin</surname><given-names>E.</given-names></name><name><surname>Lin</surname><given-names>Y. L.</given-names></name></person-group><article-title>Blocking of the alpha interferon-induced Jak-Stat signaling pathway by Japanese encephalitis virus infection</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2004</year><volume>78</volume><issue>17</issue><fpage>9285</fpage><lpage>9294</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.17.9285-9294.2004</pub-id><pub-id pub-id-type="other">2-s2.0-4143151721</pub-id><?supplied-pmid 15308723?><pub-id pub-id-type="pmid">15308723</pub-id></element-citation></ref><ref id="B264"><label>264</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Japanese encephalitis virus NS5 inhibits type I interferon (IFN) production by blocking the nuclear translocation of IFN regulatory factor 3 and NF-<italic>&#x003ba;</italic>B</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2017</year><volume>91</volume><issue>8</issue><pub-id pub-id-type="doi">10.1128/JVI.00039-17</pub-id><pub-id pub-id-type="other">2-s2.0-85016549700</pub-id><?supplied-pmid 28179530?><pub-id pub-id-type="pmid">28179530</pub-id></element-citation></ref><ref id="B265"><label>265</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>P. M.</given-names></name><name><surname>Dung</surname><given-names>N. M.</given-names></name><name><surname>Loan</surname><given-names>H. T.</given-names></name><etal/></person-group><article-title>Proinflammatory cytokines and chemokines in humans with Japanese encephalitis</article-title><source><italic toggle="yes">The Journal of Infectious Diseases</italic></source><year>2004</year><volume>190</volume><issue>9</issue><fpage>1618</fpage><lpage>1626</lpage><pub-id pub-id-type="doi">10.1086/423328</pub-id><pub-id pub-id-type="other">2-s2.0-6944246228</pub-id><?supplied-pmid 15478067?><pub-id pub-id-type="pmid">15478067</pub-id></element-citation></ref><ref id="B266"><label>266</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reisen</surname><given-names>W. K.</given-names></name></person-group><article-title>Epidemiology of St. Louis encephalitis virus</article-title><source><italic toggle="yes">Advances in Virus Research</italic></source><year>2003</year><volume>61</volume><fpage>139</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/s0065-3527(03)61004-3</pub-id><pub-id pub-id-type="other">2-s2.0-1442333336</pub-id><?supplied-pmid 14714432?><pub-id pub-id-type="pmid">14714432</pub-id></element-citation></ref><ref id="B267"><label>267</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luby</surname><given-names>J. P.</given-names></name></person-group><article-title>Sensitivities of neurotropic arboviruses to human interferon</article-title><source><italic toggle="yes">The Journal of Infectious Diseases</italic></source><year>1975</year><volume>132</volume><issue>4</issue><fpage>361</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1093/infdis/132.4.361</pub-id><pub-id pub-id-type="other">2-s2.0-0016830514</pub-id><?supplied-pmid 171314?><pub-id pub-id-type="pmid">171314</pub-id></element-citation></ref><ref id="B268"><label>268</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marques</surname><given-names>R. E.</given-names></name><name><surname>del Sarto</surname><given-names>J.</given-names></name><name><surname>Rocha</surname><given-names>R. P.</given-names></name><etal/></person-group><article-title>Development of a model of Saint Louis encephalitis infection and disease in mice</article-title><source><italic toggle="yes">Journal of Neuroinflammation</italic></source><year>2017</year><volume>14</volume><issue>1</issue><fpage>p. 61</fpage><pub-id pub-id-type="doi">10.1186/s12974-017-0837-2</pub-id><pub-id pub-id-type="other">2-s2.0-85016118133</pub-id><?supplied-pmid 28330482?><pub-id pub-id-type="pmid">28330482</pub-id></element-citation></ref><ref id="B269"><label>269</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>T. J.</given-names></name><name><surname>Phillpotts</surname><given-names>R. J.</given-names></name></person-group><article-title>Interferon-alpha protects mice against lethal infection with St Louis encephalitis virus delivered by the aerosol and subcutaneous routes</article-title><source><italic toggle="yes">Antiviral Research</italic></source><year>1999</year><volume>41</volume><issue>1</issue><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/s0166-3542(98)00063-1</pub-id><pub-id pub-id-type="other">2-s2.0-0033082830</pub-id><?supplied-pmid 10321579?><pub-id pub-id-type="pmid">10321579</pub-id></element-citation></ref><ref id="B270"><label>270</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bocci</surname><given-names>V.</given-names></name></person-group><article-title>Evaluation of routes of administration of interferon in cancer: a review and a proposal</article-title><source><italic toggle="yes">Cancer Drug Delivery</italic></source><year>1984</year><volume>1</volume><issue>4</issue><fpage>337</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1089/cdd.1984.1.337</pub-id><pub-id pub-id-type="other">2-s2.0-0021718001</pub-id><?supplied-pmid 6085757?><pub-id pub-id-type="pmid">6085757</pub-id></element-citation></ref><ref id="B271"><label>271</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westfechtel</surname><given-names>L.</given-names></name><name><surname>Werner</surname><given-names>R. N.</given-names></name><name><surname>Dressler</surname><given-names>C.</given-names></name><name><surname>Gaskins</surname><given-names>M.</given-names></name><name><surname>Nast</surname><given-names>A.</given-names></name></person-group><article-title>Adjuvant treatment of anogenital warts with systemic interferon: a systematic review and meta-analysis</article-title><source><italic toggle="yes">Sexually Transmitted Infections</italic></source><year>2018</year><volume>94</volume><issue>1</issue><fpage>21</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1136/sextrans-2017-053150</pub-id><pub-id pub-id-type="other">2-s2.0-85050693243</pub-id><?supplied-pmid 28819018?><pub-id pub-id-type="pmid">28819018</pub-id></element-citation></ref><ref id="B272"><label>272</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Trolio</surname><given-names>R.</given-names></name><name><surname>Simeone</surname><given-names>E.</given-names></name><name><surname>Di Lorenzo</surname><given-names>G.</given-names></name><name><surname>Buonerba</surname><given-names>C.</given-names></name><name><surname>Ascierto</surname><given-names>P. A.</given-names></name></person-group><article-title>The use of interferon in melanoma patients: a systematic review</article-title><source><italic toggle="yes">Cytokine &#x00026; Growth Factor Reviews</italic></source><year>2015</year><volume>26</volume><issue>2</issue><fpage>203</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2014.11.008</pub-id><pub-id pub-id-type="other">2-s2.0-84926527702</pub-id><?supplied-pmid 25511547?><pub-id pub-id-type="pmid">25511547</pub-id></element-citation></ref><ref id="B273"><label>273</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savale</surname><given-names>L.</given-names></name><name><surname>Sattler</surname><given-names>C.</given-names></name><name><surname>G&#x000fc;nther</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Pulmonary arterial hypertension in patients treated with interferon</article-title><source><italic toggle="yes">The European Respiratory Journal</italic></source><year>2014</year><volume>44</volume><issue>6</issue><fpage>1627</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.1183/09031936.00057914</pub-id><pub-id pub-id-type="other">2-s2.0-84916241478</pub-id><?supplied-pmid 25323231?><pub-id pub-id-type="pmid">25323231</pub-id></element-citation></ref><ref id="B274"><label>274</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidinger</surname><given-names>M.</given-names></name></person-group><article-title>Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors</article-title><source><italic toggle="yes">EJC Supplements</italic></source><year>2013</year><volume>11</volume><issue>2</issue><fpage>172</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/j.ejcsup.2013.07.016</pub-id><pub-id pub-id-type="other">2-s2.0-84884952345</pub-id><?supplied-pmid 26217127?><pub-id pub-id-type="pmid">26217127</pub-id></element-citation></ref><ref id="B275"><label>275</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caraceni</surname><given-names>A.</given-names></name><name><surname>Gangeri</surname><given-names>L.</given-names></name><name><surname>Martini</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Neurotoxicity of interferon-? in melanoma therapy</article-title><source><italic toggle="yes">Cancer</italic></source><year>1998</year><volume>83</volume><issue>3</issue><fpage>482</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19980801)83:3&#x0003c;482::AID-CNCR17&#x0003e;3.0.CO;2-S</pub-id><pub-id pub-id-type="pmid">9690541</pub-id></element-citation></ref><ref id="B276"><label>276</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gogas</surname><given-names>H.</given-names></name><name><surname>Bafaloukos</surname><given-names>D.</given-names></name><name><surname>Ioannovich</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study</article-title><source><italic toggle="yes">Anticancer Research</italic></source><year>2004</year><volume>24</volume><issue>3b</issue><fpage>1947</fpage><lpage>1952</lpage><?supplied-pmid 15274382?><pub-id pub-id-type="pmid">15274382</pub-id></element-citation></ref><ref id="B277"><label>277</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minami</surname><given-names>T.</given-names></name><name><surname>Kishikawa</surname><given-names>T.</given-names></name><name><surname>Sato</surname><given-names>M.</given-names></name><name><surname>Tateishi</surname><given-names>R.</given-names></name><name><surname>Yoshida</surname><given-names>H.</given-names></name><name><surname>Koike</surname><given-names>K.</given-names></name></person-group><article-title>Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C</article-title><source><italic toggle="yes">Journal of Gastroenterology</italic></source><year>2013</year><volume>48</volume><issue>2</issue><fpage>254</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1007/s00535-012-0631-y</pub-id><pub-id pub-id-type="other">2-s2.0-84880983784</pub-id><pub-id pub-id-type="pmid">22790350</pub-id></element-citation></ref><ref id="B278"><label>278</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oshansky</surname><given-names>C. M.</given-names></name><name><surname>Gartland</surname><given-names>A. J.</given-names></name><name><surname>Wong</surname><given-names>S. S.</given-names></name><etal/></person-group><article-title>Mucosal immune responses predict clinical outcomes during influenza infection independently of age and viral load</article-title><source><italic toggle="yes">American Journal of Respiratory and Critical Care Medicine</italic></source><year>2014</year><volume>189</volume><issue>4</issue><fpage>449</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1164/rccm.201309-1616OC</pub-id><pub-id pub-id-type="other">2-s2.0-84894231691</pub-id><?supplied-pmid 24308446?><pub-id pub-id-type="pmid">24308446</pub-id></element-citation></ref><ref id="B279"><label>279</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herold</surname><given-names>S.</given-names></name><name><surname>Steinmueller</surname><given-names>M.</given-names></name><name><surname>von Wulffen</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand</article-title><source><italic toggle="yes">The Journal of Experimental Medicine</italic></source><year>2008</year><volume>205</volume><issue>13</issue><fpage>3065</fpage><lpage>3077</lpage><pub-id pub-id-type="doi">10.1084/jem.20080201</pub-id><pub-id pub-id-type="other">2-s2.0-59649110031</pub-id><?supplied-pmid 19064696?><pub-id pub-id-type="pmid">19064696</pub-id></element-citation></ref><ref id="B280"><label>280</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000f6;gner</surname><given-names>K.</given-names></name><name><surname>Wolff</surname><given-names>T.</given-names></name><name><surname>Pleschka</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Macrophage-expressed IFN-<italic>&#x003b2;</italic> contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia</article-title><source><italic toggle="yes">PLoS Pathogens</italic></source><year>2013</year><volume>9</volume><issue>2, article e1003188</issue><pub-id pub-id-type="doi">10.1371/journal.ppat.1003188</pub-id><pub-id pub-id-type="other">2-s2.0-84878548127</pub-id><?supplied-pmid 23468627?><pub-id pub-id-type="pmid">23468627</pub-id></element-citation></ref><ref id="B281"><label>281</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>R. Y.</given-names></name><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Oppenheimer</surname><given-names>S. J.</given-names></name><name><surname>Tam</surname><given-names>J. S.</given-names></name><name><surname>Lau</surname><given-names>J.</given-names></name></person-group><article-title>Treatment of respiratory syncytial virus infection with recombinant interferon alfa-2a</article-title><source><italic toggle="yes">Archives of Disease in Childhood</italic></source><year>1993</year><volume>69</volume><issue>4</issue><fpage>440</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1136/adc.69.4.440</pub-id><pub-id pub-id-type="other">2-s2.0-0027329965</pub-id><?supplied-pmid 8259875?><pub-id pub-id-type="pmid">8259875</pub-id></element-citation></ref><ref id="B282"><label>282</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portnoy</surname><given-names>J.</given-names></name><name><surname>Hicks</surname><given-names>R.</given-names></name><name><surname>Pacheco</surname><given-names>F.</given-names></name><name><surname>Olson</surname><given-names>L.</given-names></name></person-group><article-title>Pilot study of recombinant interferon alpha-2a for treatment of infants with bronchiolitis induced by respiratory syncytial virus</article-title><source><italic toggle="yes">Antimicrobial Agents and Chemotherapy</italic></source><year>1988</year><volume>32</volume><issue>4</issue><fpage>589</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1128/aac.32.4.589</pub-id><pub-id pub-id-type="other">2-s2.0-0023839993</pub-id><?supplied-pmid 3377468?><pub-id pub-id-type="pmid">3377468</pub-id></element-citation></ref><ref id="B283"><label>283</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubois</surname><given-names>J.</given-names></name><name><surname>Hershon</surname><given-names>L.</given-names></name><name><surname>Carmant</surname><given-names>L.</given-names></name><name><surname>B&#x000e9;langer</surname><given-names>S.</given-names></name><name><surname>Leclerc</surname><given-names>J. M.</given-names></name><name><surname>David</surname><given-names>M.</given-names></name></person-group><article-title>Toxicity profile of interferon alfa-2b in children: a prospective evaluation</article-title><source><italic toggle="yes">The Journal of Pediatrics</italic></source><year>1999</year><volume>135</volume><issue>6</issue><fpage>782</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1016/s0022-3476(99)70104-6</pub-id><pub-id pub-id-type="other">2-s2.0-0033504699</pub-id><?supplied-pmid 10586188?><pub-id pub-id-type="pmid">10586188</pub-id></element-citation></ref><ref id="B284"><label>284</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farr</surname><given-names>B. M.</given-names></name><name><surname>Gwaltney JM Jr</surname></name><name><surname>Adams</surname><given-names>K. F.</given-names></name><name><surname>Hayden</surname><given-names>F. G.</given-names></name></person-group><article-title>Intranasal interferon-alpha 2 for prevention of natural rhinovirus colds</article-title><source><italic toggle="yes">Antimicrobial Agents and Chemotherapy</italic></source><year>1984</year><volume>26</volume><issue>1</issue><fpage>31</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1128/aac.26.1.31</pub-id><pub-id pub-id-type="other">2-s2.0-0021253968</pub-id><?supplied-pmid 6089652?><pub-id pub-id-type="pmid">6089652</pub-id></element-citation></ref><ref id="B285"><label>285</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>F. G.</given-names></name><name><surname>Gwaltney</surname><given-names>J. M.</given-names></name></person-group><article-title>Intranasal interferon 2 for prevention of rhinovirus infection and illness</article-title><source><italic toggle="yes">The Journal of Infectious Diseases</italic></source><year>1983</year><volume>148</volume><issue>3</issue><fpage>543</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1093/infdis/148.3.543</pub-id><pub-id pub-id-type="other">2-s2.0-0020616792</pub-id><?supplied-pmid 6311914?><pub-id pub-id-type="pmid">6311914</pub-id></element-citation></ref><ref id="B286"><label>286</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>F. G.</given-names></name><name><surname>Albrecht</surname><given-names>J. K.</given-names></name><name><surname>Kaiser</surname><given-names>D. L.</given-names></name><name><surname>Gwaltney JM Jr</surname></name></person-group><article-title>Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>1986</year><volume>314</volume><issue>2</issue><fpage>71</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1056/NEJM198601093140202</pub-id><pub-id pub-id-type="other">2-s2.0-0022644964</pub-id><?supplied-pmid 3001519?><pub-id pub-id-type="pmid">3001519</pub-id></element-citation></ref><ref id="B287"><label>287</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monto</surname><given-names>A. S.</given-names></name><name><surname>Schwartz</surname><given-names>S. A.</given-names></name><name><surname>Albrecht</surname><given-names>J. K.</given-names></name></person-group><article-title>Ineffectiveness of postexposure prophylaxis of rhinovirus infection with low-dose intranasal alpha 2b interferon in families</article-title><source><italic toggle="yes">Antimicrobial Agents and Chemotherapy</italic></source><year>1989</year><volume>33</volume><issue>3</issue><fpage>387</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1128/AAC.33.3.387</pub-id><pub-id pub-id-type="other">2-s2.0-0024522888</pub-id><pub-id pub-id-type="pmid">2543280</pub-id></element-citation></ref><ref id="B288"><label>288</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E. S.</given-names></name><name><surname>Choe</surname><given-names>P. G.</given-names></name><name><surname>Park</surname><given-names>W. B.</given-names></name><etal/></person-group><article-title>Clinical progression and cytokine profiles of Middle East respiratory syndrome coronavirus infection</article-title><source><italic toggle="yes">Journal of Korean Medical Science</italic></source><year>2016</year><volume>31</volume><issue>11</issue><fpage>1717</fpage><lpage>1725</lpage><pub-id pub-id-type="doi">10.3346/jkms.2016.31.11.1717</pub-id><pub-id pub-id-type="other">2-s2.0-84995442519</pub-id><?supplied-pmid 27709848?><pub-id pub-id-type="pmid">27709848</pub-id></element-citation></ref><ref id="B289"><label>289</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omrani</surname><given-names>A. S.</given-names></name><name><surname>Saad</surname><given-names>M. M.</given-names></name><name><surname>Baig</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study</article-title><source><italic toggle="yes">The Lancet Infectious Diseases</italic></source><year>2014</year><volume>14</volume><issue>11</issue><fpage>1090</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(14)70920-X</pub-id><pub-id pub-id-type="other">2-s2.0-84908285527</pub-id><?supplied-pmid 25278221?><pub-id pub-id-type="pmid">25278221</pub-id></element-citation></ref><ref id="B290"><label>290</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loutfy</surname><given-names>M. R.</given-names></name><name><surname>Blatt</surname><given-names>L. M.</given-names></name><name><surname>Siminovitch</surname><given-names>K. A.</given-names></name><etal/></person-group><article-title>Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study</article-title><source><italic toggle="yes">JAMA</italic></source><year>2003</year><volume>290</volume><issue>24</issue><fpage>3222</fpage><lpage>3228</lpage><pub-id pub-id-type="doi">10.1001/jama.290.24.3222</pub-id><pub-id pub-id-type="other">2-s2.0-0348136783</pub-id><?supplied-pmid 14693875?><pub-id pub-id-type="pmid">14693875</pub-id></element-citation></ref><ref id="B291"><label>291</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamaladasa</surname><given-names>A.</given-names></name><name><surname>Gomes</surname><given-names>L.</given-names></name><name><surname>Wijesinghe</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Altered monocyte response to the dengue virus in those with varying severity of past dengue infection</article-title><source><italic toggle="yes">Antiviral Research</italic></source><year>2019</year><volume>169</volume><fpage>p. 104554</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2019.104554</pub-id><pub-id pub-id-type="other">2-s2.0-85068525180</pub-id><pub-id pub-id-type="pmid">31288040</pub-id></element-citation></ref><ref id="B292"><label>292</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J. F. W.</given-names></name><name><surname>Zhang</surname><given-names>A. J.</given-names></name><name><surname>Chan</surname><given-names>C. C. S.</given-names></name><etal/></person-group><article-title>Zika virus infection in dexamethasone-immunosuppressed mice demonstrating disseminated infection with multi-organ involvement including orchitis effectively treated by recombinant type I interferons</article-title><source><italic toggle="yes">eBioMedicine</italic></source><year>2016</year><volume>14</volume><fpage>112</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2016.11.017</pub-id><pub-id pub-id-type="other">2-s2.0-85004000295</pub-id><?supplied-pmid 27884655?><pub-id pub-id-type="pmid">27884655</pub-id></element-citation></ref><ref id="B293"><label>293</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalil</surname><given-names>A. C.</given-names></name><name><surname>Devetten</surname><given-names>M. P.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases</article-title><source><italic toggle="yes">Clinical Infectious Diseases</italic></source><year>2005</year><volume>40</volume><issue>5</issue><fpage>764</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1086/427945</pub-id><pub-id pub-id-type="other">2-s2.0-15044352317</pub-id><?supplied-pmid 15714427?><pub-id pub-id-type="pmid">15714427</pub-id></element-citation></ref><ref id="B294"><label>294</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>J.</given-names></name><name><surname>Ryu</surname><given-names>H. S.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>S. A.</given-names></name></person-group><article-title>The first reported case of West Nile encephalitis in Korea</article-title><source><italic toggle="yes">Journal of Korean Medical Science</italic></source><year>2015</year><volume>30</volume><issue>3</issue><fpage>343</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.3346/jkms.2015.30.3.343</pub-id><pub-id pub-id-type="other">2-s2.0-84951289221</pub-id><?supplied-pmid 25729260?><pub-id pub-id-type="pmid">25729260</pub-id></element-citation></ref><ref id="B295"><label>295</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan-Tack</surname><given-names>K. M.</given-names></name><name><surname>Forrest</surname><given-names>G.</given-names></name></person-group><article-title>Failure of interferon alpha-2b in a patient with West Nile virus meningoencephalitis and acute flaccid paralysis</article-title><source><italic toggle="yes">Scandinavian Journal of Infectious Diseases</italic></source><year>2005</year><volume>37</volume><issue>11-12</issue><fpage>944</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1080/00365540500262690</pub-id><pub-id pub-id-type="other">2-s2.0-30544444274</pub-id><pub-id pub-id-type="pmid">16308241</pub-id></element-citation></ref><ref id="B296"><label>296</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>M.</given-names></name><name><surname>Amsden</surname><given-names>J. R.</given-names></name></person-group><article-title>Successful treatment of West Nile virus infection after approximately 3 weeks into the disease course</article-title><source><italic toggle="yes">Pharmacotherapy</italic></source><year>2007</year><volume>27</volume><issue>3</issue><fpage>455</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1592/phco.27.3.455</pub-id><pub-id pub-id-type="other">2-s2.0-33847257454</pub-id><?supplied-pmid 17316156?><pub-id pub-id-type="pmid">17316156</pub-id></element-citation></ref><ref id="B297"><label>297</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harinasuta</surname><given-names>C.</given-names></name><name><surname>Wasi</surname><given-names>C.</given-names></name><name><surname>Vithanomsat</surname><given-names>S.</given-names></name></person-group><article-title>The effect of interferon on Japanese encephalitis virus in vitro</article-title><source><italic toggle="yes">The Southeast Asian Journal of Tropical Medicine and Public Health</italic></source><year>1984</year><volume>15</volume><issue>4</issue><fpage>564</fpage><lpage>568</lpage><?supplied-pmid 6535269?><pub-id pub-id-type="pmid">6535269</pub-id></element-citation></ref><ref id="B298"><label>298</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>T.</given-names></name><name><surname>Dung</surname><given-names>N. M.</given-names></name><name><surname>Wills</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial</article-title><source><italic toggle="yes">Lancet</italic></source><year>2003</year><volume>361</volume><issue>9360</issue><fpage>821</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(03)12709-2</pub-id><pub-id pub-id-type="other">2-s2.0-0037426083</pub-id><?supplied-pmid 12642049?><pub-id pub-id-type="pmid">12642049</pub-id></element-citation></ref><ref id="B299"><label>299</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahal</surname><given-names>J. J.</given-names></name><name><surname>Anderson</surname><given-names>J.</given-names></name><name><surname>Rosenberg</surname><given-names>C.</given-names></name><name><surname>Reagan</surname><given-names>T.</given-names></name><name><surname>Thompson</surname><given-names>L. L.</given-names></name></person-group><article-title>Effect of interferon-alpha2b therapy on St. Louis viral meningoencephalitis: clinical and laboratory results of a pilot study</article-title><source><italic toggle="yes">The Journal of Infectious Diseases</italic></source><year>2004</year><volume>190</volume><issue>6</issue><fpage>1084</fpage><lpage>1087</lpage><pub-id pub-id-type="doi">10.1086/423325</pub-id><pub-id pub-id-type="other">2-s2.0-4444287642</pub-id><?supplied-pmid 15319857?><pub-id pub-id-type="pmid">15319857</pub-id></element-citation></ref><ref id="B300"><label>300</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>C. A.</given-names></name><name><surname>Vikram</surname><given-names>H. R.</given-names></name><name><surname>Seville</surname><given-names>M. T.</given-names></name><etal/></person-group><article-title>Neuroinvasive St. Louis encephalitis virus infection in solid organ transplant recipients</article-title><source><italic toggle="yes">American Journal of Transplantation</italic></source><year>2017</year><volume>17</volume><issue>8</issue><fpage>2200</fpage><lpage>2206</lpage><pub-id pub-id-type="doi">10.1111/ajt.14336</pub-id><pub-id pub-id-type="other">2-s2.0-85019876177</pub-id><pub-id pub-id-type="pmid">28452107</pub-id></element-citation></ref><ref id="B301"><label>301</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoggins</surname><given-names>J. W.</given-names></name><name><surname>Rice</surname><given-names>C. M.</given-names></name></person-group><article-title>Interferon-stimulated genes and their antiviral effector functions</article-title><source><italic toggle="yes">Current Opinion in Virology</italic></source><year>2011</year><volume>1</volume><issue>6</issue><fpage>519</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2011.10.008</pub-id><pub-id pub-id-type="other">2-s2.0-82955187705</pub-id><?supplied-pmid 22328912?><pub-id pub-id-type="pmid">22328912</pub-id></element-citation></ref><ref id="B302"><label>302</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>W. M.</given-names></name><name><surname>Chevillotte</surname><given-names>M. D.</given-names></name><name><surname>Rice</surname><given-names>C. M.</given-names></name></person-group><article-title>Interferon-stimulated genes: a complex web of host defenses</article-title><source><italic toggle="yes">Annual Review of Immunology</italic></source><year>2014</year><volume>32</volume><fpage>513</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120231</pub-id><pub-id pub-id-type="other">2-s2.0-84896987305</pub-id><?supplied-pmid 24555472?><pub-id pub-id-type="pmid">24555472</pub-id></element-citation></ref><ref id="B303"><label>303</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Su</surname><given-names>J.</given-names></name><name><surname>Peppelenbosch</surname><given-names>M. P.</given-names></name><name><surname>Pan</surname><given-names>Q.</given-names></name></person-group><article-title>Transcriptional regulation of antiviral interferon-stimulated genes</article-title><source><italic toggle="yes">Trends in Microbiology</italic></source><year>2017</year><volume>25</volume><issue>7</issue><fpage>573</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2017.01.001</pub-id><pub-id pub-id-type="other">2-s2.0-85010867865</pub-id><?supplied-pmid 28139375?><pub-id pub-id-type="pmid">28139375</pub-id></element-citation></ref><ref id="B304"><label>304</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crosse</surname><given-names>K. M.</given-names></name><name><surname>Monson</surname><given-names>E. A.</given-names></name><name><surname>Beard</surname><given-names>M. R.</given-names></name><name><surname>Helbig</surname><given-names>K. J.</given-names></name></person-group><article-title>Interferon-stimulated genes as enhancers of antiviral innate immune signaling</article-title><source><italic toggle="yes">Journal of Innate Immunity</italic></source><year>2018</year><volume>10</volume><issue>2</issue><fpage>85</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1159/000484258</pub-id><pub-id pub-id-type="other">2-s2.0-85035797583</pub-id><?supplied-pmid 29186718?><pub-id pub-id-type="pmid">29186718</pub-id></element-citation></ref><ref id="B305"><label>305</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Hinson</surname><given-names>E. R.</given-names></name><name><surname>Cresswell</surname><given-names>P.</given-names></name></person-group><article-title>The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts</article-title><source><italic toggle="yes">Cell Host &#x00026; Microbe</italic></source><year>2007</year><volume>2</volume><issue>2</issue><fpage>96</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2007.06.009</pub-id><pub-id pub-id-type="other">2-s2.0-34547656276</pub-id><?supplied-pmid 18005724?><pub-id pub-id-type="pmid">18005724</pub-id></element-citation></ref><ref id="B306"><label>306</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helbig</surname><given-names>K. J.</given-names></name><name><surname>Beard</surname><given-names>M. R.</given-names></name></person-group><article-title>The role of viperin in the innate antiviral response</article-title><source><italic toggle="yes">Journal of Molecular Biology</italic></source><year>2014</year><volume>426</volume><issue>6</issue><fpage>1210</fpage><lpage>1219</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2013.10.019</pub-id><pub-id pub-id-type="other">2-s2.0-84896692039</pub-id><?supplied-pmid 24157441?><pub-id pub-id-type="pmid">24157441</pub-id></element-citation></ref><ref id="B307"><label>307</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>G.</given-names></name></person-group><article-title>ZAP-mediated mRNA degradation</article-title><source><italic toggle="yes">RNA Biology</italic></source><year>2008</year><volume>5</volume><issue>2</issue><fpage>65</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.4161/rna.5.2.6044</pub-id><pub-id pub-id-type="other">2-s2.0-45849086537</pub-id><?supplied-pmid 18418085?><pub-id pub-id-type="pmid">18418085</pub-id></element-citation></ref><ref id="B308"><label>308</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>N. L.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>The C-terminal tail of TRIM56 dictates antiviral restriction of influenza A and B viruses by impeding viral RNA synthesis</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2016</year><volume>90</volume><issue>9</issue><fpage>4369</fpage><lpage>4382</lpage><pub-id pub-id-type="doi">10.1128/JVI.03172-15</pub-id><pub-id pub-id-type="other">2-s2.0-84964922496</pub-id><?supplied-pmid 26889027?><pub-id pub-id-type="pmid">26889027</pub-id></element-citation></ref><ref id="B309"><label>309</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>N. L.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Overlapping and distinct molecular determinants dictating the antiviral activities of TRIM56 against flaviviruses and coronavirus</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2014</year><volume>88</volume><issue>23</issue><fpage>13821</fpage><lpage>13835</lpage><pub-id pub-id-type="doi">10.1128/JVI.02505-14</pub-id><pub-id pub-id-type="other">2-s2.0-84911361751</pub-id><?supplied-pmid 25253338?><pub-id pub-id-type="pmid">25253338</pub-id></element-citation></ref><ref id="B310"><label>310</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watkinson</surname><given-names>R. E.</given-names></name><name><surname>McEwan</surname><given-names>W. A.</given-names></name><name><surname>Tam</surname><given-names>J. C. H.</given-names></name><name><surname>Vaysburd</surname><given-names>M.</given-names></name><name><surname>James</surname><given-names>L. C.</given-names></name></person-group><article-title>TRIM21 promotes cGAS and RIG-I sensing of viral genomes during infection by antibody-opsonized virus</article-title><source><italic toggle="yes">PLoS Pathogens</italic></source><year>2015</year><volume>11</volume><issue>10, article e1005253</issue><pub-id pub-id-type="doi">10.1371/journal.ppat.1005253</pub-id><pub-id pub-id-type="other">2-s2.0-84946011808</pub-id><?supplied-pmid 26506431?><pub-id pub-id-type="pmid">26506431</pub-id></element-citation></ref><ref id="B311"><label>311</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Espert</surname><given-names>L.</given-names></name><name><surname>Degols</surname><given-names>G.</given-names></name><name><surname>Gongora</surname><given-names>C.</given-names></name><etal/></person-group><article-title>ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses</article-title><source><italic toggle="yes">The Journal of Biological Chemistry</italic></source><year>2003</year><volume>278</volume><issue>18</issue><fpage>16151</fpage><lpage>16158</lpage><pub-id pub-id-type="doi">10.1074/jbc.M209628200</pub-id><pub-id pub-id-type="other">2-s2.0-0038521287</pub-id><?supplied-pmid 12594219?><pub-id pub-id-type="pmid">12594219</pub-id></element-citation></ref><ref id="B312"><label>312</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>He</surname><given-names>H.</given-names></name></person-group><article-title>Influenza A virus-induced expression of ISG20 inhibits viral replication by interacting with nucleoprotein</article-title><source><italic toggle="yes">Virus Genes</italic></source><year>2016</year><volume>52</volume><issue>6</issue><fpage>759</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1007/s11262-016-1366-2</pub-id><pub-id pub-id-type="other">2-s2.0-84976324039</pub-id><?supplied-pmid 27342813?><pub-id pub-id-type="pmid">27342813</pub-id></element-citation></ref><ref id="B313"><label>313</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>G.</given-names></name><name><surname>Kuzmanovic</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A new mechanism of interferon's antiviral action: induction of autophagy, essential for paramyxovirus replication, is inhibited by the interferon stimulated gene, TDRD7</article-title><source><italic toggle="yes">PLoS Pathogens</italic></source><year>2018</year><volume>14</volume><issue>1, article e1006877</issue><pub-id pub-id-type="doi">10.1371/journal.ppat.1006877</pub-id><pub-id pub-id-type="other">2-s2.0-85041510668</pub-id><?supplied-pmid 29381763?><pub-id pub-id-type="pmid">29381763</pub-id></element-citation></ref><ref id="B314"><label>314</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>D.</given-names></name><name><surname>Weidner</surname><given-names>J. M.</given-names></name><name><surname>Qing</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2010</year><volume>84</volume><issue>16</issue><fpage>8332</fpage><lpage>8341</lpage><pub-id pub-id-type="doi">10.1128/JVI.02199-09</pub-id><pub-id pub-id-type="other">2-s2.0-77954983994</pub-id><?supplied-pmid 20534863?><pub-id pub-id-type="pmid">20534863</pub-id></element-citation></ref><ref id="B315"><label>315</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helbig</surname><given-names>K. J.</given-names></name><name><surname>Carr</surname><given-names>J. M.</given-names></name><name><surname>Calvert</surname><given-names>J. K.</given-names></name><etal/></person-group><article-title>Viperin is induced following dengue virus type-2 (DENV-2) infection and has anti-viral actions requiring the C-terminal end of viperin</article-title><source><italic toggle="yes">PLoS Neglected Tropical Diseases</italic></source><year>2013</year><volume>7</volume><issue>4, article e2178</issue><pub-id pub-id-type="doi">10.1371/journal.pntd.0002178</pub-id><pub-id pub-id-type="other">2-s2.0-84876848344</pub-id><?supplied-pmid 23638199?><pub-id pub-id-type="pmid">23638199</pub-id></element-citation></ref><ref id="B316"><label>316</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brass</surname><given-names>A. L.</given-names></name><name><surname>Huang</surname><given-names>I. C.</given-names></name><name><surname>Benita</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus</article-title><source><italic toggle="yes">Cell</italic></source><year>2009</year><volume>139</volume><issue>7</issue><fpage>1243</fpage><lpage>1254</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.12.017</pub-id><pub-id pub-id-type="other">2-s2.0-72549116887</pub-id><?supplied-pmid 20064371?><pub-id pub-id-type="pmid">20064371</pub-id></element-citation></ref><ref id="B317"><label>317</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>Y.</given-names></name><name><surname>Chin</surname><given-names>W. X.</given-names></name><name><surname>Han</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Characterization of RyDEN (C19orf66) as an interferon-stimulated cellular inhibitor against dengue virus replication</article-title><source><italic toggle="yes">PLoS Pathogens</italic></source><year>2016</year><volume>12</volume><issue>1, article e1005357</issue><pub-id pub-id-type="doi">10.1371/journal.ppat.1005357</pub-id><pub-id pub-id-type="other">2-s2.0-84956778994</pub-id><?supplied-pmid 26735137?><pub-id pub-id-type="pmid">26735137</pub-id></element-citation></ref><ref id="B318"><label>318</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>R. J.</given-names></name><name><surname>Yu</surname><given-names>H. P.</given-names></name><name><surname>Chang</surname><given-names>B. L.</given-names></name><name><surname>Tang</surname><given-names>W. C.</given-names></name><name><surname>Liao</surname><given-names>C. L.</given-names></name><name><surname>Lin</surname><given-names>Y. L.</given-names></name></person-group><article-title>Distinct antiviral roles for human 2',5'-oligoadenylate synthetase family members against dengue virus infection</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2009</year><volume>183</volume><issue>12</issue><fpage>8035</fpage><lpage>8043</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0902728</pub-id><pub-id pub-id-type="other">2-s2.0-76249133498</pub-id><?supplied-pmid 19923450?><pub-id pub-id-type="pmid">19923450</pub-id></element-citation></ref><ref id="B319"><label>319</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Zou</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Interferon-stimulated TRIM69 interrupts dengue virus replication by ubiquitinating viral nonstructural protein 3</article-title><source><italic toggle="yes">PLoS Pathogens</italic></source><year>2018</year><volume>14</volume><issue>8, article e1007287</issue><pub-id pub-id-type="doi">10.1371/journal.ppat.1007287</pub-id><pub-id pub-id-type="other">2-s2.0-85053081520</pub-id><?supplied-pmid 30142214?><pub-id pub-id-type="pmid">30142214</pub-id></element-citation></ref><ref id="B320"><label>320</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>R. B.</given-names></name><name><surname>Ohlson</surname><given-names>M. B.</given-names></name><name><surname>Eitson</surname><given-names>J. L.</given-names></name><etal/></person-group><article-title>A CRISPR screen identifies IFI6 as an ER-resident interferon effector that blocks flavivirus replication</article-title><source><italic toggle="yes">Nature Microbiology</italic></source><year>2018</year><volume>3</volume><issue>11</issue><fpage>1214</fpage><lpage>1223</lpage><pub-id pub-id-type="doi">10.1038/s41564-018-0244-1</pub-id><pub-id pub-id-type="other">2-s2.0-85053527024</pub-id><?supplied-pmid 30224801?><pub-id pub-id-type="pmid">30224801</pub-id></element-citation></ref><ref id="B321"><label>321</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>P. K.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Farr</surname><given-names>D.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name></person-group><article-title>Interferon-stimulated gene 15 (ISG15) restricts Zika virus replication in primary human corneal epithelial cells</article-title><source><italic toggle="yes">The Ocular Surface</italic></source><year>2019</year><volume>17</volume><issue>3</issue><fpage>551</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1016/j.jtos.2019.03.006</pub-id><pub-id pub-id-type="other">2-s2.0-85064825786</pub-id><?supplied-pmid 30905842?><pub-id pub-id-type="pmid">30905842</pub-id></element-citation></ref><ref id="B322"><label>322</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>J.</given-names></name><name><surname>Pan</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name></person-group><article-title>ISG15 facilitates cellular antiviral response to dengue and West Nile virus infection in vitro</article-title><source><italic toggle="yes">Virology Journal</italic></source><year>2011</year><volume>8</volume><issue>1</issue><fpage>p. 468</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-8-468</pub-id><pub-id pub-id-type="other">2-s2.0-80053904402</pub-id><pub-id pub-id-type="pmid">21992229</pub-id></element-citation></ref><ref id="B323"><label>323</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morales</surname><given-names>D. J.</given-names></name><name><surname>Lenschow</surname><given-names>D. J.</given-names></name></person-group><article-title>The antiviral activities of ISG15</article-title><source><italic toggle="yes">Journal of Molecular Biology</italic></source><year>2013</year><volume>425</volume><issue>24</issue><fpage>4995</fpage><lpage>5008</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2013.09.041</pub-id><pub-id pub-id-type="other">2-s2.0-84888016188</pub-id><pub-id pub-id-type="pmid">24095857</pub-id></element-citation></ref><ref id="B324"><label>324</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hishiki</surname><given-names>T.</given-names></name><name><surname>Han</surname><given-names>Q.</given-names></name><name><surname>Arimoto</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Interferon-mediated ISG15 conjugation restricts dengue virus 2 replication</article-title><source><italic toggle="yes">Biochemical and Biophysical Research Communications</italic></source><year>2014</year><volume>448</volume><issue>1</issue><fpage>95</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2014.04.081</pub-id><pub-id pub-id-type="other">2-s2.0-84901245072</pub-id><?supplied-pmid 24769207?><pub-id pub-id-type="pmid">24769207</pub-id></element-citation></ref><ref id="B325"><label>325</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valdez</surname><given-names>F.</given-names></name><name><surname>Salvador</surname><given-names>J.</given-names></name><name><surname>Palermo</surname><given-names>P. M.</given-names></name><etal/></person-group><article-title>Schlafen 11 restricts flavivirus replication</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2019</year><volume>93</volume><issue>15</issue><pub-id pub-id-type="doi">10.1128/JVI.00104-19</pub-id><pub-id pub-id-type="other">2-s2.0-85070056258</pub-id><?supplied-pmid 31118262?><pub-id pub-id-type="pmid">31118262</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Type I interferon immune response. (a) Detection of viral infection by pathogen recognition receptors and signaling cascades resulting in the production of IFN-I. (b) IFN-I-<italic>&#x003b1;</italic>/<italic>&#x003b2;</italic> receptor (IFNAR) and activation of the JAK/STAT pathway leading to the induction of IFN-stimulated genes.</p></caption><graphic xlink:href="JIR2020-1372494.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Induction of IFN-I by influenza virus. PRRs involved in viral recognition include TLR-3, TLR-7/8, MDA5, and RIG-I that can detect viral products to signal IFN-<italic>&#x003b1;</italic>/<italic>&#x003b2;</italic> production in infected cells.</p></caption><graphic xlink:href="JIR2020-1372494.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Evasion and inhibition of respiratory virus-induced IFN-I signaling. Many respiratory viruses can inhibit and modulate their detection using diverse strategies, thereby inhibiting the IFN-I production. Circular boxes in black background represent the viral protein involved in the pathway inhibition. Abbreviations: NS: nonstructural protein; V: V protein; C: C protein; SH: small hydrophobic protein.</p></caption><graphic xlink:href="JIR2020-1372494.003"/></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Induction of IFN-I by RSV. RSV is detected by different PRRs that include TLR-2, TLR-4, TLR-3, TLR-7/8, MDA5, and RIG-I and leads to the IFN-I pathway activation.</p></caption><graphic xlink:href="JIR2020-1372494.004"/></fig><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Induction of IFN-I by flaviviruses. The TLR and RLR signaling cascades converge with the activation of transcription factors, which are critical for the induction of IFN-<italic>&#x003b1;</italic>&#x02215;<italic>&#x003b2;</italic>.</p></caption><graphic xlink:href="JIR2020-1372494.005"/></fig><fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Inhibition of the IFN-I pathway by flaviviruses. Different viral proteins are involved in the modulation of the IFN-I activation pathway. Circular boxes in black background represent the viral protein involved in the pathway inhibition. Abbreviations: nonstructural protein (NS) 1, 2, 3, 4, and 5; E: envelope protein.</p></caption><graphic xlink:href="JIR2020-1372494.006"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Role of IFN-I in respiratory virus and flavivirus infections.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Virus</th><th align="center" rowspan="1" colspan="1">Model</th><th align="center" rowspan="1" colspan="1">Effect</th><th align="center" rowspan="1" colspan="1">Main finding</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Human respiratory viruses</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">&#x02003;Influenza virus</td><td align="center" rowspan="1" colspan="1">Human (<italic>in vivo</italic>)</td><td align="center" rowspan="1" colspan="1">Protective</td><td align="center" rowspan="1" colspan="1">Hospitalized subjects show enrichment for a minor <italic>IFITM3</italic> allele that leads to reduced influenza virus restriction</td><td align="center" rowspan="1" colspan="1">[<xref rid="B70" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Human (<italic>in vivo</italic>)</td><td align="center" rowspan="1" colspan="1">Pathogenic</td><td align="center" rowspan="1" colspan="1">High levels of IFN-<italic>&#x003b1;</italic>2 at enrollment predicted progression to severe disease</td><td align="center" rowspan="1" colspan="1">[<xref rid="B278" ref-type="bibr">278</xref>]</td></tr><tr><th align="center" colspan="5" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="2" colspan="1">&#x02003;RSV</td><td align="center" rowspan="1" colspan="1">Human (<italic>in vitro</italic>)</td><td align="center" rowspan="1" colspan="1">Protective</td><td align="center" rowspan="1" colspan="1">Age and premature birth were independently associated with attenuated RIG-I-dependent IFN-<italic>&#x003b1;</italic> responses</td><td align="center" rowspan="1" colspan="1">[<xref rid="B89" ref-type="bibr">89</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Human (<italic>in vivo</italic>)</td><td align="center" rowspan="1" colspan="1">Protective</td><td align="center" rowspan="1" colspan="1">Infants with severe RSV bronchiolitis have lower type-I IFN levels</td><td align="center" rowspan="1" colspan="1">[<xref rid="B90" ref-type="bibr">90</xref>]</td></tr><tr><th align="center" colspan="5" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;hMPV</td><td align="center" rowspan="1" colspan="1">Mouse (<italic>in vivo</italic>)</td><td align="center" rowspan="1" colspan="1">Pathogenic</td><td align="center" rowspan="1" colspan="1">IFN-I contributed to disease pathogenesis due to increased inflammatory lung disease during infection</td><td align="center" rowspan="1" colspan="1">[<xref rid="B102" ref-type="bibr">102</xref>]</td></tr><tr><th align="center" colspan="5" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;PIV</td><td align="center" rowspan="1" colspan="1">Human (<italic>in vivo</italic>)</td><td align="center" rowspan="1" colspan="1">Protective</td><td align="center" rowspan="1" colspan="1">Mean quantities of the virus in the secretions of those children with interferon was significantly lower compared to those without detectable IFN</td><td align="center" rowspan="1" colspan="1">[<xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B117" ref-type="bibr">117</xref>]</td></tr><tr><th align="center" colspan="5" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;HRV</td><td align="center" rowspan="1" colspan="1">Human (<italic>in vitro</italic>)<break/>Human (<italic>in vivo</italic>)</td><td align="center" rowspan="1" colspan="1">Protective</td><td align="center" rowspan="1" colspan="1">Exogenous IFN-<italic>&#x003b1;</italic>, IFN-<italic>&#x003b2;</italic> significantly reduce HRV replication</td><td align="center" rowspan="1" colspan="1">[<xref rid="B130" ref-type="bibr">130</xref>, <xref rid="B131" ref-type="bibr">131</xref>]</td></tr><tr><th align="center" colspan="5" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="2" colspan="1">&#x02003;HCoV</td><td align="center" rowspan="1" colspan="1">Human (<italic>in vivo</italic>)</td><td align="center" rowspan="1" colspan="1">Pathogenic</td><td align="center" rowspan="1" colspan="1">High levels of IFN correlated with early sequelae</td><td align="center" rowspan="1" colspan="1">[<xref rid="B148" ref-type="bibr">148</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Human (<italic>in vivo</italic>)</td><td align="center" rowspan="1" colspan="1">Protective</td><td align="center" rowspan="1" colspan="1">Patients treated with IFN show clinical response</td><td align="center" rowspan="1" colspan="1">[<xref rid="B289" ref-type="bibr">289</xref>, <xref rid="B290" ref-type="bibr">290</xref>]</td></tr><tr><td align="center" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Emerging flaviviruses</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">&#x02003;DENV</td><td align="center" rowspan="1" colspan="1">Human (<italic>in vivo</italic>)</td><td align="center" rowspan="1" colspan="1">Protective</td><td align="center" rowspan="1" colspan="1">Higher levels of IFN-<italic>&#x003b1;</italic> are observed in patients with milder dengue disease</td><td align="center" rowspan="1" colspan="1">[<xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B190" ref-type="bibr">190</xref>, <xref rid="B193" ref-type="bibr">193</xref>&#x02013;<xref rid="B196" ref-type="bibr">196</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Human (<italic>in vivo</italic>)</td><td align="center" rowspan="1" colspan="1">Pathogenic</td><td align="center" rowspan="1" colspan="1">Higher levels of IFN-<italic>&#x003b2;</italic> in severe vs. nonsevere dengue children</td><td align="center" rowspan="1" colspan="1">[<xref rid="B197" ref-type="bibr">197</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Human (<italic>in vivo</italic>)</td><td align="center" rowspan="1" colspan="1">Pathogenic</td><td align="center" rowspan="1" colspan="1">Higher levels of IFN-<italic>&#x003b2;</italic> in primary DHF patients compared to those with primary DF</td><td align="center" rowspan="1" colspan="1">[<xref rid="B198" ref-type="bibr">198</xref>]</td></tr><tr><th align="center" colspan="5" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="2" colspan="1">&#x02003;ZIKV</td><td align="center" rowspan="1" colspan="1">Human (<italic>in vivo</italic>)</td><td align="center" rowspan="1" colspan="1">Protective</td><td align="center" rowspan="1" colspan="1">SNP at TLR-3 that decreased IFN-I response has been associated with microcephaly in newborns</td><td align="center" rowspan="1" colspan="1">[<xref rid="B232" ref-type="bibr">232</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Human (<italic>in vitro</italic>)</td><td align="center" rowspan="1" colspan="1">Protective</td><td align="center" rowspan="1" colspan="1">Replication of Asian ZIKV strain Brazil 2015 (associated with neurodevelopmental disorders) was less sensitive to IFN-I, compared to other ZIKV strains</td><td align="center" rowspan="1" colspan="1">[<xref rid="B233" ref-type="bibr">233</xref>]</td></tr><tr><th align="center" colspan="5" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="3" colspan="1">&#x02003;WNV</td><td align="center" rowspan="1" colspan="1">Human (<italic>in vitro</italic>)</td><td align="center" rowspan="1" colspan="1">Protective</td><td align="center" rowspan="1" colspan="1">PI3K that induces IFN-I controls WNV infection</td><td align="center" rowspan="1" colspan="1">[<xref rid="B238" ref-type="bibr">238</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Human (<italic>in vitro</italic>)</td><td align="center" rowspan="1" colspan="1">Protective</td><td align="center" rowspan="1" colspan="1">Early activation of RLR or IFN-I signaling could block WNV infection</td><td align="center" rowspan="1" colspan="1">[<xref rid="B239" ref-type="bibr">239</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Human (<italic>in vivo</italic>)</td><td align="center" rowspan="1" colspan="1">Inconclusive</td><td align="center" rowspan="1" colspan="1">IFN-<italic>&#x003b1;</italic> treatment was well tolerated and might have potential beneficial effects, due to treatment or chance</td><td align="center" rowspan="1" colspan="1">[<xref rid="B293" ref-type="bibr">293</xref>&#x02013;<xref rid="B296" ref-type="bibr">296</xref>]</td></tr><tr><th align="center" colspan="5" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;YFV</td><td align="center" rowspan="1" colspan="1">Human (<italic>in vitro</italic>)</td><td align="center" rowspan="1" colspan="1">Protective/pathogenic</td><td align="center" rowspan="1" colspan="1">ISGs shown to inhibit or enhance viral replication</td><td align="center" rowspan="1" colspan="1">[<xref rid="B258" ref-type="bibr">258</xref>]</td></tr><tr><th align="center" colspan="5" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="2" colspan="1">&#x02003;JEV</td><td align="center" rowspan="1" colspan="1">Human (<italic>in vitro</italic>)</td><td align="center" rowspan="1" colspan="1">Protective</td><td align="center" rowspan="1" colspan="1">IFN-<italic>&#x003b1;</italic> at higher concentrations showed more efficacy in combating the replication of JEV</td><td align="center" rowspan="1" colspan="1">[<xref rid="B297" ref-type="bibr">297</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Human (<italic>in vivo</italic>)</td><td align="center" rowspan="1" colspan="1">Inconclusive</td><td align="center" rowspan="1" colspan="1">No benefits from IFN-<italic>&#x003b1;</italic>2a treatment against children with JEV infection</td><td align="center" rowspan="1" colspan="1">[<xref rid="B298" ref-type="bibr">298</xref>]</td></tr><tr><th align="center" colspan="5" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;SLEV</td><td align="center" rowspan="1" colspan="1">Human (<italic>in vivo</italic>)</td><td align="center" rowspan="1" colspan="1">Protective</td><td align="center" rowspan="1" colspan="1">IFN-<italic>&#x003b1;</italic>2b therapy for meningoencephalitis suggested a beneficial effect on the early neurologic course of the disease and clinical improvement</td><td align="center" rowspan="1" colspan="1">[<xref rid="B299" ref-type="bibr">299</xref>, <xref rid="B300" ref-type="bibr">300</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Some interferon-stimulated genes that inhibit respiratory virus and flavivirus infections.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">ISG</th><th align="center" rowspan="1" colspan="1">Viruses shown to be susceptible</th><th align="center" rowspan="1" colspan="1">Mechanism/component of innate immune system augmented by ISG</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Respiratory viruses</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Viperin</td><td align="center" rowspan="1" colspan="1">Influenza A virus<break/>HRV<break/>RSV</td><td align="center" rowspan="1" colspan="1">TLR-7/9 (IRAK1/TRAF6)<break/>NF-<italic>&#x003ba;</italic>B1/p50, AP-1</td><td align="center" rowspan="1" colspan="1">[<xref rid="B305" ref-type="bibr">305</xref>, <xref rid="B306" ref-type="bibr">306</xref>]</td></tr><tr><th align="center" colspan="4" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">ZAP</td><td align="center" rowspan="1" colspan="1">Influenza A virus</td><td align="center" rowspan="1" colspan="1">RIG-I</td><td align="center" rowspan="1" colspan="1">[<xref rid="B307" ref-type="bibr">307</xref>]</td></tr><tr><th align="center" colspan="4" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">TRIM56</td><td align="center" rowspan="1" colspan="1">Influenza A and B viruses<break/>HCoV OC43</td><td align="center" rowspan="1" colspan="1">STING, TLR-3/TRIF</td><td align="center" rowspan="1" colspan="1">[<xref rid="B308" ref-type="bibr">308</xref>, <xref rid="B309" ref-type="bibr">309</xref>]</td></tr><tr><th align="center" colspan="4" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">TRIM21</td><td align="center" rowspan="1" colspan="1">HRV</td><td align="center" rowspan="1" colspan="1">cGAS, RIG-I,</td><td align="center" rowspan="1" colspan="1">[<xref rid="B310" ref-type="bibr">310</xref>]</td></tr><tr><th align="center" colspan="4" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">ISG20</td><td align="center" rowspan="1" colspan="1">Influenza A and B viruses</td><td align="center" rowspan="1" colspan="1">Nucleoprotein blockade</td><td align="center" rowspan="1" colspan="1">[<xref rid="B311" ref-type="bibr">311</xref>, <xref rid="B312" ref-type="bibr">312</xref>]</td></tr><tr><th align="center" colspan="4" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">TDRD7</td><td align="center" rowspan="1" colspan="1">RSV<break/>PIV</td><td align="center" rowspan="1" colspan="1">Autophagy inhibition</td><td align="center" rowspan="1" colspan="1">[<xref rid="B313" ref-type="bibr">313</xref>]</td></tr><tr><td align="center" colspan="4" rowspan="1">
<hr/>
</td></tr><tr><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Flaviviruses</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">IFITM2/3</td><td align="center" rowspan="1" colspan="1">DENV<break/>WNV</td><td align="center" rowspan="1" colspan="1">Entry and/or uncoating disruption</td><td align="center" rowspan="1" colspan="1">[<xref rid="B314" ref-type="bibr">314</xref>, <xref rid="B316" ref-type="bibr">316</xref>]</td></tr><tr><th align="center" colspan="4" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">Viperin</td><td align="center" rowspan="1" colspan="1">DENV</td><td align="center" rowspan="1" colspan="1">Restriction of early DENV RNA production/accumulation, via interaction with DENV NS3 and replication complexes</td><td align="center" rowspan="1" colspan="1">[<xref rid="B315" ref-type="bibr">315</xref>]</td></tr><tr><th align="center" colspan="4" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">RyDEN</td><td align="center" rowspan="1" colspan="1">DENV</td><td align="center" rowspan="1" colspan="1">Interference with DENV translation via interaction with viral RNA and cellular mRNA-binding proteins</td><td align="center" rowspan="1" colspan="1">[<xref rid="B317" ref-type="bibr">317</xref>]</td></tr><tr><th align="center" colspan="4" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">OAS</td><td align="center" rowspan="1" colspan="1">DENV</td><td align="center" rowspan="1" colspan="1">Blockade in DENV replication</td><td align="center" rowspan="1" colspan="1">[<xref rid="B318" ref-type="bibr">318</xref>]</td></tr><tr><th align="center" colspan="4" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">ISG15</td><td align="center" rowspan="1" colspan="1">DENV<break/>ZIKV<break/>WNV<break/>JEV</td><td align="center" rowspan="1" colspan="1">Inhibition of viral replication</td><td align="center" rowspan="1" colspan="1">[<xref rid="B321" ref-type="bibr">321</xref>&#x02013;<xref rid="B324" ref-type="bibr">324</xref>]</td></tr><tr><th align="center" colspan="4" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">IFI6</td><td align="center" rowspan="1" colspan="1">YFV<break/>WNV<break/>DENV</td><td align="center" rowspan="1" colspan="1">Prevention of virus-induced ER membrane invaginations formation, that house replication machinery</td><td align="center" rowspan="1" colspan="1">[<xref rid="B320" ref-type="bibr">320</xref>]</td></tr><tr><th align="center" colspan="4" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">TRIM69</td><td align="center" rowspan="1" colspan="1">DENV</td><td align="center" rowspan="1" colspan="1">DENV NS3 ubiquitination and degradation, thus interrupting DENV replication</td><td align="center" rowspan="1" colspan="1">[<xref rid="B319" ref-type="bibr">319</xref>]</td></tr><tr><th align="center" colspan="4" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">Schlafen 11</td><td align="center" rowspan="1" colspan="1">WNV<break/>DENV<break/>ZIKV</td><td align="center" rowspan="1" colspan="1">Viral replication restriction by regulating tRNA abundance</td><td align="center" rowspan="1" colspan="1">[<xref rid="B325" ref-type="bibr">325</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>